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 IV 
Thesis Summary 
In wound healing and tissue repair, the presence of α-smooth muscle actin (α-SMA) 
containing myofibroblasts leads to wound closure and collagen-rich scar formation. This 
thesis investigated mechanisms of transforming growth factor-β1 (TGF-β1)-mediated 
differentiation and the dysfunctions involved in age-associated loss of differentiation. The 
loss of epidermal growth factor receptor (EGFR) and hyaluronan (HA) production, and 
diminished interaction of HA with its receptor CD44 (compromising its function) were the 
principal contributors to aged fibroblast resistance to differentiation.  
In response to TGF-β1, CD44 relocated to EGFR held in cholesterol-rich membrane-bound 
lipid rafts. This was HA-dependent, as hyaluronidase or 4-methylumbelliferone treatments 
restricted CD44 motility and prevented CD44-EGFR co-localisation. Additionally the 
intracellular signalling cascade was found to be a sequential phosphorylation of extracellular 
signal regulated kinase 1 & 2 followed by Ca2+/calmodulin kinase II. The activation of both 
proteins was required for differentiation. 
Elevated microRNA-7 (miR-7) expression was found in aged fibroblasts. Overexpressing 
miR-7 in young fibroblasts attenuated the expression of EGFR and inhibited differentiation. 
When miR-7 was inhibited, EGFR and hyaluronan synthase 2 expression, CD44 membrane 
motility, and TGF-β1-mediated differentiation in aged fibroblasts were restored. Activation 
of EGFR drove miR-7 promoter activity and expression in a JAK/STAT1 dependent manner. 
Treatments of aged fibroblasts with 17β-estradiol (E2) resulted in decreased miR-7 
expression and, when TGF-β1 was added, restored the α-SMA-positive phenotype. E2 
treatments had no impact on STAT1 phosphorylation; leading to the hypothesis that E2 
regulation of inflammatory mediators may be involved. 
The data demonstrated different points of intervention for the promotion or prevention of 
TGF-β1-regulated myofibroblast differentiation. The interactions between HA-CD44 and 
EGFR were crucial elements in the differentiation process and the importance of miR-7 was 
apparent. The mechanisms shown here may have direct implications for modifying the 
wound healing response, particularly for developing therapeutic strategies to improve healing 
in the elderly. 
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1.1 Wound Healing Overview 
Wound healing is a natural and complex process in which tissue repairs itself after injury or 
trauma. In the context of skin, normally cellular shedding from the epidermis exists in steady-
state equilibrium with the proliferation of the dermis, in order to form and maintain a 
protective barrier against the external environment. When the protective barrier is damaged 
the process of wound healing is immediately set in motion. Following injury and a breach in 
tissue structure, a series of intricate cellular and biochemical events take place in an 
orchestrated cascade to repair the damage and work towards restoration of tissue function. 
The classic model of wound healing can be divided into four sequential, yet overlapping, 
phases: inflammation, proliferation, contraction and maturation/remodelling. 
The rate at which a wound heals is influenced by many factors which alter the condition of 
the wound environment, including moisture, the presence of foreign bodies or bacterial 
infection [7], the levels of hormones, cytokines, and glucocorticoids present in the blood and 
surrounding tissue [8-10]. The initial stages of wound healing, which begin immediately 
following injury, involve cascading molecular and cellular events leading to haemostasis, clot 
formation and production of an early, provisional fibrin-based extracellular matrix (ECM) 
providing structural support for cellular adhesion and proliferation [11]. Subsequently, 
multiple cell types work together to mount an inflammatory response, synthesise granulation 
tissue, restore the epithelial layer and contract the wound. The late stages include collagen 
realignment and tissue remodelling, leading to recovery of tissue function [12-14]. 
1.1.1 Inflammation 
Inflammation consists of the clotting cascade, vasoconstriction and vasodilation, and the 
influx of immune cells into the wound area. Shortly after injury, platelets aggregate at the site 
of trauma to form a fibrin clot, which acts to control haemostasis [11, 15-17]. Formation of 
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the clot signals that the inflammatory phase has been initiated. Bacteria and debris are 
phagocytosed and removed by macrophages attracted and activated by various chemokines 
and cytokines. Growth factors are released and maintained that later promote the proliferative 
phase, the production of ECM, and wound contraction; notably, vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
interleukin-1-β (IL-1β), and transforming growth factor-β (TGF-β) [10, 16].   
The clotting cascade begins with coagulation; when tissue is first wounded, collagen binds to 
the plasma glycoprotein Von Willebrand factor (vWF) as it becomes exposed to the 
bloodstream due to endothelial cell damage. Activated platelets are attracted and attach to 
collagen-vWF to begin thrombus (clot) formation. First forming a mass, the platelets then 
begin to secrete inflammatory factors (IL-1β, interleukin-6 (IL-6), and macrophage 
inflammatory protein-1α (MIP-1α)) and clotting factors (including Factors V and VII). Blood 
plasma proteins, such as Factors X and V, and thrombin, lead to the conversion of fibrinogen 
into fibrin. Fibrin cross-links with fibronectin to form a clot that prevents excessive protein 
and blood loss. The fibrin-fibronectin plug becomes the main structural support during the 
early stages of wound healing. Various cell types utilise it for adherence and migratory 
purposes [18-20]. Platelets and monocytes arriving at the wound site also adhere to the fibrin-
fibronectin clot and continue to secrete ECM proteins, chemokines and growth factors [21, 
22]. These growth factors (VEGF, PDGF, epidermal growth factor (EGF), TGF-β, IL-1β) 
help to stimulate surrounding cells, inducing proliferation and phenotypic changes.  
Immediately after blood vessel and endothelial cell rupture, vasoconstriction - the 
constriction of adjacent blood vessels - occurs to staunch further blood loss. Damaged cell 
membranes release thromboxanes causing blood vessel constriction, assisting in the 
aggregation of platelets and promoting the coagulation cascade [17, 23]. Shortly after 
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vasoconstriction, vasodilation and the widening of blood vessels caused by the release of 
histamine from platelets, helps to increase the flow of plasma proteins and increase the 
number of cells that can access the wound site [23]. 
Within an hour of the initial wounding, neutrophils arrive at the wound site, attracted by 
fibronectin and various chemokines secreted by platelets and the surrounding tissue. 
Neutrophils phagocytose debris and bacteria, secrete proteases that break down damaged 
tissue, and release free radicals to help further eliminate bacteria [24]. Helper T-cells also 
infiltrate the wound site, secreting cytokines to increase inflammation and the activity of 
macrophages [25]. Macrophages are essential for wound healing, their main role is to 
phagocytose bacteria and cell debris, and to release proteases to debride damaged tissue [25]. 
The growth factors secreted by macrophages attract cells involved in the proliferation and 
angiogenesis stages of healing to the area [24]. Macrophage secretions also stimulate cells 
that cause reepithelialisation, the creation of granulation tissue, and the production of new 
ECM [24, 26]. It is widely accepted that the ability of the macrophage to secrete these 
activating factors means that they are large contributors to promoting the next phase of the 
wound healing process and therefore prolonged macrophage presence at the wound site may 
be beneficial. 
However, in vitro evidence has suggested that the presence of macrophages may in fact delay 
wound contraction and thus the timely disappearance of macrophages from the wound may 
be essential for later phases to occur [27]. Inflammation is a necessary part of healing, 
however, it can lead to tissue damage if it lasts too long [28]. The presence of foreign bodies 
can extend the inflammatory phase for too long, leading to a chronic wound. Thus the 
reduction of inflammation is frequently a goal in therapeutic settings. As inflammation 
declines, numbers of neutrophils and macrophages are reduced at the wound site. These 
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changes indicate that the inflammatory phase is ending and the proliferative phase is 
underway. 
1.1.2 Proliferation 
Angiogenesis, collagen deposition, granulation tissue formation, and the beginning of re-
epithelialisation characterise the proliferative phase. In angiogenesis, vascular endothelial 
cells form new blood vessels. In fibroplasias and granulation tissue formation, fibroblasts 
grow and form a new, provisional ECM by secreting collagen and fibronectin. Concurrently, 
re-epithelialisation of the epidermis occurs, in which epithelial cells proliferate and migrate 
across the wound bed, providing cover and protection for the new tissue.  Approximately 48 
to 72 hours after the initial wounding, fibroblasts begin to enter the wound site, marking the 
onset of the proliferative phase before the inflammatory phase has ended [15, 16, 29]. As in 
the other phases of wound healing, there are partial overlaps between phases. 
Angiogenesis occurs in parallel with fibroblast proliferation, when endothelial cells migrate 
to the area of the wound. As the activity of fibroblasts and epithelial cells requires oxygen 
and nutrients, angiogenesis is imperative for other stages in wound healing, such as epidermal 
and fibroblast migration and proliferation [30], which in turn help to maintain 
neovascularisation [31]. 
Endothelial cells from uninjured tissue move into the wound site to establish new blood 
vessels. Endothelial cells are attracted to the wound area by fibronectin and angiogenic 
factors released by other cells: angiogenin, fibroblast growth factor (FGF), and TGF-β [17, 
30, 32]. Secreted collagenases and plasminogen activators degrade the platelet-fibrin-
fibronectin clot, releasing growth factors (VEGF, PDGF, TGF-β, etc.) from the degranulating 
platelets. Matrix metalloproteinases (MMPs) digest the cell basement membrane and ECM to 
allow cell migration, proliferation and angiogenesis [33, 34]. Once the wound site obtains 
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adequate perfusion, the migration and proliferation of endothelial cells in and around the 
wound site gradually reduces [16, 24]. 
Fibroplasia and granulation tissue formation is simultaneous with angiogenesis; fibroblasts 
begin accumulating in the wound site as the inflammatory phase is ending. Within the first 
two or three days post-injury, fibroblasts mainly migrate to and proliferate with in the wound 
site; the origins of these fibroblasts are thought to be from the adjacent uninjured cutaneous 
tissue. About one week post-wounding, fibroblasts are the most abundant cell type in the 
wound [20, 23]. Recent evidence suggests that blood-borne circulating cell precursors known 
as fibrocytes or epithelial differentiated cells may contribute to the fibroblast population [35-
37]. Initially fibroblasts utilise the fibrin cross-linking fibers to migrate across the wound, 
subsequently adhering to fibronectin [18, 20]. Fibroblasts then deposit further ECM proteins 
into the wound bed; and later collagen, promoting adhesion and migration [38]. Granulation 
tissue consists of new blood vessels, fibroblasts, inflammatory cells, endothelial cells, 
myofibroblasts, and the components of a new provisional ECM [39, 40]. The new ECM 
consists of components including: fibronectin, hyaluronan (HA), collagen, 
glycosaminoglycans (GAGs), elastin, glycoproteins, and proteoglycans (PGs) [41, 42]. Later, 
this provisional matrix is replaced with an ECM that more closely resembles that found in 
non-injured tissue [12, 16, 41, 42]. Fibroblasts also secrete growth factors that encourage 
proliferation and attract epithelial cells to the wound site. Hypoxia also contributes to 
fibroblast proliferation and secretion of growth factors, although failure of angiogenesis and 
too little oxygen will inhibit their normal growth and result in unbalanced deposition of ECM 
components; leading to excessive scarring. 
Fibroblasts have the important duty of collagen production [12, 15]. Collagen deposition 
increases the strength of the wound, replacing the fibrin-fibronectin clot. Collagen provides 
extra resistance to future injury and allows cells involved in inflammation, angiogenesis and 
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connective tissue construction to attach, grow and differentiate on the collagen matrix [43, 
44]. Fibroblast deposition of type III collagen and fibronectin are the predominating tensile 
substances until the later phase of maturation, in which they are replaced by type I collagen 
fibres, which have greater tensile strength [45, 46]. Granulation gradually ceases and 
fibroblast numbers are reduced in the wound once the ECM has been produced. Fibroblasts 
undergo apoptosis, converting granulation tissue from an environment rich in cells to one that 
consists mainly of collagen [46]. This signals the onset of the later maturation phase. 
1.1.3 Contraction 
In contraction, the wound is made smaller by the action of myofibroblasts, which establish a 
grip on the wound edges and contract themselves using a mechanism similar to that in 
smooth muscle cells. Contraction is a key phase of wound healing; however, if contraction 
continues for too long, it can lead to disfigurement and loss of tissue function [47]. Thus, 
there is a great interest in understanding the biology of wound contraction [27, 48]. 
Contraction begins with fibroblast activity, but is more effectively completed when 
fibroblasts have differentiated into myofibroblasts. Myofibroblasts are responsible for 
contraction as they contain the same type of actin found in smooth muscle cells (α-smooth 
muscle actin; α-SMA) [49, 50]. Myofibroblasts are attracted by fibronectin and growth 
factors as they migrate over fibrin-fibronectin and the provisional ECM in order to reach the 
wound edges [51]. They form connections and anchor to the ECM at the wound edges, to 
each other, and to desmosomes along the wound edge. In addition, at an adhesion called the 
fibronexus, actin in the myofibroblast is linked across the cell membrane to proteins and 
GAGs in the extracellular matrix, including fibronectin, collagen and HA [52]. Since 
myofibroblasts form many adhesions, which allow them to pull the ECM when they contract, 
they are effective at reducing the wound size. As the actin within myofibroblasts contracts, 
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the wound edges are pulled together. Fibroblasts continue to support by laying down collagen 
to reinforce the wound as the myofibroblasts contract [16, 23]. The contraction stage ends as 
myofibroblasts stop contracting and begin to undergo apoptosis [47]. The breakdown of the 
provisional matrix leads to a decrease in HA and an increase in chondroitin sulphate GAGs, 
which gradually triggers fibroblasts and myofibroblasts to stop migrating and proliferating 
[53]. These events signal full progression into the maturation stage of wound healing. 
1.1.4 Maturation and Remodelling 
In the maturation and remodelling phase, collagen is realigned and any remaining redundant 
cells are removed by apoptosis. The primary step in wound maturation is the completion of 
re-epithelialisation, which starts during the latter stages of granulation tissue formation. The 
granulation tissue allows epithelial cells to migrate across the wound surface and form a 
barrier between the wound and the external environment [14-16]. Basal keratinocytes from 
the wound edges migrate (without first proliferating) across the granulation tissue-filled 
wound [41, 42]. Migration of keratinocytes over the wound site is stimulated by the lack of 
contact inhibition and the presence of nitric oxide [54]. Like fibroblasts, migrating 
keratinocytes use the fibrin-fibronectin clot that was deposited during inflammation as an 
attachment site [39, 41, 42]. As keratinocytes migrate, they must dissolve the clot, debris, and 
parts of the ECM in order to progress. This is achievable through the production of MMPs 
[55]. They also secrete plasminogen activator, which converts plasminogen into plasmin to 
dissolve the surrounding matrix and debris [56].  The growth factors released, stimulated by 
integrins and MMPs, cause cells to proliferate at the wound edges. Keratinocytes themselves 
also produce and secrete growth factors and basement membrane proteins, which aid in 
epithelialisation and in other phases of healing [57]. Keratinocytes continue migrating across 
the wound bed from either side until the wound has become reepithelialised. When they have 
finished migrating, the keratinocytes secrete the proteins that form the new basement 
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membrane and they revert to their static form through reversal of morphological changes they 
underwent to begin migration [16, 41, 57]. 
When the levels of collagen production and degradation reach equilibrium, the maturation 
phase of tissue repair is said to have begun. During maturation, type III collagen is replaced 
by type I collagen and disorganised collagen fibres are rearranged, cross-linked, and aligned 
along tension lines [45, 46]. The maturation phase can last for up to a year or even longer, 
depending on wound type [15, 16]. As the phase progresses, the tensile strength of the wound 
increases, with the strength approaching 50% that of normal tissue by three months after 
injury and ultimately becoming as much as 80% as strong as normal tissue [23].  
Although the division of wound healing into phases is a useful construct, this model employs 
considerable overlapping among individual phases. Recently, a complementary model has 
been described, such that the many elements of wound healing are more-clearly delineated. In 
this new model, cutaneous wound healing may be described in terms of an  ‘early phase’ and 
a ‘cellular phase.’ This description renders less overlapping of the many elements involved. 
In the early phase, haemostasis is accomplished and cytokines are released, initiating the 
inflammation process. In the cellular phase, an inflammatory response is mounted, the dermis 
is repopulated, wound coverage is achieved (re-epithelialisation) and a scar is formed. The 
importance of this new model becomes more apparent through its utility in the fields of 
regenerative medicine and tissue engineering [58]. 
1.2 Cellular Components of Wound Healing 
The process of wound healing involves a wide range of cell types. However, in fibrotic 
disease, progressive tissue fibrosis and chronic non-healing wounds, the fibroblast and its 
differentiated form, the myofibroblast, play pivotal roles in the pathological outcome. These 
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cells contribute to the speed and efficiency of normal wound healing, the extent of scar tissue 
formation, and wound contraction, closure and resolution. 
1.2.1 Fibroblasts 
A fibroblast is a type of cell that occupies the majority of connective tissue space in most 
animal species. This cell provides the structural framework of tissues through the synthesis of 
ECM proteins (e.g. collagens, GAGs and PGs) and biochemical mediators (e.g. growth 
factors and proteases). Fibroblasts play a critical role in the synthesis, degradation, and 
remodelling of the ECM; the normal functioning of these processes is necessary for efficient 
wound healing. Fibroblasts are derived from the primitive mesenchyme, and therefore 
similarly to other connective tissue cells, express the intermediate filament protein and 
marker of mesodermal origin; vimentin [59, 60].    
Regarding the origin of tissue fibroblasts, in vitro evidence for a bone marrow origin was first 
presented 4 decades ago [61]; colonies consisting of fibroblasts were identified through the 
culturing of bone marrow cells. These fibroblast colony forming units (CFU-Fs) were 
discovered to form fibroblast populations in a number of tissues, including bone marrow, 
spleen, thymus, lymph node, and peritoneal and pleural fluids. An alternative concept to the 
bone marrow mesenchymal stem cell (MSCs) origin of fibroblasts is the model of epithelial-
mesenchymal transition (EMT); the generation of fibroblasts from epithelium [62]. EMT is 
thought to be a fundamental mechanism in many embryonic and developmental processes. 
Epithelial cells detach from surrounding cells and following a sequence of growth factor or 
sensory stimulations develop into mesenchymal cells. Evidence for both mechanisms of 
fibroblast generation has been well documented. Hepatic stellate cells, pericryptal 
myofibroblasts in the intestine and colon, myofibroblasts in wounded skin, and fibroblasts in 
pulmonary fibrosis, were found to all be derived from bone marrow [63-65]. In contrast, 
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fibroblasts and myofibroblasts isolated from kidney and peritoneal tissue have been identified 
as originating from epithelial cell sources [62, 65, 66]. 
The characterisation of fibroblasts relies primarily on morphological, proliferative and 
phenotypical characteristics. Morphologically fibroblasts are flat, elongated, narrow and 
spindle-shaped cells, with multiple processes originating from the cell body. Although there 
has been much examination of the fibroblast phenotype in various organs, no exclusively 
expressed marker proteins have been identified [67]. This may contribute to the fibroblast’s 
inconspicuous persistence and presence in tissues, which could potentially result in 
complications such as fibrotic diseases. 
The locomotion of fibroblasts involves structural membrane extensions called filopodia and 
lamellipodia. Where these extensions meet the surface for adherence, firm and stable focal 
adhesions (FAs) assemble [68]. The machinery that powers cell migration and acts as anchor 
points for FAs is built from the actin cytoskeleton, the largest cell organelle. Radially 
oriented actin filament bundles are present at the leading edge of the migrating cell. Axial 
bundles, called stress fibers, underlie the cell body. In addition, a network of smaller 
individual actin filaments fills the rest of the cell [68]. 
The large actin filament structure that makes up the cell cytoskeleton is able to control the 
shape of the fibroblast and provides a framework that supports the plasma membrane. The 
actin cytoskeleton can alter cell morphology through assembly or disassembly of varying 
lengths of actin filaments. In migratory cells, the cytoskeleton must assemble rapidly and 
does not always have the chance to form highly ordered structures. This allows cells, such as 
the fibroblast, to tailor the actin framework to perform various tasks involving motion of the 
entire cell or sub-cellular parts [68]. 
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The richest area of actin filaments in a cell lies in the cortex, a narrow zone just beneath the 
plasma membrane. In this region, most actin filaments are arranged into a network that 
excludes most organelles from the cortical cytoplasm [68]. In fibroblasts, the cortical 
cytoskeleton of actin filaments is part of a three-dimensional network that fills the cytosol 
and anchors the cell to the substratum, through which sensory information, such as 
mechanical stress of tension, can be mechanotransduced from the adhesive surface into the 
cytoplasm via FA anchor points [68-70]. Mechanical stress or force-induced deformations in 
the surrounding ECM can lead to a cellular response, causing the production and release of 
excess cytokines resulting in the cell altering its morphology [71] to adapt to the conditions it 
is presented with. Upregulation of fibrogenic genes, involved in fibroblast to myofibroblast 
differentiation and excessive ECM protein production, are common responses when 
mechanical stress is introduced to the ECM scaffold on which fibroblasts are adhered [68, 71].   
Other than mechanotransduction, the major regulator of fibroblast-myofibroblast 
differentiation is the stimulation of cell surface receptors (Alk5/transforming growth factor-β 
receptor I; TGF-βRI) by transforming growth factor-β1 (TGF-β1) [50, 72-74]. In wound 
healing, degranulating platelets release TGF-β1 into the surrounding tissue [14, 25, 75]. 
When fibroblasts become activated by TGF-β1, profibrogenic genes are activated for 
transcription. The fibroblast then begins to produce excessive amounts of ECM proteins, 
proteinases, and cytoskeletal proteins [12, 41, 46, 48]. The definitive marker of fibroblast 
activation is the upregulation of α-SMA [49, 74], the upregulation of which grants the cell 
contractile abilities and is attributed to the term ‘myofibroblast’ used to describe the activated 
fibroblast as an intermediate cell between a resting fibroblast and smooth muscle cells [49, 74, 
76].  
The successful generation of ECM components by fibroblasts is pivotal to the successful 
resolution and closure of a wound. The ECM proteins facilitate the attachment and migration 
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of many cell types and provide wound site integrity [77-79]. The production of ECM proteins 
is rapid as the fibroblasts proliferate to fill the wound space, creating a network within 
granulation tissue [76, 80]. Specific ECM components, such as fibronectin, collagens, and 
HA, help support the adhesion and integrity of the tissue. Fibronectin links cell surface 
integrins and cell adhesion molecules to collagens and ECM proteins, aiding attachment and 
migration of cells [81, 82]. Collagen provides tensile strength whilst HA confers tissue 
resistance to compression, by providing a turgor swelling force due to the binding of water 
molecules [83, 84].  
Secretion of growth factors (bFGF, VEGF, TGF-α, TGF-β) self-stimulate fibroblasts and 
activate surrounding cells, signalling changes in gene expression and maintaining cell 
viability in the surrounding tissue, whilst attracting new cells to the wound space [16, 57, 80]. 
Morphological changes and phenotypic transitions occur within fibroblasts, influenced by a 
number of factors (as described above) and resulting in the reorganisation of the actin 
cytoskeleton into large bundles of fibers (parallel, terminating at the cell periphery) and an 
increase in the number and thickness of stress fibers [49, 74]. Changes in the distribution and 
composition of stress fibers can influence further alterations in FAs; the formation of super-
mature FAs. These include the proteins: tensin, α-SMA, extra domain-A fibronectin (EDA-
FN), and α5β1 integrin [50, 85]. TGF-β1 stimulation in particular has been described as being 
the major cytokine responsible for driving the differentiation of fibroblasts into an activated 
and contractile phenotype: myofibroblasts [22, 74]. Myofibroblasts, in addition to β- and γ-
actin, express α-actin [49], synthesise excessive ECM proteins (fibronectin, collagens, elastin, 
GAGs, and PGs), and release remodelling enzymes (MMPs, tissue inhibitors of 
metalloproteinases; TIMPs) and growth factors (MCP-1, IL-1, IL-6, IL-8, TGF-β1, HGF, 
EGF), to increase the stability of the granulation tissue and activate the surrounding cells [16, 
17, 39, 57].  
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The gain of contractile properties and the increased production of FA sites on the 
myofibroblast cell membrane grant the ability of the cell to anchor the wound edge and begin 
wound contraction i.e. pulling the wound closed [48, 74]. Decreasing the surface area of the 
wound exposed to the external environment allows the migration of keratinocytes to cover 
the wound for re-epithelialisation. Myofibroblasts are important cell types in the process of 
wound healing, however, in fibrotic disease, myofibroblasts are thought to promote the 
pathological process by contributing to the increased synthesis and contraction of ECM 
characteristic of the disorders [72, 73, 86, 87]. 
1.2.2 Myofibroblasts 
Myofibroblasts are specialised cells within the body that aid in normal wound healing 
processes by exerting large contractile forces on their microenvironment with the primary job 
of assisting in the closure of wounds.  The myofibroblast could be considered the primordial 
emergency cell contributing to ECM production and tissue remodelling. However, aberrant 
and chronic activation of myofibroblasts can lead to the development of pathological 
conditions including fibrosis, disease progression and the induction of the tumour stroma 
reaction lending to cancer invasiveness [72, 86, 88]. 
Myofibroblasts are important contributors to scar tissue formation and wound closure [49, 52, 
74], but can severely impair organ function when they persist within the wound due to 
excessive contraction and ECM protein secretion. Examples of conditions central to 
myofibroblast activity include hypertrophic scars, scleroderma and Dupuytren’s disease, as 
well as in heart and kidney fibrosis [76, 89, 90].  Moreover, myofibroblasts present in the 
stroma reaction of epithelial tumours may promote the progression of cancer invasion [88].  
Morphologically, myofibroblasts have characteristic flattened, irregular shapes that are large 
in comparison to most cells; and well-developed cell-matrix interactions and intracellular gap 
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junctions [89, 91]. They can be distinguished by their increased expression of EDA-FN and 
in some cases, their ability to express other markers of smooth muscle cells, such as desmin, 
calponin and smooth muscle myosin [92].  
Myofibroblast differentiation is a complex phenomenon that follows a distinct pattern and 
effect in many different organs. To therapeutically counteract the organ dysfunction caused 
by myofibroblasts, it is crucial to understand the cellular events and signalling pathways 
regulating their commencement and function, to distinguish the mechanisms common to all 
situations from those specific to a given organ or disease. 
The origins of myofibroblasts may be very heterogeneous (Figure 1.1). However, the 
transformation of cells into a myofibroblastic phenotype follows a well-documented cascade 
of events, resulting in upregulation of pro-fibrotic genes and proteins. The fibroblast is a 
definitive source of myofibroblasts [48-50, 74, 93]. Following tissue injury, activated 
fibroblasts migrate into the damaged tissue and to upregulate the synthesis of ECM 
components, triggered by locally released cytokines from inflammatory or resident cells. 
Another important stimulus for this phenotypic activation is the change of the mechanical 
microenvironment. Fibroblasts in intact tissue are stress-shielded by the crosslinked ECM, 
however in injured tissue, the continuous remodelling of the wound environment and ECM 
results in a loss of protective function against stress [29, 47, 68, 71]. In response to 
mechanical challenge, fibroblasts acquire contractile stress fibers that are first composed of 
cytoplasmic actins, hallmarking the “protomyofibroblast.” Stress fibres can connect to fibrous 
ECM proteins at sites of integrin-containing, cell-matrix junctions and adherens junctions [47, 
52]. These features where identified when cultured fibroblasts were mechanically activated 
by the rigid plastic substrate, whereas stress fibers did not form on soft culture substrate 
hydrogels or in compliant collagen gels [47, 89]. 
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In culture, the ‘protomyofibroblast’ is a stable phenotype [89], representing an intermediate 
step in most in vivo conditions that is proceeding towards the fully differentiated 
myofibroblast. Expression of α-SMA in stress fibres of myofibroblasts confers at least a 
twofold stronger contractile activity, compared with α-SMA-negative fibroblasts in culture 
[94]. At least three local events have been shown to generate α-SMA-positive differentiated 
myofibroblasts: the accumulation of biologically active TGF-β1, the presence of specialised 
ECM proteins (e.g. EDA-FN) and high extracellular mechanical stress [40, 47, 50, 74].  
Figure 1.1. Various sources of fibroblasts derive from processes such as differentiation (circulating 
blood fibrocytes, satellite fibroblasts, bone-derived mesenchymal stem cell (MSCs), hepatic stellate 
cells (HSCs), and kidney pericytes), dedifferentiation of smooth muscle cells (SMCs), and epithelial to 
mesenchymal transition (EMT) of epithelial and endothelial cells. With the stimuli of mechanical stress 
or TGF-β1, fibroblasts transform into protomyofibroblasts (morphological change, focal adhesion 
kinase (FAK) and cortical and cytoplasmic actin generation). Further mechanical stress, TGF-β1, and 
EDA-fibronectin stimuli can drive protomyofibroblasts toward the terminally differentiated 
myofibroblasts (expressing α-smooth muscle actin; α-SMA, and large FAKs). Whether or not fully 
differentiated myofibroblasts can dedifferentiate into fibroblasts is not known. Image was adapted from 
Hinz et al. 2007 [127], and Tomasek et al. 2002 [130]. 
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Mechanoperception is mediated through specialised cell-matrix junctions, the fibronexus in 
vivo, or supermature FAs in vitro [47, 52]. With regards to myofibroblast contractile ability, 
ECM rigidity determines the size of the cell’s anchors, which in turn limits the level of 
tension generated within stress fibres [47, 89]. Only when substrate stiffness permits 
formation of supermature FAs (8-30μm long) and the generation of approximately fourfold 
greater stress compared with usual FAs (2-6μm long), does α-SMA become incorporated into 
pre-existing cytoplasmic β-actin stress fibers [95]. Hence, α-SMA can be considered a 
mechanosensitive protein. The myofibroblast cytoskeleton can function as a 
mechanotransducer, translating mechanical tension into biochemical signals involving 
tyrosine phosphatase and kinase pathways – as shown in force-induced p38 phosphorylation 
[96, 97]. Cell adhesion signalling via FA kinase (FAK) represents another pathway through 
which biochemical and biophysical ECM signals as well as soluble growth factor signals are 
integrated [69, 70]. The main myofibroblast inducer, TGF-β1, up-regulates expression of 
fibronectin and its integrin receptors in fibroblasts; this is linked to activation of FAK [98-
100]. At the end of tissue repair, the reconstructed ECM resumes control over the mechanical 
load, this stress release is a powerful promoter of myofibroblast apoptosis in vivo [101]. 
Therefore, interrupting the mechanical feedback loop of myofibroblast contraction and 
gradually increasing ECM tension at the level of stress perception (i.e. cell-ECM contacts) is 
one promising strategy to prevent tissue contracture. 
To prevent myofibroblast formation in the first place and help prevent the subsequent 
propagation of fibrosis, knowledge of the origins of myofibroblasts is required. Depending on 
the type of tissue to be remodelled, myofibroblast precursor cells are recruited from different 
sources; among these, locally residing fibroblasts seem to be the most common [102]. Other 
mesenchymal cells sources suggested include pericytes and SMCs [103]; SMCs have been 
suggested to contribute to fibrosis in scleroderma [104]. In addition, bone marrow (BM)-
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derived circulating cells known as fibrocytes (cells expressing CD45, CD34, collagen I and 
CXCR4 markers) [105] have been suggested as a myofibroblast source during wound healing 
of skin, liver, lungs, and kidneys [106-109]. Finally, myofibroblasts have been shown to 
derive from EMT [110, 111]. Damaged organs seem to recruit myofibroblast precursors from 
several sources to satisfy the temporarily high demand of tissue remodelling cells; however 
the two latter cases have been subject to much debate. 
Examples of mixed fibroblast and myofibroblast origins can be seen in early studies in lung 
injury and fibrosis. The perivascular and peribronchiolar adventitial fibroblasts have been 
suggested as precursors [112], whereas other studies have demonstrated that BM-derived 
fibrocyte progenitors gave rise to lung fibroblasts [63, 113]. However, BM-derived 
fibroblasts to myofibroblast differentiation could not be demonstrated in some studies [63, 
114]. Thus, the evidence for BM-derived myofibroblasts in organ fibrosis is controversial, 
suggesting instead that there are potentially multiple origins. Additional possibilities include 
EMT; as has been demonstrated in studies in vitro and in vivo [110, 111, 115, 116]. However, 
again there are studies where EMT could not be demonstrated [117]. Therefore the relative 
contribution by these different potential sources of myofibroblasts requires further study. 
The fate of recruited and activated myofibroblasts in injured tissues may ultimately determine 
whether normal healing occurs or progression to end-stage fibrosis ensues. Resolution with 
myofibroblast apoptosis would terminate progression, however, persistence of TGF-β1 
expression, ECM deposition and accumulative stress-induced FAK, promote pro-survival and 
anti-apoptotic phenotypes [118-120]. Selective susceptibility of myofibroblasts to nitric 
oxide-induced apoptosis has been reported in vitro [120]. Therefore, a reduction in growth 
factor expression, increased ECM turnover and nitric oxide generation may set the stage for 
triggering myofibroblast apoptosis during resolution of tissue repair and remodelling. Future 
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studies into the physiological triggers for myofibroblast apoptosis could potentially lead to 
identification of novel, more effective therapies for chronic fibrotic diseases. 
In the liver, the most accepted myofibroblast progenitors are hepatic stellate cells (HSCs), 
which become activated and differentiate into myofibroblasts, in response to various factors 
including reactive oxygen species (ROS) and growth factors [121, 122]. Concomitantly, 
HSCs up-regulate the expression of key inflammatory receptors, including intercellular 
adhesion molecule-1 (ICAM-1) and toll-like receptor 4 (TLR4) [123]. Paracrine and 
autocrine-produced TGF-β1 is the most potent pro-fibrogenic cytokine capable of activating 
HSCs [124]. In addition to HSCs, other resident cells of organs have recently been described 
as sources of myofibroblasts: portal fibroblasts, parenchymal cells and second-layer 
fibroblasts in liver fibrosis [122, 125, 126]; and pericytes in kidney fibrosis [127]. 
Dedifferentiation of SMCs and the questions of their potential myofibroblastic nature have 
been raised [103]. Presently, it is well accepted that myofibroblasts share with SMCs the 
expression of α-SMA, which is considered an early differentiation marker of vascular SMCs 
[128]. Unlike SMCs, however, myofibroblasts express relatively low amounts of smooth 
muscle myosin heavy chain and do not express smoothelin, a late marker of SMC 
differentiation [129]. SMC-to-myofibroblast transition becomes relevant in view of recent 
work indicating that during fibrotic situations, myofibroblasts develop the capacity of 
producing a long-lasting tension essentially regulated at the level of Rho/Rho kinase-
mediated inhibition of myosin light chain phosphatase, compared with the usual contraction-
relaxation activity depending on Ca2+-induced phosphorylation of myosin light chain kinase 
taking place in SMCs [130]. 
Less is known about the role of myofibroblasts during embryological development. Early 
embryological and scarless wound healing indicates an absence of myofibroblasts. The 
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transition from scarless tissue repair to healing with scar formation that occurs during late 
gestation has been shown to be accompanied by an increased presence of myofibroblasts in 
the wound environment [131].    
Although it seems that TGF-β1 together with mechanical stress play important roles in 
fibrosis development, much less is known about factors inhibiting myofibroblast activities 
and the control of fibrosis. Interferon-γ (IFNγ), bone morphogenic protein-7 (BMP-7), and 
hepatocyte growth factor (HGF) have been shown to exert such actions, possibly through 
anti-TGF-β1 effects [115, 132-134]. The α-SMA N-terminal peptide AcEEED reduces force 
generation by the myofibroblast and exerts an anti-fibrotic activity through its capacity to 
displace α-SMA from stress fibers [135]. Utilisation of these tools and the discovery of novel 
methods to control myofibroblast function will be useful for studying mechanisms regulating 
tissue remodelling and the invalidating diseases characterised by the development of fibrosis. 
Delineating the mechanisms of myofibroblast activation seems indispensable for designing 
rational therapeutic strategies to inhibit the fibrogenic processes of organ fibrosis or to 
promote effective wound healing in chronic non-healing wounds. 
1.3 Wound Repair Versus Regeneration 
An injury is the disturbance of morphology and functionality of a tissue. When injury and the 
associated inflammatory response have resulted in the death (necrosis) of specialised cells 
and damage to the surrounding ECM, steps must be taken to replace dead cells with healthy 
tissue. This response is referred to as healing and comprises two processes. The first involves 
the replacement of specialised tissue by proliferation of surviving cells or infiltration of 
precursor cells. The second response is a reparative process and entails a connective tissue 
synthesis response characterised by the formation of granulation tissue and its subsequent 
maturation into fibrous tissue. The relative roles of both processes vary depending on tissue 
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type, with some tissues showing increased propensity to heal through either regeneration or 
repair. 
The difference between wound repair and regeneration is subtle. Repair refers to the 
physiologic adaption of a tissue to injury in an attempt to restore structural continuity without 
regards to exact replacement of lost or damaged specialised tissue. True tissue regeneration is 
defined as the replacement of lost or damaged tissue with an exact copy, i.e. morphologically 
and functionally restored into the exact condition of the original tissue. In some instances 
such as with the skin, partial regeneration may be induced through the use of biodegradable 
(collagen-GAG) scaffolds [136, 137]. These scaffolds are structural analogues of the ECM 
found in uninjured dermis. In addition to providing support for fibroblast and endothelial cell 
attachment, biodegradable scaffolds inhibit wound contraction, thereby granting the time 
needed for the healing process to proceed towards a regenerative and scarless pathway. One 
other such method to prevent wound contraction may be in disabling myofibroblast 
differentiation, which has been investigated through the use of pharmaceutical agents [93, 
138]. However, dermal tissue is also capable of healing with excessive and unregulated 
scarring, such as that found in hypertrophic and keloid scars. Injuries, such as burns, can 
occur over very important flexural joint surfaces, leading to contractures resulting in severe 
restriction of movement and functional disability. The liver best illustrates another example 
of partial regeneration. In experimental animal models, it was shown that when large amounts 
of the liver were removed surgically, the remaining parenchyma regenerated to a normal and 
sufficient mass, structure, and function [139]. In acute liver injury, there may be mass 
necrosis of hepatocytes, however, in most cases complete regeneration occurs with almost 
full restoration of liver architecture [139-141]. In contrast, repeated insults in chronic liver 
injury lessen the regenerative ability of hepatocytes, resulting in the substantial accumulation 
of fibrous tissue constituting hepatic cirrhosis [134, 142, 143]. 
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In tissues such as lung, kidney and cardiac tissue, the healing process is dominated by a 
connective tissue response. Production of fibrous tissue leads to pathological scarring of the 
implicated organ or tissue. This is a sub-optimal response, although healing may have 
restored structural defect of the tissue, it has impaired function as specialised cells have been 
replaced with dense ECM and fibrous tissue. The outcome is also affected by the nature, 
severity, and duration of the injury. Interestingly, fundamental conditions required for tissue 
regeneration often oppose conditions that favour efficient wound repair; including the 
inhibition of platelet activity, low levels of inflammatory cells and their mediators (IL-6, IL-
8), and prevention of wound contraction. These conditions are present in the early-gestation 
foetus, which heals skin wounds without scar formation [144]. This observation was 
confirmed in both animal models and human foetuses [145, 146]. Additionally, foetal 
fibroblasts display unique patterns of intracellular signalling and demonstrate differences in 
the composition and generation of ECM components, such as collagens and hyaluronan [147, 
148]. The only tissue in adults that demonstrates what can be definitively classed as 
regeneration is the oral mucosa. In addition to healing in a scarless manner, oral mucosal 
wounds heal rapidly, comparable to foetal wounds [149, 150].  However, whilst regeneration 
of all tissues would be preferable, the absent conditions listed above that may contribute 
toward regeneration, are very important in the wound healing process and the prevention of 
the formation of chronic wounds.  
1.3.1 Chronic Disease in Wound Healing 
As the average lifespan of the general population increases, the problems of some diseases 
are shifting toward association with the ageing population - from communicable disease to 
chronic diseases. Chronic conditions have become the leaders in world mortality rates; with 
approximately 63% of all deaths attributed to chronic conditions; and only 25% of those 
deaths being in individuals under the age of 60 [151]. Chronic diseases have become the 
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major contributor to disability, affecting the quality of life of sufferers and their relatives. 
Another problem arises in the costs of healthcare; the annual cost for overall management of 
chronic wounds in the US alone is greater than $20 billion, not including the additional costs 
to society in terms of lost workdays or productivity [152]. Prevalent forms of chronic disease 
associated with wound healing include chronic non-healing wounds and progressive fibrosis; 
both pose a challenge for therapeutic treatments. 
1.3.2 Non-healing Chronic Wounds 
Chronic wounding occurs when the phases of wound healing, which normally progress in a 
predictable and timely manner, become dysfunctional. Healing may progress inappropriately 
to a chronic wound such as venous or diabetic ulcers, peripheral arterial disease, or pressure 
ulcers. Since wound healing consists of complex phases with several steps to each, it is 
susceptible to interruption or failure of scar formation, leading to the formation of non-
healing chronic wounds. Factors which may contribute to this include diabetes, venous or 
arterial disease, old age and chronic infection [153-155].  
Non-healing chronic wounds result from wound healing becoming detained in one of the 
earlier phases; commonly, wounds remain within the inflammatory phase for too long [23]. 
Since chronic wounding often lasts months or years, treatment and management of the pain 
associated usually takes priority over the treatment of the underlying problems [156]. The 
molecular causes of chronic wounds can be multiple; rapid degradation of ECM components 
or dysregulated collagen synthesis by fibroblasts can lead to an inadequate matrix to support 
angiogenesis, cell adhesion, and migration [23, 157]. The persistence of bacterial infection 
and the release of their toxins and proteases can severely inhibit the activity and function of 
surrounding cells and proteins [154]. Suppression of the immune system can result in chronic 
infection and insufficient removal of cellular debris leading to cytotoxicity [25, 158]. Loss of 
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cellular function through ageing or senescence can play a large role in the inability of wounds 
to heal [13]. In the context of ageing, the skin of older people is more easily damaged due to 
weakened matrix integrity. Aged cells become slow to proliferate and have increased 
resistance to growth factor stimulation; this in turn leads to insufficient gene upregulation and 
protein synthesis [159, 160]. The advances in treating age-related chronic wounds are lagging 
behind other fields of disease research, one of the contributing factors to this is that animal 
models of age-related chronic wounding are difficult to generate. Animal models usually 
have life spans that are too short to develop chronic disease naturally [161]. Therefore, cell-
based models of age-related wound healing are a useful method for studying the underlying 
cellular mechanisms and dysfunction that arise from chronic non-healing wounds. An 
inadequate supply of growth factors can also contribute to chronic wounding. Growth factors 
are essential for timely wound healing; an inadequate supply can lead to dysfunctions in 
fibroblast ECM secretion and differentiation as well as keratinocyte re-epithelisation [80]. 
Diabetic ulcers are often attributed to the inability of fibroblasts to respond to growth factors, 
due to the conditions of the wound environment [162]. The longer the chronic wound persists, 
the more generations of fibroblasts are cycled through, thus senescence and debilitated 
growth factor responses become a more evident and real problem. Replacement of the 
inadequate supply of growth factors may help speed the healing process, through increased 
stimulation of the cells in the surrounding healthy tissue, e.g. fibroblasts [13, 57, 80, 153].   
1.3.3 Fibrosis  
Progressive tissue fibrosis arises due to failure of the normal wound healing response to 
terminate and resolve [46, 50]. Progressive and excessive fibrosis is a key component of 
numerous chronic diseases and can result in an array of clinical conditions. Fibrosis is 
defined as the formation of excess fibrous connective tissue and its contraction in an organ or 
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tissue, during a reparative or reactive process. Scarring is confluent fibrosis that obliterates 
the architecture and heavily impairs functionality of the underlying organ or tissue.  
Less severe fibrosis forms cosmetically undesirable or disfiguring scars. However, more 
severe cases of fibrotic disease lead to tissue destruction, dysfunction and/or death from 
organ failure. Many clinical conditions are a result of progressive fibrosis, including 
pulmonary fibrosis, chronic kidney disease, liver cirrhosis, biliary atresia, retinopathy, 
macular degeneration, congestive cardiac failure, scleroderma, hypertrophic or pathological 
scarring, such as a keloid scars [85-87, 163-167]. In progressive organ fibrosis, the initial 
injury is responded to as normal with the activation of resident cells and the inflammatory 
cytokine release. The infiltrating inflammatory cells produce ROS, and fibrogenic and 
inflammatory cytokines [168, 169]. Fibroblasts migrate into the wound site, proliferate and 
undergo phenotypic activation. A large amount of ECM is synthesised and deposited by the 
activated fibroblasts and myofibroblasts. Resolution of the granulation tissue and the wound, 
however, does not occur. Therefore, fibroblasts persistently produce excessive ECM leading 
to qualitative changes in its composition, i.e. more collagen type III and I. Generation of 
components that would not usually be found in the wound space are also produced, including 
splice variants of fibronectin and laminin [170]. Over time, the disorganised ECM becomes 
cross-linked and resistant to degradation, cell penetration, and may prevent growth factors 
functioning correctly [88]. It is not completely clear as to why the usually self-limiting 
normal healing response fails and instead the progressive fibrotic response is presented. 
Fibrosis can be driven by many fibrogenic factors; their release contributes to the progressive 
nature of fibrosis. These include TGF-β1, connective tissue growth factor (CTGF), VEGF, 
angiotensin II, FGF, PDGF and IL-1 [76, 171-176]. TGF-β1 is the most widely implicated in 
tissue fibrosis and its aberrant expression is a universal finding in virtually every type of 
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fibrotic disease [50, 72, 73, 171, 177]. However, TGF-β1 has many functions; it is able to 
stimulate its own production, stimulate differentiation, and ECM synthesis and deposition. 
Understanding the cellular factors involved in ECM generation and turnover is crucial in 
determining the pathogenic mechanisms underlying progressive fibrosis and may provide 
novel insights into developing new therapeutic strategies. 
1.4 Transforming Growth Factor-β1 
Cytokines and growth factors are important regulators of wound resolution and tissue repair. 
The cytokine that is central to both initiation and termination of tissue repair is TGF-β. In 
mammals, TGF-β exists in three isoforms with almost identical biological properties and 
targets. Encoded by different genes, the three isoforms: TGF-β1, TGF-β2, and TGF-
β3, activate similar receptors and intracellular signalling pathways [178-180]. Although 
important for successful wound healing, persistent expression of TGF-β1 can promote the 
development of tissue fibrosis and progression. TGF-β1 is the isoform most extensively 
studied and has the highest expression in fibrosis, correlating with the severity of progressive 
fibrosis [178].  
TGF-β1, a member of the transforming growth factor-β super-family is a secreted protein that 
performs many cellular functions, including the control of cell growth, proliferation and 
differentiation. In humans, the TGF-β1 gene encodes TGF-β1. Dysregulation of TGF-β1 
activation and signalling may result in apoptosis [181]. Many cells synthesise TGF-β1 and 
have specific receptors on their cell surface for this peptide. TGF-β1 was first identified in 
human platelets as a protein with a molecular mass of 25 kilodaltons (kDa), and an important 
role in wound healing. It was later characterised as a large protein, synthesised as an inactive 
390 amino acid precursor that is secreted as a large latent complex, covalently bound with 
latency associated peptide (LAP); and stored in an inactive form in the matrix. The inactive 
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form of TGF-β1 is proteolytically processed to produce a bio-active mature peptide of 112 
amino acids [179].  
TGF-β binds to at least three membrane receptor proteins, TGF-β receptor (TGF-βR) I, II, 
and III. They can exist in homo- or heterodimers. The type I and II receptors are 
transmembrane serine-threonine kinases that typically interact with one another to form a 
heterodimer in order to facilitate signalling [182]. The type III receptor, also known as 
betaglycan, is a membrane anchored PG with no signalling structure but can act to present 
TGF-β to the other receptors on the cell surface [183]. When TGF-β interacts with these 
receptors, a cascade of intracellular signalling results in altered gene transcription profiles. 
The principal route of activation is through the Smad signal transduction pathway [184]. 
However, TGF-β has also been described to recruit alternative pathways including the 
epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 and 2 (MAPK; 
ERK1/2), Rho-GTPase, protein kinase B, and the Akt/mTOR pathway [160, 185-187].    
TGF-β1 shows a diverse range of different activities on different types of cell depending on 
biological context, or cells at different developmental stages. Many cells secrete TGF-β1 
including fibroblasts, myofibroblasts and most immune cells (leukocytes) [188, 189]. The 
TGF-β family also play important roles in controlling the immune system, the inflammatory 
response and foetal development [190, 191]. Specifically TGF-β1 is a known promoter of 
fibroblast terminal differentiation and EMT; upregulating α-SMA expression in vitro and in 
vivo [192]. The production and secretion of fibronectin, collagens, and matrix turnover 
proteins (MMPs and TIMPs) are also processes regulated by TGF-β1 signalling [193].  
The traditional TGF-β signalling cascade involves the binding of TGF-β1 to TGF-βRI 
otherwise known as Alk5, which upon activation forms an active heterodimer with TGF-βRII 
[182]. The subsequent phosphorylation of targets follows a well-documented cascade event, 
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first through the phosphorylation of Smad2 and Smad3. When bound to co-Smad4, this 
Smad-signalling complex translocates to the nucleus where in it acts as a transcription 
regulator, binding target sites on gene promoters and either enhancing or suppressing gene 
transcription [184]. A classic gene target of TGF-β1 signalling includes SERPINE1, which 
encodes for the protein plasminogen activation inhibitor 1 (PAI-1), the expression of which is 
often used as a marker of TGF-β1 activity [194]. 
TGF-β-Smad signalling is an essential phase in the differentiation of fibroblasts to 
myofibroblasts. The signalling mechanism underlying the genesis of the myofibroblast is 
complex; with respect to the TGF-β1-Smad signalling pathway, the presence of the Smad3-
binding element is important for myofibroblast differentiation and oral mucosal fibroblast 
proliferation [195, 196]. Despite shared expression, the regulation of the α-SMA gene in 
fibroblasts is more complex and in many respects different from that in SMCs [197]. In 
addition to transcriptional inducers, suppressors may have a higher basal activity in 
fibroblasts, compared to SMCs; and serve to keep the fibroblast in an undifferentiated state 
under normal homeostasis.  
Dysregulation of TGF-β1 action has been implicated in a variety of pathological processes, 
including cancer and autoimmune diseases; and its involvement in progressive tissue fibrosis 
has been confirmed in human disease and in numerous models of animal disease [72, 73, 178, 
198]. Its fibrotic actions have been attributed to its combined abilities to induce fibroblast 
differentiation, epithelial cell trans-differentiation and to promote accumulation of matrix 
proteins, including collagens, fibronectin and PGs. As discussed above, TGF-β1 also induces 
production of TIMPs and inhibits some MMPs and plasmin protease generation, thereby 
preventing matrix degradation and contributing to the fibrotic process [168]. Furthermore, it 
modulates expression of FA molecules that contribute to intracellular signalling, 
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mechanotransduction, stress generation; and facilitate cell-matrix adhesion and matrix 
deposition [77, 119].  
Additional evidence supporting the pro-fibrotic role of TGF-β1 was shown in vivo, where 
treatment of foetal wounds with exogenous TGF-β1 promoted scarring [131, 145]. 
Additionally, incisional rat wounds treated with anti-TGF-β1 antibodies or anti-sense 
nucleotides were shown to suppress ECM synthesis and scarring [199]. However, TGF-β1 
knock-out mice models have been shown to have a high rate of intra-uterine death [200], 
indicating the important role of TGF-β1 in development and cell survival. The few that 
survived to birth later died of a multi-focal inflammatory syndrome [201], signifying a TGF-
β1 role in modulating immune and inflammatory cell types. Furthermore, mice heterozygous 
for TGF-β1 deletion, although demonstrated a normal phenotype at birth had a greatly 
increased frequency of carcinoma formation, when challenged with carcinogens [202]. These 
studies highlighted the potential challenges relating to the direct targeting of TGF-β1 in anti-
fibrotic treatments. Therefore, further detailed characterisations of responses involved in the 
modulation of TGF-β1 actions are necessary to develop more selective, clinically appropriate, 
anti-fibrotic therapies.  
1.5 The Extracellular Matrix 
The ECM is the non-cellular, structural complex present within all mammalian tissues and 
organs. The ECM provides essential physical scaffolding for cellular constituents and can 
initiate crucial biochemical and biomechanical signals that are required for tissue 
morphogenesis, homeostasis, cell differentiation, migration and adhesion. 
ECM components are synthesised by a variety of mesenchymal and parenchymal cells. Its 
extracellular distribution can be in the form of cell-associated pericellular matrices and 
structures that surround the periphery of cells; or in the form of a more extensive intracellular 
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matrix, which surrounds, connects and adheres to the connective tissue cells. The principal 
components that make up the ECM are collagens, elastin, structural glycoproteins, PGs and 
GAGs. The formation of ECM is an important event during both tissue repair and fibrosis; 
and an understanding of how various constituents may be involved in the regulation of 
cellular processes may provide valuable insights into the pathological mechanisms underlying 
progressive tissue disease and fibrosis. The importance of the ECM is vividly illustrated by 
the wide range of syndromes with varying degrees of severity that can arise from genetic 
abnormalities in ECM proteins [203]. Although fundamentally, the ECM is composed of 
water, proteins and polysaccharides, each tissue has an ECM with unique composition and 
topology that is generated during tissue development through a dynamic and reciprocal, 
biochemical and biophysical dialogue between the various cellular components (e.g. 
epithelial, fibroblast, adipocyte, endothelial elements); and is adapted to suit the specific 
cellular and protein microenvironment functionality [204].  
1.5.1 ECM Turnover 
The tissue remodelling enzymes, MMPs and ADAMs (a disintegrin and metalloproteinases), 
are endopeptidases central to the degradation and remodelling of the ECM. These proteases 
can also exhibit regulatory activity in cell signalling pathways, under normal conditions and 
in many diseases [205]. The process of connective tissue remodelling is an important 
mechanism contributing to tissue homeostasis and morphogenesis in development; and when 
in unbalance, can lead to disease states including progressive tissue fibrosis.  
MMPs were discovered because of their role in amphibian metamorphosis, yet they have 
attracted more attention because of their roles in disease. Despite intensive scrutiny in vitro in 
cell cultures and in vivo in animal models, the normal physiological roles of MMPs remain 
elusive. Recent studies in mice and flies point to essential roles of MMPs as mediators of 
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change and physical adaptation in tissues, whether developmentally regulated, 
environmentally induced, or disease associated. An example of how MMPs contribute to 
disease progression is through the upregulation of MMP-2 and MMP-3. These can promote 
tissue fibrosis through the processing of pro-MMP-9, an enzyme involved in the activation of 
pro-fibrotic cytokine activity [206]. 
The MMPs are inhibited by specific endogenous TIMPs, which comprise a family of four 
protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4. Overall, all MMPs are inhibited by 
TIMPs once they are activated, except the gelatinases (MMP-2 and MMP-9), which can form 
complexes with TIMPs [207] when the enzymes are in the latent form. However, the roles of 
MMP/TIMP complexes are largely unknown. TIMP activity has been implicated in 
promotion of tissue fibrosis through mechanisms, in response to TGF-β1-stimulated 
invasiveness and proliferation of pro-fibrotic cells. For example, the imbalance of TIMP-2 
expression to MMP-2 and MMP-4 in the liver can lead to dysregulation of tissue turnover 
and progressive liver cirrhosis [208]. Therefore, TIMPs and MMPs can fine-tune the outcome 
of healing and fibrosis; and identification of their activation and inhibitions mechanisms 
could help reveal potential routes for fibrotic disease management.   
The ADAM family of peptidase proteins, also known as the adamalysin family or MDC 
family (metalloproteinase-like, Disintegrin-like, cysteine rich) are classified as “sheddases,” 
because they shed extracellular portions of transmembrane proteins [209]. For example, 
ADAM10 can remove part of the HER2 receptor, resulting in its activation [210]. Studies in 
mouse models have shown that ADAM-TS1 is upregulated with collagen accumulation in 
myocarditis and is involved in collagen metabolism. Thus, dysregulation can lead to the 
development of myocardial fibrosis [211]. Development of therapeutic ADAM inhibitors 
could potentiate anti-fibrosis and anti-cancer therapy [34, 212]. 
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Hyaluronidases are a family of enzymes that degrade HA. In humans, there are six associated 
genes, the main genes being HYAL1, HYAL2 and HYAL3 [213]. By catalysing the 
hydrolysis of HA, hyaluronidase lowers the viscosity of HA thereby increasing tissue 
permeability. Hyaluronidases are therefore implicated in bacterial pathogenesis, the spread of 
toxins and venoms, the acrosomal reaction/ovum fertilisation, and cancer progression [214-
218]. Hyaluronidases are typically expressed alongside high expression of HA and are 
thought to maintain and regulate hyaluronan chain length, deposition and function.  
Hyaluronidases are known to be involved in physiological and pathological processes, 
ranging from fertilisation to ageing. Depolymerisation of HA adversely affects the role of the 
ECM as a reservoir of growth factors, cytokines and various enzymes involved in signal 
transduction [219]. Hyaluronidase inhibitors are potent ubiquitous regulating agents that are 
involved in maintaining the balance between the anabolism and catabolism of HA. 
Hyaluronidase inhibitors can also serve as contraceptives, anti-tumour agents, and could 
possibly have antibacterial activities [220].  
The role of hyaluronidases in cancers is controversial. Limited data support a role in 
metastasis, while other data support a role in tumour suppression [214]. Hyaluronidases are 
also thought to have a role in angiogenesis, although most hyaluronidase preparations are 
contaminated with large amounts of angiogeneic growth factors [215, 219]. Some bacteria, 
such as Staphylococcus aureus, Streptococcus pyogenes and Clostridium perfringens, 
produce hyaluronidase as a means of using HA as a carbon source. It is often speculated that 
Streptococcus and Staphylococcus pathogens use hyaluronidase as a virulence factor to 
destroy polysaccharides that hold animal cells together, making it easier for the pathogen to 
spread through the tissues of the host organism [216, 217], but no valid experimental data are 
available to support this hypothesis. In most cases of mammalian fertilisation, hyaluronidase 
is released by the acrosome of the sperm cell after it has reached the oocyte, digesting the 
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concentrated HA in the corona radiata. Once this occurs, the sperm is capable of binding with 
the zona pellucida; and the acrosome reaction can occur [218]. 
1.5.2 Collagens 
The most abundant of the matrix proteins are the collagens, a large family of closely related 
but genetically distinct proteins. Collagens contain, at least in part, polypeptide α-chain triple 
helical structures. Collagens are widespread throughout the body and are important for a 
broad range of functions including tissue scaffolding, cell adhesion and migration, 
angiogenesis, tissue morphogenesis, and tissue repair. Collagen is best known as the principal 
tensile element of vertebrate tissues, such as tendon, cartilage, bone and skin; where it occurs 
in the ECM as elongated fibrils [221]. 
Some collagen types (e.g. I, III, and V) form fibrils by virtue of lateral cross-linking of the 
triple helices; and form a major proportion of the connective tissue in healing wounds. Other 
collagens (e.g. IV) are non-fibrillar and become components of basement membranes – for 
example, in the kidney glomerulus, where it contributes to functions in molecular filtration. 
The predominant type of collagen differs in different tissues. In those tissues exposed to shear 
and tensile forces, such as skin, tendons, bone, and cartilage, the predominant collagens 
present are types I, II, III, V and XI [222]. These collagens assemble into highly orientated 
aggregates. In scar tissue, the proportions of type I and III collagen are significantly increased 
and changes in the ratio of these collagens are thought to be involved in conferring resistance 
to matrix degradation in fibrous tissue [223]. The identification of transmembrane collagens 
on the surfaces of a variety of cells, and collagens that are precursors of bioactive peptides 
(BCPs) with paracrine function, has resulted in a revival of interest in collagen research.  
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1.5.3 Glycoproteins 
Glycoproteins are high molecular weight, structurally diverse proteins, which function as 
matrix adhesion molecules. They include fibronectin, laminin, entactin and thrombospondin. 
The most abundant and best characterised is fibronectin, which exists in two forms: plasma 
and tissue fibronectin. It has binding sites for several other matrix proteins, such as collagens; 
and can also attach to cell surface integrins [20, 42]. This property allows fibronectin to act as 
a link between cells and the matrix. Therefore it is involved in regulating the structure of the 
ECM and is able to influence cellular processes, such as migration, growth and differentiation. 
Specifically, expression of EDA-FN is upregulated in cells treated with the pro-fibrotic 
cytokine, TGF-β1; and is demonstrated to be marker of myofibroblastic differentiation and 
necessary for the upregulation of α-SMA expression [50, 170]. 
1.5.4 Elastin 
Elastin is a connective tissue protein that is composed of cross-linked tropoelastin molecules, 
producing a large, insoluble and durable protein. It confers elastic properties to connective 
tissues, allowing resumption of original shape following stretching or contraction. It 
specifically serves an important function in arteries, large blood vessels (e.g. the aorta) and is 
also important in the structure and function of cartilage, ligaments, lung tissue, the bladder, 
and the skin [203]. 
1.5.5 Proteoglycans 
The proteoglycan (PG) super-family contains over 30 hydrophillic, heavily glycosylated 
glycoproteins, that fulfil a wide variety of biological functions. PGs consist of a protein core, 
the variation of which is responsible for the biosynthesis of PGs with different molecular 
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constructions and functions [203, 224]. Attached to the protein core are one or more 
covalently linked GAGs, which provide unique functions to various PGs [225].  
PGs act as tissue organisers, influence cell growth and the maturation of specialised tissues, 
play a role as biological filters, modulate growth-factor activity, regulate collagen 
fibrillogenesis and skin tensile strength, affect tumour cell growth and invasion; and 
influence corneal transparency and neurite outgrowth [225]. Additional roles derived from 
studies of mutant animals, indicate that certain PGs have functions essential to life whereas 
others might be redundant [226, 227]. PGs vary in molecular organisation of the protein core, 
the utilisation of protein modules, and transcriptional control. PGs have been grouped into 
distinct gene families and sub-families offering a simplified nomenclature, based on their 
protein core design [228]. The structure-function relationship of some paradigmatic PGs has 
been discussed in depth and novel aspects of their biology have been examined [225, 228]. 
1.5.6 Glycosaminoglycans 
Glycosaminoglycans (GAGs), otherwise known as mucopolysaccharides, are long 
unbranched polysaccharides consisting of repeating disaccharide units. The repeating unit 
(with exception for keratin sulphate), consists of an amino sugar (N-acetylglucosamine or N-
acetylgalactosamine) along with uronic acid (glucuronic acid or iduronic acid) or galactose 
[224]. GAGs have high degrees of heterogeneity with regards to molecular weight, 
disaccharide construction, and sulphation, due to the fact that GAG synthesis, unlike proteins 
or nucleic acids, is not template driven but dynamically modulated by processing enzymes 
[224]. 
Based on core disaccharide structures, GAGs are classified into four groups. Heparin/heparan 
sulphate (HSGAGs) and chondroitin/dermatan sulphate (CSGAGs) are synthesised in the 
Golgi apparatus, where protein cores made in the rough endoplasmic reticulum are post-
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translationally modified with O- and N-linked glycosylations by glycosyltransferases, 
forming a proteoglycan [229]. Unlike HSGAGs and CSGAGs, the third class - keratan 
sulphate (KSGAGs), are driven towards biosynthesis through particular protein sequence 
motifs. The fourth class of GAG, HA, is not synthesised by the Golgi, but instead by three 
transmembrane synthases that exist in three isoforms: HA synthase (HAS) 1, 2, and 3. These 
synthases immediately secrete the dynamically elongated disaccharide chain [229]. 
The functions of GAGs vary greatly. For example, highly negatively charged endogenous 
heparin functions to electrostatically retain and store histamine within mast cells [230]. 
Heparan sulphate (HS) has numerous biological activities and functions, including cell 
adhesion, growth and proliferation, developmental processes, cell binding of lipoprotein 
lipase and other proteins, angiogenesis, viral invasion, and tumour metastasis [231]. 
CSGAGs interact with heparin binding proteins, specifically dermatan sulphate interacts with 
FGF-2 and FGF-7, implicating it in cellular proliferation and wound repair [232], while 
interactions with HGF activate the c-Met signalling pathway and generating an anti-fibrotic 
effect. Other biological functions include inhibition of axonal growth and regeneration in 
central nervous system development, brain development, neuritogenic activity, and pathogen 
infection [231, 232]. 
One of the main functions of KSGAGs is the maintenance of tissue hydration [233]. In 
disease states such as macular corneal dystrophy, in which keratan sulphate (KS) levels are 
altered, loss of hydration within the corneal stroma is believed to be the cause of corneal haze, 
supporting the hypothesis that corneal transparency is dependent on KS levels [234]. 
KSGAGs are found in many other tissues, where they regulate macrophage adhesion, contain 
neurite growth, regulate embryo implantation, and affect the motility of endothelial cells 
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[233]. In summary, KS plays an anti-adhesive role, which suggests very important functions 
in cell motility and attachment. 
1.6 Hyaluronan 
The fourth class of GAG, HA, is a major component of synovial tissues and fluid, and soft 
tissue ECMs; endowing their environments with remarkable properties [235]. For example, 
solutions of HA are known to be viscoelastic; viscosity changes with sheer stress levels. At 
low sheer stress, HA viscosity can be 106 times that of the solvent, while under high sheer 
stress, viscosity may drop by 103 times [236]. This property of HA in solution makes it ideal 
for cartilage and joint lubrication. In vivo, HA has a stiff helical structural configuration that 
gives the molecule an overall random hydrated coil structure, which entangles with other HA 
molecules to form a network. HA networks retard diffusion by forming a barrier that 
regulates transport of substances through intercellular spaces [235]. For example, HA 
partitions plasma proteins between vascular and extravascular spaces; this excluded volume 
phenomenon affects the solubility of macromolecules in the interstitium, changing chemical 
equilibria, and stabilising collagen fibers [237]. 
 
HA is a multifunctional, high molecular weight polysaccharide, classed as a non-sulphated 
negatively-charged GAG; and is distributed widely throughout connective tissue, epithelial 
and neural tissues [235]. First characterised from the vitreous of bovine eyes, its exact 
Figure 1.2. The molecular structure of HA, a polymer made of repeated sequences of the 
disaccharides N-acetylglucosamine and D-glucuronic acid, linked together by alternating β-1,4 and 
β-1,3 glycosidic bonds. 
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chemical structure was determined in 1954 as a polymer made of repeated sequences of the 
disaccharides, N-acetylglucosamine and D-glucuronic acid, linked together by alternating β-
1,4 and β-1,3 glycosidic bonds [235] (Figure 1.2). The number of disaccharide unit repeats 
varies between tissues and can approach 30,000 in some tissues, giving a molecular mass of 
10x106Da [238]. However, smaller HA fragments and oligosaccharides have also been 
described under certain physiological and pathological conditions. HA is thought to 
participate in many biological processes and has elevated levels during embryogenesis, cell 
migration, wound healing, malignant transformation, fibrosis, and tissue turnover [239, 240].  
Other functions include matrix interactions with HA binding proteins (hyaladherins) such as 
hyaluronan binding protein (HABP), collagen VI, TNF-stimulated gene-6 protein (TSG-6), 
and inter-α-trypsin inhibitor (IαI) [237, 241, 242]. Cell surface interactions involving HA 
include its well-known coupling with CD44, which has been linked to tumour progression as 
well as regulation of cell interactions; and also with RHAMM (receptor for hyaluronan-
mediated motility), which has been implicated in developmental processes, tumour metastasis 
and pathological reparative processes [240, 243]. Fibroblasts, myofibroblasts, mesothelial 
cells and certain types of stem cells surround themselves in a HA pericellular coat (varying in 
structure, size and HA content), in order to shield themselves from bacteria, red blood cells, 
matrix molecules, or to grant unique properties and lend to cellular adhesion and other 
functions [244, 245]. For example, HA helps to form the stem cell pericellular shield, 
protecting from the effects of growth factors. During progenitor division, the daughter cell 
moves outside of this pericellular shield where it can then be influenced by growth factors to 
further differentiate [246]. 
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1.6.1 Hyaladherins and TSG-6  
HA binding proteins or hyaladherins are proteins that bind, interact and modulate the function 
of HA. Several types of hyaladherins exist (Table 1.1), as either cellular receptors or 
extracellular hyaladherins [247, 248]; and have specific roles in cellular functions. One 
notable hyaladherin recently described as having a role in cellular differentiation and 
modulation of HA function is TSG-6, which in humans is encoded by the TNFAIP6 gene 
[249]. TSG-6 is a ~35kDa secreted protein containing a HA-binding LINK domain A, 
grouping it with the hyaladherin family of proteins [249]. The HA-binding domain is known 
to be involved in ECM stability and cell migration. This protein has been shown to form a 
stable, covalent complex with IαI; enhancing the serine protease inhibitory activity of IαI, 
which has importance in inflammation [249]. The expression of this gene can be induced by a 
number of signalling molecules, principally tumour necrosis factor-α (TNF-α) and IL-1 [250]. 
TSG-6 expression can also be induced by mechanical stimuli in vascular smooth muscle cells, 
and is found to be correlated with PG synthesis and aggregation [249]. 
TSG-6 interacts with a plethora of matrix-associated molecules, such as aggrecan, versican, 
thrombospondin-1 and -2, pentraxin-3, and fibronectin. Its role in HA-binding is important in 
key steps of inflammation and ovulation [247, 249]. TSG-6-mediated cross-linking of HA has 
been proposed as a functional mechanism (e.g. regulating leukocyte adhesion and creating 
HA networks). Full-length TSG-6 binds to and can cross-link HA at physiologically relevant 
concentrations. The co-operative binding of full-length TSG-6 arises from HA-induced 
protein oligomerisation, with TSG-6 oligomers acting as cross-linkers. Although the HA-
binding domain of TSG-6 can bind regardless of whether the full-length protein is present, 
only when the LINK module and full-length TSG-6 bind and cross-link HA together can 
condensed and rigidified HA films form, implying that the full-length TSG-6 protein is 
required for assembly of functional cross-linked HA networks. Therefore, TSG-6 can be 
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described in whole as a potent HA cross-linking agent [251]. In the case of fibroblast 
differentiation, TSG-6 activity was found to be upregulated and a necessary component of 
TGF-β1 and HA-mediated myofibroblast generation, as small interfering RNA targeting 
TSG-6 abolished HA-pericellular coat formation and prevented successful myofibroblastic 
transformation [244, 252]. 
 
 
 
 
 
 
 
1.6.2 HA in Wound Healing 
HA plays an important role throughout the process of wound healing. The long chain, high 
molecular weight HA polymers (4000–20,000kDa or 1000–5000 saccharide units) seen in 
wound healing create long, twisting hydrophilic chains [83]. The water attracting properties 
of HA grants characteristic elastic and cushioning properties, illustrated by its concentration 
in skin and cartilage. High concentrations of HA in this form create porous scaffolding 
networks, allowing for select diffusion of cells and proteins, and creating pathways for cell 
Table 1.1. Hyaladherin chart displaying well documented hyaladherins, including the size and 
location of each protein. Note that hyaladherins can be divided into extracellular and cell surface 
hyaladherins. Extracellular hyaladherins are mostly structural, binding and fortifying HA networks. 
Cell surface hyaladherins can act to anchor HA to the cell surface, but some can also signal through 
intracellular protein kinases. Chart was adapted from Day and Prestwich 2002 [241]. 
 41 
migration. This is a key feature of HA, as cell migration and proliferation are essential to 
successful wound healing [83, 253]. Smaller molecular size HA fragments also encourage 
cell migration and receptor organisation and movement. These very short, low-weight (four 
saccharides) HA fragments are capable of inducing chemotaxis, whilst medium sized HA 
chains (1000–1250 saccharides) can stimulate inflammatory cytokine expression [83, 253]. 
As HA is required in various shapes and weights for each wound healing phase, its 
catabolism and synthesis are vital for normal wound healing. HA is manufactured on the cell 
surface by three membrane bound enzymes called HA synthases (HAS1, HAS2, HAS3) [160, 
195]. While other GAGs, such as HS, are manufactured within the cell and then released by 
exocytosis, HAS production of HA on the outside of the cell membrane, enables it to interact 
readily with the extracellular environment, other cells and hyaladherins [229, 238].  
The properties, catalytic rate and mode of regulation for each of the three HAS isoenzymes 
are different and may underlie physiologically distinct functions. Moreover, many biological 
and physiological roles of HA have been related to its molecular weight [238, 254]. The 
molecular sizes of HA synthesised by the different HAS isoforms have, therefore, also been 
determined. HAS1 is demonstrated to be the least active and drives the synthesis of high 
molecular weight HA (up to 2x106Da), suggesting low constitutive levels of synthesis. HAS2 
is more catalytically active and generates high molecular HA polymers of more than 2x106Da 
in size. HAS3 is expressed late in embryonic development and in many adult tissues. It shows 
the highest constitutive activity of the three isoforms and drives synthesis of large amounts of 
lower molecular weight HA chain (2x105-3x105Da) [255]. Studies have demonstrated the 
importance of HAS2 in development [256], the progression of fibrosis [257], cell 
differentiation and proliferation [160, 195, 244, 252]. Recently, HAS2 has also been 
described in an anti-cancer mechanism, where exceptionally high-molecular-weight HA is 
synthesised in the skin of the naked mole rat, conveying resistance to tumour formation [258].  
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HA catabolism primarily occurs in two main ways, through hyaluronidases/HYALs and ROS 
[83, 220, 259]. Hyaluronidases are responsible for altering HA size for specific functions 
needed during each of the wound healing phases. The significance of the functions of HA 
polymers and their antioxidant and free-radical scavenging properties have been 
demonstrated with the emergence of various HA-based wound dressings [7, 44]. 
The cell surface interactions of HA are crucial in understanding its role in wound healing, as 
the size and shape of HA dictates its differing roles and interactions at each wound stage. 
During the inflammatory phase of wound healing, platelet synthesis of heavy molecular 
weight HA increases rapidly [83]. These HA fragments bind to fibrinogen to commence the 
clotting pathway. The large amounts of hydrophilic HA released at wounding saturates the 
wound site with fluid, leading to oedema of the surrounding tissue and creating a porous 
framework for cells to migrate to the injury site [83]. Additionally, oedema allows for the 
chemotaxis of inflammatory cells, which release cytokines (TNF-α, IL-1β, IL-8) triggered by 
the high concentrations of HA, increasing cellular recruitment. The HA-cytokine release loop 
continues to regulate HAS expression, although this appears to be cell type and tissue specific 
[253]. For example, oral and dermal fibroblasts exhibit different HAS isoform expression 
patterns in response to TGF-β1, with HAS2 preferentially expressed and at higher levels in 
dermal fibroblasts [244, 260]. 
Conversely, HA can also reduce and moderate the inflammatory response, through its 
interaction with TSG-6 [251]. TSG-6 is stimulated by inflammatory cytokines IL-1, TNF-α, 
and TGF-β1, causing fibroblasts and other inflammatory cells to increase expression of the 
TSG-6 protein [250]. Once expressed by cells, TSG-6 proteins are retained in HA-rich 
environments, associating with IαI and binding to high molecular weight HA polymers, 
which form heavy chains [261]. These heavy HA chains prevent inflammation by inhibiting 
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neutrophil migration and inhibition of plasmin through negative feedback loops [249, 261]. 
As the classic inflammatory signs recede, granulation tissue begins to form in preparation for 
the proliferative phase. This phase is also heavily influenced by HA's multifaceted properties. 
Following on from the late inflammatory phase, the proliferative phase of wound healing 
marks the arrival of fibroblast migration. These cells are drawn to wound tissue by small HA 
fragments (6–20 saccharides) and growth factors [83]. Fibroblasts synthesise collagen and 
GAGS (including HA), for the construction and anchoring of the newly formed ECM. 
Differing HA lengths stimulate the production of specific collagen types, which can promote 
or inhibit scar formation. One important function that fibroblasts exert on the developing 
ECM is collagen synthesis, providing tensile strength to the healing wound [83]. The 
developing ECM is visibly identifiable as granulation tissue, with collagen and elastin 
providing the fibrous scaffolding. HA influx forms a cushioning gel-like structure, which 
upon saturation, displays elastic recoil properties similar to cartilage [235, 250]. This 
malleability is an important clinical feature of granulation tissue, as wound healing often 
occurs in areas of high movement or pressure (e.g. joints and plantar surface of feet). Without 
hydrophilic and porous HA networks, the macroscopic granulation tissue would not be able 
to hold its shape to allow for normal wound healing [83]. 
HA contributes to angiogenesis through short chain oligomers (6–20 molecules in length). 
These oligomers bind to CD44, stimulating MMPs, which break down the basement 
membrane of the wound allowing neovascularisation and capillary sprouting [83, 253]. The 
final component of the proliferative phase is re-epithelialisation. The skin contains most of 
the body's HA concentrated in the deeper stratum basale of the epidermis and dermis. The 
main cell type in the basal layer is the keratinocyte, which expresses CD44 in large amounts 
[262]. In the skin, HA mainly functions to hydrate and provide elasticity, but also to create 
the aforementioned porous structures for nutrient channelling [83]. 
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Upon wounding, damaged keratinocytes and their HA bound matrices are ruptured, releasing 
HA fragments and commencing the inflammatory phase of wound healing. During re-
epithelialisation, newly formed HA scaffolds promote keratinocyte migration to the wound 
edge and over the wound space, through interactions with CD44 displayed on the cell surface. 
Early studies highlighted HA presence as a requirement for effective re-epithelialisation; 
without its signalling and physiochemical properties, excessive scarring and delayed wound 
healing may occur [220, 253, 263]. 
Gradually, during wound resolution the wound-specific cells, structures, and HA are 
degraded and replaced by an avascular collagenous scar. Clinically, minimal scar tissue 
occurs with advanced age because of HA being primarily located in the upper dermis, as seen 
in foetal subjects [147, 223]. This might lead to the assumption that HA skin concentrations 
change at various ages. A study by Meyer and Stern in 1994 found that the polymer size and 
concentration of HA remains consistent throughout a lifetime. However, tissue association 
did change, suggesting that although the amount of HA remains the same, the amount of 
extractable HA changes with age because of hyaladherin binding or reorganisation [264]. 
This shows that while HA is present in human skin of all ages, its location and the extent of 
potential hyaladherins could affect its function, binding and contribution to effective wound 
healing or scarring. 
1.6.3 HA in Fibrosis 
Although HA is an essential molecule needed for efficient wound healing, it is also 
implicated in tissue fibrosis and its accumulation often correlates with the severity of fibrotic 
disease progression; and has been detected in numerous fibrotic conditions associated with 
organ dysfunction [257, 265, 266]. Diseases that demonstrate elevated levels of HA include: 
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idiopathic pulmonary fibrosis (IPF), chronic kidney disease, liver cirrhosis, liver hepatitis, 
scleroderma, sarcoidosis and rheumatoid arthritis, among others [73, 85, 166, 250, 257].  
Simple assays for serum HA determination makes it possible to use HA as a diagnostic 
marker for fibrotic diseases. For example, because HA is a component of liver fibrosis and is 
cleared from the blood by liver endothelial cells, most investigations found increased serum 
levels of HA in patients with liver diseases [265, 266]. Although the pathophysiological 
mechanisms involved are not fully understood, an increase in HA production as well as a 
decrease in removal might be involved. Observed increases in HA production may be caused 
by the induction of cell proliferation and ECM synthesis, via excessive cytokine release. 
Decreases in serum HA uptake and degradation may be caused by endothelial cell injury. The 
measurement of serum HA levels has therefore been suggested as a method to monitor 
fibrotic progression in chronic liver diseases [265]. 
Tissue fibrosis is a major cause of morbidity and IPF is a terminal illness characterised by 
unremitting matrix deposition in the lung. Myofibroblasts accumulate at sites of tissue 
remodelling and produce ECM components, such as collagen and HA, that ultimately impair 
organ function. In a murine model study by Li et al. 2011, targeted overexpression of HAS2 
by myofibroblasts produced severe lung fibrosis and death after bleomycin-induced injury. 
Fibroblasts isolated from transgenic mice overexpressing HAS2 showed a greater capacity to 
invade matrix. Conditional deletion of HAS2 in mesenchymal cells abrogated the invasive 
fibroblast phenotype, reduced myofibroblast accumulation and inhibited development of lung 
fibrosis. In the absence of CD44, both the invasiveness of fibroblasts and progressive fibrosis 
were inhibited, highlighting the dependency of IPF progression on HAS2 and CD44 
expression [257]. Understanding the mechanisms leading to an invasive fibroblast phenotype 
could lead to novel approaches to the treatment of disorders characterised by severe tissue 
fibrosis. 
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Aberrant expression of the HAS2 gene and the increased production of HA have also been 
implicated in the pathology of pulmonary arterial hypertension, osteoarthritis, asthma, thyroid 
dysfunction, and large organ fibrosis [267]. Renal fibrosis is associated with increased 
cortical synthesis of HA and correlated with interstitial fibrosis in vivo [267]. In vitro data 
suggested that both HAS2 transcriptional induction and subsequent HAS2-driven HA 
synthesis may contribute to kidney fibrosis, via EMT of the renal proximal tubular epithelial 
cells (PTC), driven primarily by TGF-β1 [111].  
In contrast, the lack of scarring in foetal skin wounds may relate to a prolonged presence of 
HA, increased expression of CD44, and reduced expression of hyaluronidase [144, 268]. The 
major differences may be in the size of HA produced, influencing its biological action, 
especially in angiogenesis, which is also reduced in foetal wound healing [144]. In a foetal 
wound study, HA and hyaluronidase activity were determined and it was found that in adult 
wound fluids hyaluronidase levels were higher than in foetal wound fluids [268]. The data 
generated by the study suggests that lower hyaluronidase levels may underlie the different 
pattern of HA deposition seen in foetal wounds and influence the anti-fibrotic wound healing 
mechanisms in foetal wound healing. 
1.7 The Differentiation Mechanism 
Activation of the transmembrane epidermal growth factor receptor (EGFR) has been 
acknowledged to occur in response to TGF-β1 stimulation of fibroblasts. It was found that the 
phosphorylation of EGFR was necessary for fibroblast to myofibroblast differentiation, 
indicating a crossover of the two signalling pathways; the TGF-β1/Smad2/3 pathway and the 
EGFR/ERK pathway, signalling in parallel to drive differentiation to a myofibroblastic 
phenotype (Figure 1.3) [195, 269]. Inhibition of either TGF-βRI or EGFR resulted in failure 
of differentiation, in response to TGF-β1 treatment [160]. The loss of EGFR described in 
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aged fibroblast cells was partly responsible for TGF-β1 resistance and failure of 
differentiation [160], further supporting the necessity of both pathways in myofibroblast 
transformation. Interestingly, HA production by HAS2, which is essential for HA pericellular 
coat formation, was also a required process in fibroblast differentiation [160, 252]. It was 
hypothesised that the HA receptor, CD44, could co-localise with and activate EGFR in 
response to TGF-β1, thus illustrating a mechanism whereby TGF-β1 stimulation could 
activate EGFR. Removal of EGF activity (upregulated by TGF-β1 in fibroblasts) using a 
blocking antibody did not change EGFR activation by TGF-β1 [160], suggesting an initial 
ligand-independent activation of EGFR by HA-CD44.  
Indeed, ligand-independent activation of EGFR has been reported [270, 271]. The mechanism 
of HA-CD44 activation of EGFR is largely unknown. This thesis aims to investigate and 
detail the co-localisation of CD44 and EGFR and to further elucidate the initiation, 
localisation and down-stream signalling pathways that result from the interaction.  
Figure 1.3. TGF-β1 stimulated and HA-mediated fibroblast to myofibroblast mechanism – when 
fibroblasts are stimulated by TGF-β1, TGF-βR is phosphorylated (P), signalling through Smad2/3 and 
co-Smad4. HA-mediated CD44/EGFR signalling is through ERK1/2. When both pathways signal in 
parallel the cell undergoes differentiation into a myofibroblast. Image adapted from Meran et al. 2011 
[189] and Simpson et al. 2010 [79].  
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1.8 Project Aims and Objectives 
The medical problems that stem from progressive tissue fibrosis are abundant, causing loss of 
organ function, tissue flexibility, or cosmetically undesirable outcomes. However, slow 
wound resolution, the loss of scar tissue formation and the inability to shield a wound from 
the external environment, can lead to chronic non-healing wounds; particularly afflicting the 
elderly population. The overall purpose of this thesis is to identify the mechanisms that are 
involved in driving fibroblast to myofibroblast differentiation; and those that are lost in aged 
fibroblast resistance to myofibroblast transformation. Specifically, this thesis aims to 
establish the role of each component of the TGF-β1 and HA-regulated pathways contributing 
to myofibroblast generation and fibrosis, revealing potential targets for therapeutic inhibition 
of scar tissue formation, but also elucidating mechanisms that could promote and restore the 
differentiation of aged fibroblasts and therefore, provide therapeutic benefit for chronic non-
healing wounds. Through investigation of downstream signalling pathways, genetic 
regulation and macromolecular modulation, this thesis aims to provide potential targets for 
intervention. 
My specific objectives were: 
1. To characterise the co-localisation between EGFR and CD44, identify where in the 
cell that this association occurs; and also which components, growth factors, ECM 
proteins or receptors, are needed for co-localisation. 
2. To investigate the mechanism resulting in EGFR and CD44 co-localisation, through 
analysis of receptor movement and how HA influences receptor association. 
3. To make comparisons between young and aged fibroblasts, identify differences and 
pinpoint specific routes of re-establishing: a) the potential for aged fibroblasts to 
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differentiate into myofibroblasts; and b) targets for inhibition of myofibroblast 
differentiation in young fibroblasts. 
4. To examine the role of genetic modulators of gene expression (e.g. microRNAs) in 
the age-related resistance of TGF-β1-stimulated differentiation; and how promotion of 
these genetic modulators are controlled. 
5. To utilise potential routes for: a) the restoration of the differentiation response in aged 
cells through upregulation of the key differentiation components; and b) the inhibition 
of key regulators of differentiation in young cells, and to produce in vitro treatments 
for these purposes. 
The results attained from these in vitro experiments could be used to identify significant 
points of difference between young cells, which readily differentiate into myofibroblasts, and 
aged cells, which resist differentiation. Those differences could reveal factors that are 
necessary for the initiation and progression of fibrosis or for successful wound healing; and 
could potentially be used in the development of therapies that target scar-free healing or the 
promotion of wound healing in the elderly. 
 
 50 
 
 
 
 
Chapter 2 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
2.1 Materials 
All general and tissue culture reagents were purchased from Sigma-Aldrich (Poole, UK), 
Thermo-Fisher Scientific (Roskilde, Denmark), BD Biosciences (San Jose, USA), and 
GIBCO/Life Technologies (Paisley, UK) unless otherwise stated. PCR and QPCR reagents 
and primers were purchased from Invitrogen and Applied Biosystems (Life Technologies, 
Paisley, UK). Cytokines used were TGF-β1, EGF and IFNγ from R&D Systems (Abingdon, 
UK), and 17β-estradiol (E2) from Merck Millipore (Darmstadt, Germany). Chemical 
treatments used were cytochalasin-B, nystatin, AG1478 and SB431542 from Merck Millipore. 
The sources of any other inhibitors or reagents used are described in the following sections 
and results chapters. 
2.2 Cell Culture 
Primary human lung fibroblasts (AG02262; NIA Ageing Cell Respiratory Corriel Institute, 
Camden, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) and F-12 
Medium (D8062; Sigma-Aldrich), containing 2mM L-glutamine, 100 units/ml penicillin and 
100µg/ml streptomycin supplemented with 10% foetal calf serum (FCS) (Biologic Industries 
Ltd., Cumbernauld, UK). The cells were maintained at 37°C in a humidified incubator in an 
atmosphere of 5% CO2; and fresh growth medium was added to the cells every 3-4 days, 
until confluence. Once confluence had been attained, cells were sub-cultured. Prior to 
experimentation, all cells were growth-arrested in serum-free medium for 48h to allow cell-
cycle synchronisation (arrest at G0). All experiments, unless otherwise stated, were 
performed in serum-free medium to avoid any influence of serum factors. Furthermore, all 
experiments were performed on approximately equivalent cell numbers. 
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2.2.1 Sub-culture 
Once fibroblast confluence was attained, the cell populations were sub-cultures at a ratio of 
1:3 and either utilised for experiments, cultured further, or cryopreserved as described below. 
In the case of a 75cm2 culture flask (T-75; scale up or down as appropriate), confluent 
monolayers of fibroblasts were sub-cultured by treatment with 5mL 0.05% (w/v) trypsin and 
0.53mM EDTA in phosphate buffered saline (PBS). The trypsin was evenly distributed over 
the base of the flask and incubated at 37°C for 1-3 minutes with slight agitation, or until cells 
became detached and appeared rounded, when examined under a light microscope. The 
resulting cell suspension was treated with an equal volume of FCS to neutralise the protease 
activity. The total volume was then transferred to a centrifuge tube and the suspension 
centrifuged at 1500×g for 6 minutes at room temperature. The cells were then re-suspended 
in 50mL medium supplemented with 10% FCS and seeded into fresh tissue culture flasks for 
continued growth, or seeded onto tissue culture plates for experimentation. Fibroblasts were 
cultured, sub-cultured and cryopreserved at various passages until senescence, at which point 
in time, senescent cells were no longer cultured and were discarded. Lung fibroblast 
senescence was determined to be at ~passage 16.   
2.2.2 Cryostorage and Revival 
At sub-culture, if deemed necessary, fibroblasts were harvested for cryogenic preservation. 
For one T-75 flask of confluent cells, following trypsin treatment and neutralisation, the cells 
were resuspended in a 4.5mL solution containing 10% dimethyl sulphoxide (DMSO), 10% 
FCS and 80% DMEM/F12 medium. 1.5mL was transferred into each of 3 cryogenic vials 
(Thermo-Fisher Scientific). Vials were initially placed in a -80°C freezer for 24h and then 
subsequently transferred to liquid nitrogen (-196°C) for long-term storage. Cryopreserved 
cells were revived by rapid thawing at 37°C, using a water bath. Upon complete defrosting of 
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contents, the cell solution from each cryogenic vial was transferred directly into a T-75 tissue 
culture flask, containing pre-warmed 37°C medium supplemented with 10% FCS.    
2.2.3 Cell Counting and Population Doubling Level Calculations 
For assessment of cell numbers, fibroblasts in culture were sub-cultured, as above, using 
trypsin. Upon cell resuspension in 10% FCS medium and prior to cell seeding, three 20μL 
volumes of cell-suspension were taken and each added to 20mL of sterile isotonic water in 
Coulter Counter compatible sample cups. The average cell counts of three readings were 
taken for each sample using a Coulter Z2 Series cell counter (Beckman Coulter Inc., 
Indianapolis, USA). The formulae shown below were used to calculate the total number of 
cells in the resuspension solution: 
Cells/mL = (Average cell number) x 2000 
Total cell count = (Cells/mL) x (Volume resuspension solution) 
In order to determine the PDL at the end of each passage number, the following equations 
were used: 
Total seed number [1:3 ratio sub-culture] = Total cell number  
                                                                           3 
PDL = 3.32 x (log10(Total cell count) - log10(Total seed number)) 
Cumulative population doubling levels were calculated by adding the derived increase to the 
previous PDL. Fibroblasts were received at passage 3 and at a population doubling level 
(PDL) of 11.9. 
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2.2.4 Determination of Young and Aged Cell Groups 
Using the cell counts PDL determination as described above, fibroblast growth curves were 
used to identify which passage numbers to assign to young and aged fibroblast groupings. 
Cellular senescence was found to occur at ~ passage 16, as PDL did not increase beyond the 
sub-culture of passage 15 fibroblasts (Figure 2.1). Using total seed number and total cell 
counts; a graphical representation of the fibroblast growth rate was produced (Figure 2.2). 
For the young fibroblast range, passages between 6 and 9 were used, as the seed number and 
end of passage cell counts remained approximately constant. For the aged fibroblast group, 
cells between passages 13 and 15 were used, as these were still pre-senescent cells capable of 
growth and proliferation. Note the number of days in culture needed before confluence 
increased two to three-fold, when compared to the young cell group. Beyond passage 16, 
cells became senescent and did not increase in PDL.  
2.3 Cytokine Stimulations 
Following growth arrest, the medium was removed and the cells washed with PBS. 
Stimulations were performed by incubation of fibroblasts with the desired stimuli (TGF-β1, 
E2, IFNγ and EGF) in serum-free medium for appropriate times and concentrations, before 
analysis. All cytokine treatments were determined by dose response experiments and 
cytotoxicity assessed by alamarBlue assay (Biosource International, Camarillo, USA). The 
specific details of the cell-stimulations performed for each experiment are covered in the 
subsequent results chapters. 
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Figure 2.1. Human lung fibroblast growth curve over 90 days, the state of cellular senescence is 
indicated by the black arrow at approximately 76 days in culture, as the PDL did not increase after this. 
Red markers indicate the PDL at each passage sub-culture.  
Figure 2.2. A graphical representation of human lung fibroblast growth curves detailing cell numbers 
(log10 scale) and days in culture (0-90). At each passage, total cell numbers were counted and total seed 
numbers were calculated. Blue curves represent the growth phase from cell seeding to sub-culture. Red 
dashed lines indicate passage divisions. Young and aged groupings used for experimentation are 
indicated on the graph.   
 56 
2.4 Chemical Treatments and Cytotoxicity Testing 
Cytochalasin-B and nystatin were used to breakdown the cell cytoskeleton and membrane-
bound lipid rafts, respectively. Both of these mycotoxins were used to identify localisation of 
cell receptors, EGFR and CD44. In eukaryotic cells, cytochalasin-B acts to inhibit network 
formation and the polymerisation of actin filaments, nystatin acts as a cholesterol-
sequestering agent, disrupting cholesterol-rich lipid rafts of the cell membrane. As these 
chemicals disrupt cell infrastructure and membranes, there is potential of cell death. 
Therefore, the cytotoxicity of cytochalasin-B and nystatin was assessed. 
Cytotoxicity was assessed using the commercially available alamarBlue assay (Biosource 
International), which is designed to measure cell numbers and viability. The assay utilises an 
oxidation-reduction indicator that fluoresces in response to the reduction of growth medium 
resulting from cell growth and metabolism; demonstrating a linear relationship between 
fluorescent intensity and cell numbers and viability. Continued growth maintains a reduced 
environment, while inhibition of growth maintains an oxidised environment. Reduction 
related to growth causes the REDOX indicator to change colour; from oxidised non-
fluorescent blue to reduced fluorescent red. 
For this assay, following growth arrest, sub-confluent fibroblasts were incubated for 24h in 
serum-free medium alone or serum-free medium containing 5μM, 10μM, and 20μM of 
cytochalasin-B (Figure 2.3A) or 10μg/mL, 50μg/mL, and 100μg/mL of nystatin (Figure 2.3B). 
Then, 10% (v/v) alamarBlue was added to the medium for 1h and incubated at 37°C, 5% CO2. 
Aliquots were removed from each treatment and added in 100μL triplicates to a MicroFluor-2 
Black, 96-well plate (Thermo-Fisher Scientific). Subsequently, fluorescence was measured in 
a FluorStar Optima plate reader (BMG Labtech, Ortenburg, Germany), at an excitation 
wavelength of 540nm and an emission wavelength of 590nm. 
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2.5 Immunocytochemistry 
Indirect immuno-fluorescent identification of α-SMA was used as confirmation of 
myofibroblastic differentiation. Immuno-fluorescent visualisation of EGFR and CD44 were 
used to analyse receptor expression and interaction. All immunocytochemistry was 
performed on cells grown on 8-well glass chamber slides (Nunc; Thermo-Fisher Scientific). 
Cells were grown to 70% confluence, growth arrested for 48h, and then stimulated under 
serum-free conditions. 
Following stimulation, cells were fixed in cold 4% paraformaldehyde for 15 minutes and then 
washed thoroughly in PBS. For visualisation of α-SMA, cells were permeabilised with 0.1% 
Triton X-100 for 5 minutes and then washed with PBS. Non-specific binding was blocked 
with 1% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich) in PBS (herein referred to as 
BSA-PBS), for 1h at room temperature and on a STR6 platform shaker (Stuart Scientific, 
Stone, UK). The cells were washed thoroughly in 0.1% (w/v) BSA-PBS. Cells were 
incubated with the appropriate primary antibody (Table 2.1), diluted in 0.1% (w/v) BSA-PBS 
Figure 2.3. Cytotoxcity tests using the alamarBlue assay for cell viability and numbers. A. Fluorescent 
intensity is shown for each of the given concentrations of cytochalasin-B; 5µM was determined to be 
suitable for cell treatments. B. Fluorescent intensity is shown for each of the given concentrations of 
nystatin; 50µg/ml was determined to be suitable for cell treatments. 
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overnight at 4°C on a plate Gyro-Rocker (Stuart Scientific). The cells were washed 
repeatedly in 0.1% (w/v) BSA-PBS, then incubated with the appropriate secondary horse-
radish peroxidise (HRP) conjugated antibody (Table 2.2), diluted in 0.1% (w/v) BSA-PBS for 
1h at room temperature, on a platform shaker in darkness. The cells were washed extensively 
with 0.1% (w/v) BSA-PBS, before incubation with Hoechst nuclear stain (Sigma-Aldrich; 
dilution 1:2000 in 0.1% (w/v) BSA-PBS) for 30 minutes at room temperature in darkness. 
Following further thorough washes with 0.1% (w/v) BSA-PBS, the slides were mounted with 
FluorSave mountant (Merck Millipore) and examined under fluorescent UV-light on a Leica 
Dialux 20 Fluorescent Microscope (Leica Microsystems UK Ltd, Milton Keynes, UK). 
Table 2.1. Primary Antibodies for Immunocytochemistry 
Antibody Type Host Dilution 
Anti-α-SMA  
(Dako, Cambridgeshire, UK) 
 
Anti-EGFR (528)  
(Merck Millipore) 
 
Anti-CD44 (A020)  
(Merck Millipore) 
Monoclonal 
 
 
Monoclonal 
 
 
Monoclonal 
Mouse 
 
 
Mouse 
 
 
Rat 
1:25 
 
 
1:200 
 
 
1:200 
 
Table 2.2. Secondary Antibodies for Immunocytochemistry 
Antibody Type Host Dilution 
Anti-Mouse-IgG AlexaFluor 488 (FITC)  
 (Merck Millipore) 
 
Anti-Rat-IgG AlexaFluor 555 (TRITC)   
(Merck Millipore) 
Polyclonal 
 
 
Polyclonal 
Goat 
 
 
Goat 
1:5,000 
 
 
1:5,000 
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2.6 RNA Extraction and Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Fibroblasts were grown to confluence in 35mm dishes and washed with PBS, prior to lysis 
with 500μL TRIzol reagent (Ambion; Life Technologies). RNA was purified from the 
samples according to the manufacturer’s protocol. Briefly, 100μL of chloroform was added to 
the sample and agitated by inversion for 15 seconds. The sample was incubated at room 
temperature for 5 minutes and then centrifuged at 12,000×g for 15 minutes, at 4°C. The 
transparent aqueous phase was transferred to fresh eppendorfs and mixed with 250μL of 
isopropanol. The mixture was incubated at room temperature for 10 minute, briefly vortexed 
and then centrifuged at 12,000×g for 10 minutes, at 4°C. The supernatant was removed and 
the pellet washed with 500μL of 75% (v/v) ethanol, briefly vortexed and then centrifuged at 
7,500×g for 8 minutes, at 4°C. The supernatant was removed and the pellet air-dried at room 
temperature for 15 minutes. The pellet was then dissolved in 16μL of RNase-free distilled 
H2O (MilliQ; Merck Millipore). The absorbance was measured at 260nm and 280nm, using a 
Beckman UV-DU64 Spectrophotometer (Beckman Instruments Ltd, High Wycombe, UK), 
through the addition of 1μL sample to 49μL of RNase-free distilled H2O. The ratio of 
260:280 gave an indication of protein contamination (>1.8 was considered to indicate 
sufficiently pure RNA for further analysis). The concentration of RNA was calculated from 
the absorbance at 260nm: 
ABS260 x dilution factor (50) x RNA coefficient (40) = RNA in μg/μL 
                                                         1000 
The RT was performed using the random primer method. The RT was carried out in a final 
volume of 20μL per reaction, containing 1μg of RNA sample (in 10μL RNase-free distilled 
H2O), 2μL of 10x RT random primers, 2μL of 10x RT buffer, 0.8μL of 25x 100mM dNTPs 
(deoxynucleotide triphosphates; mixed nucleotides: dATP, dCTP, dGTP, and dTTP), 1μL of 
Multiscribe reverse transcriptase, and 1μL of RNase inhibitor. All reagents used were 
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supplied as a high-capacity cDNA reverse transcriptase kit (Applied Biosystems). The RT 
was performed using a PTC-225 Peltier Thermal Cycler (Bio-Rad Laboratories Inc., Berkeley, 
USA). As a negative control, RT was performed with sterile H2O replacing the RNA sample. 
The solution was incubated at 25°C for 5 minutes, to allow the random hexamer primers to 
anneal to the RNA. The primers were then extended using the reverse transcriptase in the 
presence of the dNTPs by heating to 37°C for 2h, generating cDNA. The cDNA was then 
heated to 85°C for 5 minutes, to separate the hybridised complexes consisting of the RNA 
template and the newly synthesised cDNA, deactivating the reverse transcriptase in the 
process. The resulting single stranded complementary DNA (cDNA) was stored at -20°C 
until further use.  
2.7 Real Time Quantitative Polymerase Chain Reaction (RT-QPCR) 
2.7.1 TaqMan Gene Expression QPCR 
Following RT-PCR, cDNA samples were made up to 80μL by the addition of 60μL of 
RNase-free distilled H2O (MilliQ, Merck-Millipore). QPCR was carried out in a final volume 
of 20μL per reaction, containing 4μL of cDNA, 10μL of TaqMan Fast Universal PCR Master 
Mix (20X) (Applied Biosystems), 5μL of H2O, and 1μL of a TaqMan gene expression assay 
primer and probe mix (Applied Biosystems) (Table 2.3). A negative control was prepared 
with H2O substituted for the cDNA. QPCR was simultaneously performed for 18S ribosomal 
RNA (Applied Biosystems), as a standard reference gene.  
2.7.2 Power SYBR Green QPCR 
Following RT-PCR, cDNA samples were made up to 80μL by the addition of 60μL of 
RNAse-free distilled H2O (MilliQ, Merck-Millipore). QPCR was carried out in a final 
volume of 20μL per reaction, containing 4μL of cDNA, 10μL of Power SYBR Green PCR 
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Master Mix (Applied Biosystems), 4.8μL of H2O, 0.6μL of 10μM custom-designed forward 
primer, and 0.6μL of 10μM custom-designed reverse primer (Table 2.4). A negative control 
was prepared with H2O substituted for the cDNA. PCR was simultaneously performed for 
GAPDH (Table 2.4), as a standard reference gene.   
2.7.3 QPCR and Relative Quantification (RQ) 
QPCR was performed using the ViiA-7 Real Time PCR System (Applied Biosystems), using 
either TaqMan Universal or Power SYBR Green PCR Master Mixes (Applied Biosystems) 
following the manufacturer’s instructions. Following completion of the QPCR run, the 
comparative CT method was used for relative quantification of gene expression. The CT 
(threshold cycle where amplification is in the linear range of the amplification curve) for the 
standard reference gene (rRNA or GAPDH) was subtracted from the target gene CT, to 
obtain the delta CT (dCT). The mean dCT for the experimental control group was then 
calculated. The expression of the target gene in experimental samples relative to the 
expression in control samples was then calculated using the formula: 
2-( dCT(Experimental Sample) - dCT(Mean Control Group) )  
Table 2.3. TaqMan Gene Expression Assays* 
Target TaqMan Gene Expression Assay 
18S rRNA 
α-SMA (ACTA2) 
EGFR 
CD44 
HAS2 
TSG-6 (TNFAIP6) 
STAT1 
Catalog #: 4319413E 
Hs00426835_g1 
Hs01076078_m1 
Hs01075861_m1 
Hs00193435_m1 
Hs01113602_m1 
Hs01013996_m1 
*Applied Biosystems do not supply sequences of their QPCR primers. 
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Table 2.4. Custom Designed Primers for SYBR Green Assays* 
Target Custom Primer Sequences 
GAPDH 
 
 
EDA-Fibronectin (EDA-FN) 
 
Forward: 5’-CCTCTGACTTCAACAGCGACAC-3’ 
Reverse: 5’-TGTCATACCAGGAAATGAGCTTGA-3’ 
 
Forward: 5’-GCTCAGAATCCAAGCGGAGA-3’ 
Reverse: 5’-CCAGTCCTTTAGGGCGATCA-3’ 
*Primer efficiency was checked using 10-fold dilution series (90-100% efficiency accepted). 
 
2.8 Western Blot Analysis 
Cells were grown to confluence in 35mm dishes and were scraped and collected in ice-cold 
PBS. The samples were then centrifuged at 10,000×g for 10 minutes at 4°C and the 
supernatant discarded, the cell pellet was then resuspended in RIPA lysis buffer, containing 
1% protease cocktail inhibitor, 1% phenylmethylsulfonyl fluoride and 1% sodium 
orthovanadate (Santa Cruz Biotechnology Inc., Heidelberg, Germany). The samples were 
thoroughly vortexed and kept on ice for 5 minutes, before being centrifuged at 10,000×g for 
10 minutes at 4°C. The resulting supernatant was collected and transferred to fresh 
eppendorfs. Protein concentrations were determined by Bradford assay (Bio-Rad 
Laboratories Inc.); and the samples were stored at -80°C until further use. Equal amounts of 
protein were mixed with equal volumes of 1x reducing buffer and boiled for 5 minutes at 
99°C, before being vortexed, briefly centrifuged and allowed to cool on ice for 5 minutes. 
The samples were then loaded alongside a protein ladder onto 7.5% SDS-PAGE gels. 
Electrophoresis was carried out at 100V for 20 minutes, followed by 150V for 40 minutes; 
using the Mini-PROTEAN II system (Bio-Rad Laboratories Inc.). The separated proteins 
were then transferred at 100V for 1h to a nitrocellulose membrane (GE Healthcare, Hatfield, 
UK). The membrane was blocked with PBS containing 0.1% (v/v) Tween-20 (herein referred 
to as Tween-PBS) and 5% (w/v) non-fat powdered milk for 1h; and incubated with the 
appropriate primary antibody (Table 2.5) diluted in Tween-PBS on a plate rocker, at 4°C 
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overnight. The blots were subsequently washed with Tween-PBS, prior to incubation with the 
appropriate HRP-conjugated secondary antibody (Table 2.6), for 1h at room temperature on a 
plate shaker. Proteins were visualised using enhanced chemiluminescence (ECL) reagent (GE 
Healthcare), exposed to HyperFilm X-ray film (GE Healthcare), and developed using a 
Curix-60 developer (AGFA Healthcare, Greenville, USA) according to the ECL 
manufacturer’s protocol. 
2.9 Immunoprecipitation 
Immunoprecipitation was used to examine total protein co-localisation of CD44 with EGFR. 
Cells were grown to confluence in 35mm dishes and total cellular protein was extracted, as 
described under Western Blot Analysis (Section 2.8). Approximately 10μg of anti-EGFR 
antibody (Table 2.5) was conjugated to 200μL MagnaBind Goat Anti-Mouse IgG magnetic 
beads (Thermo-Fisher Scientific), by incubation for 2h at 4°C, whilst on a constant mix. The 
beads were then washed with PBS, using a magnetic strip to separate beads from solution. 
Equal amounts of each of the cell protein samples were incubated with the anti-EGFR 
antibody-conjugated MagnaBind beads, overnight at 4°C. Following three washes with 
Nonidet P-40 buffer (Sigma-Aldrich), the beads were resuspended in PBS and transferred to 
clean microcentrifuge tubes. The bead-antibody-protein complex was boiled with 1x reducing 
buffer for 5 minutes, before brief centrifugation. The supernatant was transferred into gel 
lanes for SDS-PAGE (as in Section 2.8). Western Blotting with rat anti-CD44 primary 
antibody (Table 2.5) was used for further analysis (secondary HRP antibody in Table 2.6). 
The specificity of immunoprecipitation was confirmed by negative control reactions 
performed with mouse serum IgG. 
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Table 2.5. Primary Antibodies and Dilutions used in Western Blot Analysis 
Antibody Type Host Dilution 
Anti-EGFR (528)  
(Merck Millipore) 
 
Anti-Phospho-EGFR (Y1068)  
(Cell Signaling Technology, Beverly, USA) 
 
Anti-CD44 (A020)  
(Merck Millipore) 
 
Anti-Phoshpo-p44/42 MAPK (ERK1/2) 
(T202/Y204)  
(Cell Signaling Technology) 
 
Anti-p44/42 MAPK (ERK1/2)  
(Cell Signaling Technology) 
 
Anti-Phospho-CaMKII (T286)  
(Cell Signaling Technology) 
 
Anti-CaMKII (pan)  
(Cell Signaling Technology) 
 
Anti-Caveolin-1 
 (Sigma-Aldrich) 
 
Anti-EEA1  
(BD Biosciences) 
 
Anti-TGF-βRI  
(Santa-Cruz Biotechnology Inc.)  
 
Anti-Phospho-STAT1  
(Cell Signaling Technology) 
 
Anti-STAT1 
(Cell Signaling Technology) 
 
Anti-Phospho-Smad2 (S465/467)  
(Cell Signaling Technology) 
 
Anti-Smad2  
(Cell Signaling Technology) 
 
Anti-GAPDH  
(Abcam, Cambridge, UK) 
Monoclonal 
 
 
Polyclonal 
 
 
Monoclonal 
 
 
Monoclonal 
 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Monoclonal 
 
 
Polyclonal 
 
 
Monoclonal 
 
 
Monoclonal 
 
 
Polyclonal 
 
 
Monoclonal 
 
 
Polyclonal 
Mouse 
 
 
Rabbit 
 
 
Rat 
 
 
Rabbit 
 
 
 
Rabbit 
 
 
Rabbit 
 
 
Rabbit 
 
 
Rabbit 
 
 
Mouse 
 
 
Rabbit 
 
 
Rabbit 
 
 
Mouse 
 
 
Rabbit 
 
 
Mouse 
 
 
Rabbit 
1:1,000 
 
 
1:5,000 
 
 
1:5,000 
 
 
1:10,000 
 
 
 
1:10,000 
 
 
1:2,000 
 
 
1:5,000 
 
 
1:500 
 
 
1:5,000 
 
 
1:1000 
 
 
1:2,000 
 
 
1:2,000 
 
 
1:5,000 
 
 
1:5,000 
 
 
1:5,000 
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Table 2.6. Secondary Antibodies and Dilutions used in Western Blot Analysis 
Antibody Type Host Dilution 
Anti-Mouse-IgG HRP 
 (Abcam) 
 
Anti-Rat-IgG HRP  
(Abcam) 
 
Anti-Rabbit-IgG HRP  
(Cell Signaling Technology) 
Polyclonal 
 
 
Polyclonal 
 
 
Polyclonal 
Goat 
 
 
Goat 
 
 
Goat 
1:5,000 
 
 
1:5,000 
 
 
1:5,000 
 
2.10 Laser Confocal Microscopy and Fluorescent Recovery After Photobleaching 
(FRAP) Analysis 
Cells were grown to 70% confluence on sterilised 22mm diameter glass coverslips, in 35mm 
dishes. Following appropriate experimental methods, the coverslip was removed from the 
medium and mounted on a microscope stage heated at 37°C. After ensuring a watertight seal 
between stage and coverslip was made, 500μL of medium was placed onto the coverslip and 
the appropriate primary fluorophore-conjugated antibodies/ligands were added (Table 2.7). 
Analysis was performed by laser confocal microscopy and FRAP. Briefly, an approximately 
10μm area of the cell membrane was chosen for photobleaching with high intensity laser light 
of appropriate wavelength (Table 2.7), for 5-10 seconds or until the antibody fluorophore 
diminished. A time-lapse video was recorded, clips were recorded for >500 frames over 5 
minutes.  
Co-localisation data were analysed using ImageJ (NIH Software) and Intensity Correlation 
Analysis (ICA), including the following statistical tests: Mander’s Co-localisation Coefficient 
(percentage of FITC co-localisation with TRITC), Pearson’s Correlation Coefficient (Rr); 
where perfect correlation = 1; and Intensity Correlation Quotient (ICQ), where with random 
staining ICQ = ∼0 and for dependent staining 0 < ICQ ≤ +0.5 [272]. 
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Leica Confocal Software (Leica Microsystems, Hamburg GmbH) was used to assess FRAP 
data and generate fluorescence intensity ratios (FI ratio); defined as FI ratio=Fz/Fo, where Fz 
is the intensity of the photobleached zone and Fo is the intensity of the control region taken 
from outside of the photobleached zone. Average diffusion constants (D) were calculated 
from the D=(w2/2t½)γD equation, where w is the radius of the photobleached area, t½ is the 
half time of fluorescent recovery, and γD is a constant that is dependent on experimental 
conditions [273]. Mobile fractions (MF) represent the fraction of receptors that had the ability 
to recover into the photobleached zone, over the observed time.  
Table 2.7. Antibodies/Markers and Dilutions used in Confocal Laser Microscopy and FRAP 
Antibody Wavelengths (nm) Dilution Excitation Emission 
Anti-EGFR FITC 
(Abcam) 
 
Anti-CD44 FITC 
(Abcam) 
 
Anti-CD44 PE-R 
(Abcam) 
 
CTX-B AlexaFluor 555 
(Life Technologies) 
488 
 
 
488 
 
 
528 
 
 
555 
525 
 
 
525 
 
 
578 
 
 
565 
1:500 
 
 
1:500 
 
 
1:500 
 
 
1:500 
 
2.11 Flow Cytometry 
Fibroblasts were grown to confluence and growth arrested in serum-free medium for 48h, 
before treatment with serum-free medium alone or serum-free medium, containing 50µg/ml 
nystatin for 1h. Cells were washed with PBS and incubated with 0.01% trypsin-EDTA to lift 
the cells. Trypsin was subsequently neutralised with FCS and the cell solution was 
centrifuged at 1,500×g for 5 minutes, at 20°C. The supernatant was aspirated and the cell 
pellet resuspended in 1% BSA-PBS, containing anti-EGFR-FITC (1:1000) and anti-CD44-
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PE-R (1:1000) or CTX-B AlexaFluor 555 (1:1000) (Table 2.7); and incubated on ice for 30 
minutes. Cells were then centrifuged at 1,500×g for 5 minutes at 4°C; and washed with ice-
cold PBS, before resuspension in 1% (w/v) BSA-PBS. Flow cytometry was then performed 
using a FACSCanto II Flow Cytometer (BD Biosciences) and data was analysed using 
FlowJo, version 7 (Tree Star, Olten, Switzerland).  
2.12 Plasmid Generation 
2.12.1 EGFR Promoter Luciferase Reporter 
A 247bp insert encoding the EGFR promoter was PCR amplified, using the Phusion DNA 
polymerase system (New England Biolabs, Hitchin, UK) from the forward primer, 5’-
ACTCCCGCCGGAGACTAGGT-3’; and the reverse primer, 5’-
CCGCGTCGGGCGCTCACACC-3’, with the addition of KpnI and XhoI endonuclease 
restriction sites, respectively. Amplified promoter inserts were PCR purified, digested with 
the appropriate endonuclease restriction enzymes (New England Biolabs), for 2h at 37°C, 
electrophoresed; and extracted from 1% agarose gel, according to Qiagen Gel Extraction Kit 
protocol (Qiagen, Barcelona, Spain). Inserts were then ligated together with KpnI and XhoI 
digested pGL3Basic (pGL3b) Vector using the T4 DNA Ligase System (New England 
Biolabs), overnight at 16°C. The pGL3b plasmid, containing the 247bp EGFR promoter 
insert (pGL3b-EGFR), was then transformed using the 42°C heat-shock method into one-shot 
competent Escherichia coli (New England Biolabs); and grown overnight on ampicillin 
containing agar. Single colonies were extracted, cloned and DNA purified according to the 
Miniprep Kit protocol (Sigma-Aldrich). Cloned pGL3b-EGFR Vector uptake of insert was 
confirmed with DNA sequencing (BIOCore Sequencing, Cardiff University, UK).  
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2.12.2 miRNA-7 Promoter Luciferase Reporter 
A 424bp insert encoding the miR-7 promoter was PCR amplified using the Phusion DNA 
Polymerase System (New England Biolabs), from the forward primer, 5’-
CTTGACAGGTTTAGGGAGCGT-3’; and the reverse primer, 5’-
AGGTCCCCAAAAGGTTGAGAC-3’, with the addition of KpnI and XhoI endonuclease 
restriction sites, respectively. Amplified promoter inserts were PCR purified, digested with 
the appropriate endonuclease restriction enzymes (New England Biolabs), for 2h at 37°C, 
electrophoresed; and extracted from 1% agarose gel, according to Qiagen Gel Extraction Kit 
protocol (Qiagen). Inserts were then ligated together with KpnI and XhoI digested 
pGL3Basic (pGL3b) Vector using the T4 DNA Ligase System (New England Biolabs), 
overnight at 16°C. The pGL3b plasmid, containing the 424bp miR-7 promoter insert (pGL3b-
miR-7), was then transformed using the 42°C heat-shock method into one-shot competent 
Figure 2.4. Diagram of pGL3-Basic Vector (pGL3b), indicating size (4818bp) and layout of the 
components within the vector, note the restriction endonuclease sites; KpnI and XhoI were used to first 
digest the plasmid and inserts, before ligation into a plasmid of approximately 5065bp. Test digestion 
of ligated pGL3b-EGFR plasmid resulted in two bands with correct sizes, in relation to the empty 
vector (4818bp) and the EGFR promoter insert (247bp). Lanes: 10kb DNA ladder (A), 1kb DNA 
ladder (B), pGL3b-EGFR digest (C), empty pGL3b digest (D), pGL3b-EGFR digest (E). 
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Escherichia coli (New England Biolabs); and grown overnight on ampicillin containing agar. 
Single colonies were extracted, cloned and DNA purified, according to the Miniprep Kit 
protocol (Sigma-Aldrich). Cloned pGL3b-miR-7 Vector uptake of insert was confirmed with 
DNA sequencing (BIOCore Sequencing).  
 
 
 
 
 
2.12.3 HAS2 Overexpression Vector 
The HAS2 open reading frame [244] was inserted into the Vector pCR3.1, using a standard 
ligation reaction with T4 DNA Ligase (New England Biolabs). Amplification of the cloned 
vector was performed via bacterial transformation into one-shot competent Escherichia coli 
(New England Biolabs); and grown overnight on ampicillin containing agar. Single colonies 
were extracted, cloned and DNA purified, according to the Miniprep Kit protocol (Sigma-
Aldrich). Cloned pCR3.1-HAS2 Vector uptake of inserts was confirmed with DNA 
sequencing (BIOCore Sequencing). Negative RT experiments were performed alongside 
HAS2 mRNA QPCR, to ensure that pCR-3.1-HAS2 Vectors weren’t conveying false-positive 
overexpression. 
 
 
Figure 2.5. Test digestion of ligated pGL3b-
miR-7 plasmid (approximately 5242bp), 
resulted in two bands with correct sizes in 
relation to the empty vector (4818bp) and 
the miR-7 promoter insert (424bp). Lanes: 
10kb DNA ladder (A), 1kb DNA Ladder 
(B), pGL3b-miR-7 digest (C), empty pGL3b 
digest (D), pGL3b-miR-7 digest (E). 
  
 70 
 
2.13 Transient Transfection 
Plasmids pGL3b-EGFR/miR-7 and pCR3.1-HAS2, and miRCURY LNA (Exiqon, Vedbaek, 
Denmark) transfections were completed using the Lipofectamine LTX system (Invitrogen; 
Life Technologies), according to manufacturer’s protocol, following optimisation of 
transfection. Pre-miR-7 (Ambion; Life Technologies) and small interfering RNA (siRNA) 
(Applied Biosystems) transfections were completed using the Lipofectamine 2000 system 
(Invitrogen; Life Technologies), according to manufacturer’s protocol, following 
optimisation. Transfection optimisation and efficiency for luciferase reporter plasmids were 
determined by co-transfection of a Renilla luciferase reporter. Transfection optimisation and 
efficiency for overexpression vectors were determined by co-transfection of pmaxGFP vector 
(Amaxa, Cologne, Germany) (Figure 2.7). Pre-miR-7, siRNA and LNA transfections were 
optimised according to the manufacturers’ protocols. All transfections were performed on 60-
70% confluent cell monolayers. Cells were incubated for 24h following transfection, prior to 
continuation of experiments. 
Figure 2.6. Structure of the pCR3.1 overexpression 
vector (5060bp), including the sequences for the T7 
promoter priming and BGH reverse priming sites. 
Note the PCR product (i.e. HAS2 open reading 
frame) ligation site.   
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2.13.1 Luciferase Reporter Transfection 
Transfections of luciferase reporter plasmids were performed on cells grown on 22mm dishes 
(12-well tissue culture plates), according to the Lipofectamine LTX transfection reagent 
protocol (Life Technologies). Briefly, 1μg of plasmid DNA (empty pGL3b, pGL3b-EGFR, or 
pGL3b-miR-7) and 1μL PLUS-reagent were added to 100μL of OPTIMEM transfection 
medium. Following 5 minutes incubation at room temperature, 2μL of Lipofectamine LTX 
transfection reagent was added, mixed well and left to incubate at room temperature for 40 
minutes. Renilla luciferase was co-transfected with pGL3b plasmids at a ratio of 1:4 
(0.25μg:1μg) and used as a control for transfection efficiency and for the normalisation of 
data. Reporter analysis was performed 24h after transfection using the Dual-Luciferase 
Reporter Assay Kit (Promega, Southampton, UK); and detected with a FLUOstar OPTIMA 
plate reader (BMG Lab Technologies).  
 
Figure 2.7. Transfection efficiency of empty pCR3.1 and pCR3.1-HAS2 overexpression vectors was 
optimised through the co-transfection of pmaxGFP nucleofector vector (Amaxa), as described in 
section 2.13.2. The cells were imaged using light (top row; total cell number) and fluorescent 
microscopy (bottom row; cells successfully transfected), at 48h post-transfection. The transfection 
efficiency of empty pCR3.1 and pCR3.1-HAS2 was 68% and 66%, respectively. Non-transfected 
cells were used as a negative control for pmaxGFP expression.  
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2.13.2 Overexpression Vector Transfection 
Overexpression vectors using the pCR3.1 plasmid were transfected with the Lipofectamine 
LTX Transfection Kit according to the manufacturer’s protocol (Life Technologies). Briefly, 
for two 22mm cell culture dishes, 750ng plasmid DNA, 0.75μL PLUS reagent and 4μL 
Lipofectamine LTX were added to 400μL OPTIMEM transfection medium, mixed well and 
incubated at room temperature for 40 minutes. Following incubation, 200μL of transfection 
solution was then added to each 22mm cell culture dish containing DMEM/F-12 growth 
medium with 10% FCS. Cells were incubated for 24h, before the medium was replaced with 
serum-free growth medium for further cell experimentation or analysis. To ensure 
transfection efficiency was optimum, 750ng pmaxGFP (Amaxa) was co-transfected with the 
pCR3.1 plasmid and GFP fluorescence was visualised 48h post-transfection, using a UV light 
microscope (Axiovert 135; Zeiss, Jena, Germany). As a negative control, an empty pCR3.1 
plasmid (containing no open reading frame sequence) was transfected into cells. 
2.13.3 Small interfering RNA (siRNA) Transfection  
Transient transfection of fibroblasts was performed with specific siRNA nucleotides targeting 
CD44 (I.D.: 4390824, Applied Biosystems) and HAS2 (I.D.: 4392420, Applied Biosystems). 
Transfection was performed in 35mm dishes using Lipofectamine 2000 transfection reagent 
(Invitrogen), in accordance with the manufacturer’s protocol. Briefly, for transfection of a 
single 35mm well: two solutions were made, the first consisted of the target siRNA (final 
transfection concentration of 30nM) in 100μL OPTIMEM transfection medium. The second 
solution consisted of 4μL Lipofectamine 2000 transfection reagent in 100μL OPTIMEM 
transfection medium. The solutions were mixed together and incubated for 40 minutes, at 
room temperature. Following incubation, an additional 800μL of OPTIMEM was added to 
the transfection solution. The cells were washed with OPTIMEM medium and the 1mL 
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transfection solution was incubated with the cells for 5-7 hours, after which an additional 
1mL of cell culture medium containing 20% FCS was added to the well. Following 24h of 
incubation, the medium was removed and replaced with serum-free media, in preparation for 
further cell treatments or analysis. As a negative control, cells were transfected with negative 
control siRNA (a scrambled sequence that bore no homology to the human genome) (I.D.: 
AM17110, Applied Biosystems).  
2.13.4 Pre-MicroRNA-7 Transfection 
Following growth arrest, pre-miR-7 (I.D.: PM10047; Ambion) was transfected into cells 
using the Lipofectamine 2000 Transfection System (Life Technologies). Two solutions were 
prepared; the first consisted of pre-miR-7 (final working concentration of 125nM) in 100μL 
OPTIMEM transfection medium; and the second consisted of 5μL Lipofectamine 2000 
transfection reagent in 100μL OPTIMEM. Solutions were mixed and incubated for 40 
minutes at room temperature. Solutions were then made up to 1mL by the addition of 
OPTIMEM. Cells were washed with OPTIMEM and the 1mL solution was added to the 
35mm cell culture dish. After 5-7 hours, 1mL of DMEM/F-12 growth medium containing 
20% FCS was added to the cell culture dish, which was then incubated for a further 24 hours. 
As a negative control, a scrambled pre-miR (I.D.: AM17110; Ambion) was transfected into 
cells (a sequence that codes for no known pre-miR). Medium was then removed and replaced 
with serum-free medium for further experimentation. 
2.13.5 miRCURY miR-7 Inhibitor LNA Transfection 
MicroRNA-7 locked nucleic acid (LNA) (I.D.: 410428-00; Exiqon) transfection was 
performed using the Lipofectamine LTX transfection reagent (Life Technologies). A solution 
of 1μL PLUS reagent, 2.5μL Lipofectamine LTX and miR-7 LNA (final working 
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concentration of 125nM) in 400μL OPTIMEM transfection medium was prepared. The 
transfection solution was incubated for 40 minutes and then added to the 35mm cell culture 
dish containing 2mL of DMEM/F-12 growth medium with 10% FCS. The cells were 
incubated in the transfection solution and growth medium mix for 24 hours, before the 
medium was replaced with serum-free DMEM/F-12 growth medium for further cell 
treatments or analysis. As a negative control, the commercially available Negative Control A 
LNA (I.D.: 199004-00; Exiqon) was used in place of the miR-7 LNA (a LNA sequence of 
similar length with no known miR targets). 
2.14 MicroRNA RT-PCR 
RNA was extracted and purified according to the methods described in conventional RT-PCR 
(Section 2.6). The RNA sample was diluted to 10ng and RT was performed for each miR, 
according to the instructions provided with TaqMan miR Gene Expression Assay Kits 
(Applied Biosystems). Briefly, a master mix containing 3μL TaqMan looped miR RT primer, 
0.15μL 100mM dNTPs, 1μL MultiScribe reverse transcriptase, 1.5μL 10x RT buffer, 0.19μL 
RNase inhibitor, 4.16μL nuclease-free H20 was made. Each RT-PCR reaction had a final 
volume of 15μL, consisting of 10μL master mix and 5μL RNA sample. The RT used the 
following parameters: 30 minutes at 16°C to allow looped RT primer to anneal to the target 
miR, 30 minutes at 42°C to allow random dNTP and transcriptase extension of the cDNA 
strand; and 5 minutes at 85°C to dissociate the looped RT primer from the miR/cDNA strands. 
The RT was performed on a PTC-225 Peltier Thermal Cycler (Bio-Rad Laboratories Inc.). 
Samples were cooled to 4°C and then transferred to -20°C, until further use. 
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2.15 MicroRNA RT-QPCR 
MicroRNA RT-QPCR was performed, according to the TaqMan MicroRNA Gene 
Expression Assay Kit protocol (Applied Biosystems). A master mix solution was made 
consisting of 1μL TaqMan MicroRNA Assay (20X), 10μL TaqMan 2X Universal PCR 
Master Mix, and 7.67μL nuclease-free H2O. Analysis was performed in triplicate on a 96-
well plate with a final reaction volume of 20μL, consisting of 1.33μL of cDNA and 18.67μL 
of master mix solution. The plate was briefly centrifuged and the QPCR was performed using 
the ViiA-7 Real Time PCR System (Applied Biosystems), using TaqMan 2X Universal PCR 
Master Mix (Applied Biosystems), following the manufacturer’s instructions. Following the 
completion of the QPCR run, the data was calibrated against a house-keeping miR, with no 
expression change under any experimental conditions performed (miR-16), using the 
comparative CT method as described in Section 2.7.3.   
Table 2.8. TaqMan miR Expression Assays 
Target TaqMan miR Expression Assay 
miR-16 
miR-7 
miR-7-1-3p 
miR-7-2-3p 
hsa-miR-16 (UAGCAGCACGUAAAUAUUGGCG) 
hsa-miR-7-5p (UGGAAGACUAGUGAUUUUGUUGU) 
hsa-miR-7-1-3p (CAACAAAUCACAGUCUGCCAUA) 
hsa-miR7-2-3p (CAACAAAUCCCAGUCUACCUAA) 
 
2.16 Biochemical Isolation of Lipid Rafts 
All procedures were carried out on ice. Fibroblast or myofibroblast monolayers were washed 
twice with ice-cold PBS; and cells from two 35mm confluent dishes were then scraped into 
1mL of ice-cold lysis buffer, containing 1% Triton X-100 and 1% protease inhibitor mixture 
(Sigma-Aldrich). Samples were vortexed thoroughly and left to incubate on ice for 30 
minutes, before centrifugation (1500×g for 5 minutes, at 4°C). The sample supernatants were 
 76 
placed at the bottom of a 5mL ultracentrifuge tube. Discontinuous OptiPrep gradients (35–
20% and 0%) (Sigma-Aldrich) were made according to the manufacturer's protocol; and 
added to the ultracentrifuge tube, containing the sample by overlaying. The gradients were 
centrifuged at 200,000×g for 14 hours with 2 hours of gentle acceleration and deceleration on 
either side in an Optima-Max ultracentrifuge (Beckman Coulter). Centrifugation time was 
sufficient to gain a continuous gradient, from which ten 500μL fractions were carefully 
collected, starting from the top of each tube. 
2.16.1 Fraction Analysis 
The collected fractions were subjected to SDS-PAGE and transferred to a nitrocellulose 
membrane, as described by Western Blot Analysis (Section 2.8). The presence of proteins of 
interest was examined using specific antibodies. The presence of caveolin-1 (Cav-1) and 
early endosomal antigen-1 (EEA1) was used to determine whether the fraction represented 
lipid raft or non-raft proteins, respectively. Following transfer of proteins to the nitrocellulose 
membrane, the membrane was blocked with 5% non-fat powdered milk in 0.5% Tween-PBS 
for 1 hour; and then incubated with rabbit anti-caveolin-1 or mouse anti-EEA1 (Table 2.5) in 
1% BSA, 0.1% Tween-PBS, at 4°C overnight. The blots were subsequently washed with 
0.1% Tween-PBS and then incubated with the appropriate secondary antibody, and visualised 
using ECL reagent (GE Healthcare). Cholera Toxin subunit B-HRP conjugate (CTX-HRP) 
(Sigma-Aldrich; dilution 1:500) was incubated with cell monolayers on ice for 1 hour, prior 
to lysis. CTX-HRP bound samples were used for dot-blot analysis, to confirm the presence of 
lipid rafts. 5µL of each fraction was pipetted onto a pre-washed nitrocellulose membrane and 
allowed to dry, the membrane was washed briefly with PBS and visualised with ECL reagent 
(GE Healthcare). 
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2.17 In Silico Analysis 
In silico analysis was performed to determine promoter start sites, transcription factor binding 
regions, miR protein or pathway target analysis, and for primer design. Putative transcription 
start sites were analysed using miRStart (National Chiao-Tung University, Hsinchu, Taiwan) 
and Genomatix MatInspector (Genomatix Software GmbH, Munich, Germany). Potential 
transcription factor binding regions were analysed using Genomatix MatInspector 
(Genomatix Software GmbH). TargetScan v6.2 (Whitehead Institute, Cambridge, USA), 
miRBase (Manchester University, UK) and GoDAVID v6.7 (National Cancer Institute, 
Frederick, USA) software were used to analyse potential miR protein and pathway targets, 
including details of conserved miR binding sites on the 3’UTR of targets. UCSC Genome 
Browser and PrimerBLAST (UCSC Genome Bioinformatics Group, Santa Cruz, USA) were 
used to design custom primers for use in QPCR or for PCR product amplification, for ligation 
into plasmids.     
2.18 Statistical Analysis 
Western blot images were densitometrically analysed by ImageJ (NIH Software). Graphical 
data are expressed as averages ± standard error mean (s.e.m.). To test for normal distribution 
of data and variances, the One-Way ANOVA, followed by Anderson-Darling and Bartlett’s 
Test, was used. The unpaired two-tailed Student’s t test was used for pairwise comparisons 
(excluding time course experiments), to identify statistical significance. Data were analysed 
using the software MiniTab version 15.0 (Minitab Solutions) and *P=<0.05 or **P=<0.01 
wereaconsideredasignificant. 
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3.1 Introduction 
3.1.1 The HA Receptor CD44 
The CD44 antigen is a glycoprotein and the major cell surface receptor for HA, essential for 
many HA-regulated intracellular influences. In humans, the CD44 antigen is encoded by the 
CD44 gene on chromosome 11 and is expressed in a large number of mammalian cell types 
[262, 263]. The standard isoform, designated CD44s, comprising exons 1–5 and 16–20, is 
expressed in most cell types. Alternative splicing of CD44 results in several splice variants 
containing variable exon regions, these are designated CD44vN (where N = 1 to 10). Some 
epithelial cells also express a larger isoform (CD44E), which includes exons v8–10 [274]. It 
is not yet clear whether or not certain CD44 variants have specific roles in cellular function. 
However, it has been suggested that higher expression of CD44v3 and v6 may be related to 
tumour metastasis [275, 276]. 
Although CD44 is the main receptor for HA, it can also interact with other ligands, such as 
osteopontin, collagens, MMPs; and other cell surface or transmembrane receptors, such as 
TGF-βRI and EGFR [160, 252, 262, 263]. CD44 function is controlled by post-translational 
modifications. One critical modification involves discrete sialofucosylation of glycan regions 
present on CD44v isoforms that have been noted to be involved in the migration of human 
hematopoietic and mesenchymal stem cells, but also in cancer cell metastasis [277, 278]. 
CD44 glycosylation also directly controls its binding capacity to fibrin and immobilised 
fibrinogen. Acylation through palmitoylation has recently been described as a mechanism of 
directly regulating CD44 endocytosis, lipid raft association and signal transduction [279]. 
The cellular functions of CD44 are diverse with participation in actions, including 
lymphocyte activation, cell-cell and cell-ECM interactions, migration, proliferation, 
differentiation, haematopoiesis, and tumour metastasis [262, 263].  
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3.1.2 HA-CD44 Binding 
The extracellular domain of CD44 contains a HA binding site referred to as the Link domain 
which shares a 100-amino acid region of homology with other hyaladherins. However, CD44 
differs in important ways from other HA-binding proteins. Whilst the Link module of TSG-6 
can bind HA on its own, HA binding by CD44 requires sequences outside the link module, 
regulated by cell-specific factors; and requires multiple CD44/HA engagements to achieve a 
functional avidity. Depending on the type and activation state of the cell in which it is 
expressed, CD44 may be inactive (unable to bind HA), inducible (able to bind HA upon 
treatment with certain CD44-specific mAb or with inducers of cell activation), or 
constitutively active (able to bind HA without any treatment). The activation state seems to 
be determined, at least in part, by post-translational modification (especially glycosylation) of 
the CD44 molecule itself [262, 263]. 
The most significant feature that distinguishes CD44 from other HA-binding proteins is that 
CD44 binding to HA takes place at the cell surface, where multiple, clustered or closely 
arrayed CD44 receptor molecules, interact with the highly multivalent repeating disaccharide 
chain of HA [254]. The affinity of a single CD44 HA-binding domain for HA is likely to be 
very low. Thus, binding of a CD44-positive cell to an HA substrate, or of a soluble HA 
molecule to the surface of a CD44-positive cell, involves multiple weak receptor-ligand 
interactions. This is a feature common to cell surface adhesion receptor-ligand interactions, 
but is especially important in the case of CD44, because of the highly repetitive nature of its 
ligand HA [263]. 
3.1.3 CD44 in Fibrosis and Myofibroblast Differentiation 
The functional relationship between HA and CD44 is of significant importance during TGF-
β1 stimulated differentiation, as the HA composition on the cell surface is modified. The 
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network of HA chains, bound to the cell surface by CD44, surrounding the cell; and linked 
together by heavy chain transfer from IαI – a process facilitated by and reliant on TSG-6 [280] 
– forms what is known as the HA pericellular matrix or coat. The HA pericellular coat is 
pivotal for myofibroblast differentiation, as knockdown of either CD44 or TSG-6 using 
siRNA transfection, resulted in a loss of pericellular coat formation and failure of 
differentiation in response to TGF-β1 stimulation [244, 252]. The functional significance of 
HA pericellular coat formation on the cell-surface or the intracellular interactions of CD44, 
its localisation and function as a co-receptor; and how the CD44 receptor properties are 
affected by HA-binding, remains unclear. Recent evidence suggests that other cell surface 
receptors, such as EGFR, can be activated in a CD44-dependent manner, leading to signal 
transduction via the MAPK/ERK pathway [160, 281]. Clusters of CD44 receptors appear to 
have the potential to surround, co-localise with and activate EGFR. Whether this is due to 
direct binding motif association, growth factor shuttling by CD44 (some CD44 variants are 
reportedly able to bind growth factors to ‘handle domains’ or able to bind and present HB-
EGF to cell surface receptors) [275, 276], or direct phosphorylation of EGFR by CD44, is 
unknown. This complex activation mechanism has also been suggested to be an essential step 
in driving both proliferation and differentiation in fibroblasts, in response to TGF-β1 
stimulation [160, 195]. Therefore, the roles of CD44 in both wound healing and the 
development of fibrosis are apparent. The invasive qualities gained from fibroblast and 
myofibroblast expression of HA and CD44 have been described as being necessary for the 
progression of severe lung fibrosis. Treatment with a CD44 blocking antibody abrogated the 
development of lung fibrosis in mice in vivo [257]; and in vitro work has demonstrated the 
importance of CD44 in the differentiation mechanism, as blocking CD44 activity prevented 
myofibroblast formation in response to TGF-β1 treatments [160]. 
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3.1.4 CD44 Localisation 
CD44 exists as a transmembrane receptor that has association with different cellular 
components, including both cytoskeletal and membrane-bound lipid rafts [282-285]. Through 
interaction with the cortical cytoskeleton [285], CD44 has been shown to have involvement 
in cytoskeletal reorganisation; and direct association with and activation of cytoskeletal 
bound proteins, such as ankyrin and cortactin, both of which are involved in structural 
cytoskeletal changes [282]. CD44 association with the cytoskeleton has been described as a 
means of signalling transduction from extracellular HA and could be a means of cell adaption 
to the extracellular environment [286]. However, previous research has reported a strong 
association between CD44 and cholesterol-rich membrane-bound lipid rafts, micro-domains 
of the membrane composed of a combination of glycosphingolipids and receptors. These 
specialised regions can compartmentalise and regulate cellular processes, by serving as 
organising centres for the assembly of signalling receptors and protein trafficking [287]. It 
has been reported that the localisation of CD44 in lipid rafts serves as a means of both 
restricting CD44 protein-protein interactions, in the case of the pro-migratory protein ezrin 
[283]; and promotion of protein-protein interactions, such as with integrin-β1, leading to 
endocytosis of CD44 and bound HA [284]. Since EGFR has been reported to exist both 
inside and outside of lipid raft domains [288, 289], the localisation of the TGF-β1-dependent 
association between CD44 and EGFR has not yet been pinpointed to a specific location in 
fibroblasts. It also remains unknown whether EGFR moves to localise with CD44 at either 
the cytoskeleton or lipid raft domains, or whether CD44 re-localises to areas of EGFR 
expression. Identification of the cellular location where CD44 and EGFR association and 
signalling occurs could therefore build upon what components of the differentiation 
mechanism have previously been shown [160, 195, 196, 244, 252, 260]; and reveal novel 
targets for intervention of myofibroblast differentiation and progressive fibrosis.    
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3.1.5 Intracellular Signalling 
Intracellular signalling through MAPK (ERK1/2) and Ca2+/calmodulin-dependent kinase II 
(CaMKII) has been previously shown to be activated by TGF-β1, as well as EGFR and CD44 
[187, 195, 290]. Whether these activators are independent or co-dependent, as part of the 
differentiation mechanism, has not yet been investigated. ERK1/2 has important cellular 
functions including the promotion of cell survival, proliferation, differentiation and migration 
[291-293]; and has been shown to be activated rapidly following TGF-β1 stimulation and 
crucial for myofibroblast differentiation [195]. Although CaMKII has been shown to be 
involved in cytoskeletal reorganisation, actin bundling and actin formation [290, 294-296], 
the information regarding CaMKII activity in myofibroblast differentiation is limited. Due to 
the nature of the function of CaMKII and its reported involvement in HA-CD44 mediated 
signalling [290], investigation into its role in the differentiation response is warranted. 
Investigation into the TGF-β1-induced or HA-CD44/EGFR activation of ERK1/2 and 
CaMKII signalling in fibroblast to myofibroblast differentiation, would provide insight into 
the mechanism of activation and a hierarchy of signalling; whether through TGF-β1 directly 
or through CD44 interaction with EGFR; and whether or not activation of one is dependent 
on the other. 
3.1.6 Summary of Aims 
The work outlined in this Chapter aimed to further describe the TGF-β1-dependent 
myofibroblast differentiation mechanism and expand upon previous findings [160, 195, 196, 
244, 252, 260]; and to investigate the hypothesis that compartmentalisation of CD44 with 
EGFR within a specific cellular location is necessary for activation of intracellular signal 
cascades, leading to myofibroblast differentiation. Specifically, the aim of this Chapter was to 
characterise the role of CD44 in the myofibroblast differentiation response in relation to: 
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i. Co-localisation with EGFR. 
ii. The affect of differentiation on membrane receptor dynamics. 
iii. The localisation of CD44-EGFR association. 
iv. Downstream intracellular signalling pathways: 
a. Characterisation of ERK1/2 and CaMKII signalling responses. 
b. Determination of hierarchy of signalling. 
v. HA-regulation of CD44 interaction, function and signalling. 
The results from this Chapter will detail the role of CD44, its interactions with EGFR, its 
receptor behaviour, its intracellular actions; and help to characterise its relationship with HA 
in the myofibroblast differentiation mechanism.   
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3.2 Results 
3.2.1 Characterisation of the Phenotypic Changes Associated With Terminal 
Myofibroblast Differentiation 
Fibroblasts were grown to 70% confluence for immunocytochemistry, or 100% confluence 
for QPCR analysis. Cells were deprived of serum for 48 hours, before the addition of 
recombinant TGF-β1 (10ng/ml) in serum-free medium, for 72 hours. To assess the 
phenotypic changes associated with myofibroblast differentiation, the expression of the 
myofibroblastic marker, α-SMA, was visualised using immunocytochemistry. In comparison 
to untreated control fibroblasts (average width approximately 5μm ± 1μm), the 
myofibroblasts displayed larger morphology (average width approximately 11μm ± 2μm). 
Myofibroblasts also expressed clearly defined α-SMA fibres, which were not observed in 
untreated cells (Figure 3.1A). In addition, QPCR analysis showed a TGF-β1 induced increase 
in α-SMA of approximately 42-fold (Figure 3.1B); and an increase in the myofibroblastic 
marker EDA-FN of approximately 32-fold (Figure 3.1C).  
Components contributing to the formation of the HA pericellular coat were also assessed for 
mRNA expression and were also significantly upregulated by TGF-β1 stimulation. The HA 
synthase, HAS2 – previously identified as the major contributor to HA coat formation in 
fibroblasts [244] (with the exception of oral fibroblasts [297]), was upregulated by 
approximately 3-fold (Figure 3.1D). TSG-6, the hyaladherin involved in HA-cross-linking, 
was upregulated by approximately 15-fold (Figure 3.1E). The observations made indicate the 
phenotypic alterations that occur in fibroblast to myofibroblast differentiation, highlighting 
the key components that are upregulated, in order to alter the cell morphology through 
intracellular and pericellular matrix production. 
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3.2.2 Analysis of the Regulation of TGF-β1-dependent Differentiation by CD44 and its 
Co-localisation With EGFR 
Confocal Laser Scanning Microscopy was used to assess the expression of EGFR and CD44 
in fibroblasts and changes associated with TGF-β1-dependent differentiation (Figure 3.2A). 
Both receptors were expressed in fibroblasts, with strong independent staining along the cell 
membrane. Following TGF-β1-induced differentiation to myofibroblasts, however, CD44 
(red) expression was found in areas of co-localisation with EGFR (green), visible as yellow 
(merged). Following lysis of myofibroblasts, CD44 was found to co-immunoprecipitate with 
EGFR (Figure 3.2B). Potential changes in the expression of CD44 receptor protein were 
examined and no significant changes were found (Figure 3.2C). Both transfection of siRNA 
targeting CD44 (siCD44) and treatment with the chemical inhibitor of EGFR activation, 
AG1748, inhibited phosphorylation of EGFR and of the down-stream signalling proteins, 
ERK1/2 (Figure 3.3A-C). CD44 knockdown was confirmed by QPCR (Figure 3.3D) and the 
effect of each treatment on differentiation was assessed by QPCR (Figure 3.3E). These data 
highlight the importance of both EGFR and CD44 and their active roles in the differentiation 
and signalling response. 
3.2.3 Analysis of Cellular Membrane Dynamics of CD44 and EGFR in Fibroblasts 
CD44 membrane dynamics change following differentiation. Fluorescence Recovery After 
Photobleaching (FRAP) was used to investigate receptor dynamics in the plasma membrane 
of fibroblasts and myofibroblasts (Figure 3.4).  In fibroblasts, EGFR was bound in clusters, 
within discrete areas of the cell membrane (Figure 3.4A); and did not diffuse into the 
bleached zone (Figure 3.4B). CD44, however, diffused rapidly (<100 seconds) into the 
bleached area (Figure 3.4C).  In myofibroblasts, EGFR was also found in static membrane 
domains (Figure 3.4D). In contrast to fibroblasts, however, CD44 on the surface of 
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myofibroblasts had a reduced mobility, with a diffusion constant of only 10% of that in 
fibroblasts (Figure 3.4E).  The mobile fraction (MF) of CD44 receptors was also reduced 
from approximately 60% in fibroblasts to 15% in myofibroblasts.  These results suggest that 
the loss of CD44 mobility in the membrane may be an important factor in the mechanism of 
myofibroblast induction.  
3.2.4 Determination of the Cellular Localisation of CD44 and EGFR 
The transmembrane receptor EGFR has been described to exist within lipid raft domains in 
tumour cells and neuronal cells [298, 299]; and can have ligand-independent activation 
outside of raft domains [288, 289, 300] – a possible mechanism through which CD44 may be 
responsible. CD44 itself has been documented to associate with different cellular structures, 
such as the cytoskeleton [282, 286] and membrane bound lipid rafts [279, 283]. To determine 
the cellular location where CD44 and EGFR co-localisation occurs, the chemicals 
cytochalasin-B (5μM), an inhibitor of actin formation; or nystatin (50μg/ml), a cholesterol 
sequestering agent and inhibitor of cholesterol synthesis, were used to pre-treat growth 
arrested cells for 1 hour, prior to incubation with TGF-β1 (10ng/ml) in serum-free medium 
for 72 hours. To assess each chemical’s action on α-SMA stress-fibre formation, 
immunocytochemistry was used to visualise α-SMA (Figure 3.5A). In cells treated with 
either cytochalasin-B or nystatin, the ability for the cells to produce α-SMA fibres was 
abolished. To determine whether this effect was due to the loss of EGFR (green) and CD44 
(red) co-localisation, fixed cells were stained using antibodies against each receptor (Figure 
3.5B). It was observed that both chemical treatments resulted in loss of stress-fibre generation. 
The loss of receptor co-localisation was more prominent in cells treated with nystatin, with 
areas of co-localisation remaining following cytochalasin-B treatments. Analysis of mRNA 
expression of α-SMA (Figure 3.5C) and HAS2 (Figure 3.5D) was assessed to determine 
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changes in gene activation and transduction. Although both chemical treatments significantly 
down-regulated expression of both mRNAs, compared to TGF-β1 stimulated untreated cells, 
there remained a smaller activation of both genes with TGF-β1 in those cells pre-treated with 
cytochalasin-B. Nystatin pre-treatment prevented gene induction from TGF-β1 stimulation.  
Assessment of total receptor and ERK1/2 signalling protein was required to determine 
whether chemical treatments were preventing signalling and gene induction; and hence 
myofibroblast differentiation, through disruption of cellular structures or through direct 
downregulation of proteins. Western blotting of total EGFR, CD44, and ERK1/2 proteins 
from whole cell lysate was performed (Figure 3.5E). Total EGFR protein remained unaltered 
in all experimental conditions, as shown in the densitometry graph. CD44 and ERK1/2 total 
protein was significantly down-regulated in cells treated with cytochalasin-B. These data 
suggest that the cellular location of CD44 interaction with EGFR was not the cytoskeleton, as 
co-localisation of the receptors persisted despite disruption of the actin cytoskeleton, 
suggesting lipid rafts as a potentially viable area of co-localisation. The loss of differentiation 
from cytochalasin-B treatment was likely not due to the loss of co-localisation, but primarily 
due to the nature of the chemical inhibition of actin formation and cytoskeletal disruption, 
with both CD44 and ERK1/2 - proteins with cytoskeletal association - reduced in pre-treated 
fibroblasts. 
3.2.5 The Co-localisation of CD44-EGFR in Membrane-bound Lipid Raft Domains and 
the Role of Lipid Rafts in Differentiation  
To investigate whether EGFR or CD44 were located in lipid rafts in primary human 
fibroblasts, Laser Confocal Scanning Microscopy was performed using cholera toxin subunit-
B (CTX-B)-555 (TRITC) conjugate, which binds GM1 containing, cholesterol-rich regions of 
the cell-membrane (Figure 3.6). Figure 3.6A indicates that in fibroblasts, wherever EGFR 
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was located, there were also cholesterol-rich domains containing CTX-B (yellow merged 
images). In contrast, CTX-B and CD44 had areas of no co-localisation, in addition to some 
areas of co-localisation, as can be seen in the merged images.  In myofibroblasts (Figure 
3.6B), there was also co-localisation of EGFR with CTX-B at the cell surface (white arrows), 
although CTX-B binding was not exclusively found in areas positive for EGFR.  In contrast 
to fibroblasts, however, CD44 on myofibroblasts was highly co-localised to areas positive for 
CTX-B (merged panel).  
To confirm the involvement of lipid rafts, both nystatin and methyl-β-cyclodextrin (MβCD) 
were used independently (Figure 3.6C) to disrupt rafts.  Following incubation of 
myofibroblasts with either compound, the co-localisation of both EGFR and CD44 with 
CTX-B was reduced. EGFR or CD44 expression was visible in areas absent of CTX-B 
binding (indicated by white arrows).  The summary of results from three independent 
experiments, showing the degree of co-localisation and the intensity correlation quotient 
(ICQ), is shown in Figure 3.6D.  These data indicate that there was a 4- to 5-fold decrease in 
EGFR association with CTX-B following nystatin treatment, before addition of TGF-β1. 
They also demonstrate a 3-fold increase in CD44 association with CTX-B, following 
myofibroblastic induction with TGF-β1, which is lost in cells pre-treated with nystatin. 
To further test the hypothesis that lipid rafts serve as the primary location of EGFR and co-
localisation with CD44 following differentiation, lipid rafts were biochemically isolated by 
ultracentrifugation and the collected fractions were examined for the lipid raft markers; Cav-1 
and CTX-HRP. EEA1 was used to determine non-raft regions of the cell membrane. In 
fibroblasts, EGFR was primarily found in lipid raft domains (Cav-1/CTX-B positive fractions; 
5 & 6) and CD44 in non-raft regions (EEA-1 positive fractions; 8, 9 & 10) (Figure 3.7A). In 
differentiated myofibroblasts, a proportion of CD44 was found to move into the fractions 
positive for lipid raft markers, demonstrating that CD44 existed in two populations, within 
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and outside lipid raft regions (Figure 3.7B). The quantification of receptors in lipid raft 
fractions (Figure 3.7C) indicated that the quantity of EGFR found in lipid raft fractions did 
not alter significantly between cellular phenotype. The presence of CD44 in lipid raft 
fractions significantly increased from approximately 10% to more than 40%, following 
differentiation. Cellular expression of Cav-1 (Figure 3.7D) had no significant change between 
fibroblasts and myofibroblasts, signifying that the increase of CD44 directed toward lipid raft 
fractions was a primary change as a result of differentiation, and not a consequence of an 
increased generation of Cav-1 positive rafts. 
To investigate the degree to which lipid rafts were involved in the mechanism controlling 
myofibroblast induction, α-SMA expression was assessed by immunocytochemistry (Figure 
3.8A). α-SMA was markedly downregulated in cells pre-treated with nystatin. QPCR (Figure 
3.8B) demonstrated that this was also a transcriptional effect on α-SMA mRNA. Co-
localisation of EGFR and CD44 in fibroblasts pre-treated with nystatin before the induction 
of differentiation with TGF-β1 was prevented, indicating that lipid rafts were key locations of 
the EGFR-CD44 association (Figure 3.8C). Statistical analysis showed a decrease in CD44 
co-localisation with EGFR in myofibroblasts from 70% to approximately 10%, if cells were 
pre-treated with nystatin (Figure 3.8D). Flow cytometry and Western blot analysis showed 
that nystatin treatment did not alter the expression nor total protein levels of EGFR or CD44 
over the course of treatment times (Supplementary Figure 3.SA). These results support the 
importance of lipid rafts in the TGF-β1-dependent differentiation pathway. 
3.2.6 TGF-β1 Activation of the ERK and CaMKII Signalling Cascade 
Previous research has shown that ERK1/2 are involved in the differentiation and proliferation 
of various cell types [195, 301-304]. Western blotting was used to assess the degree of 
phosphorylation of these kinases, following incubation with TGF-β1 (Figure 3.9A-B). Figure 
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3.9A shows the characteristic bi-phasic phosphorylation of ERK1/2, peaking at 10 minutes 
and again at 3 hours after the addition of TGF-β1.  
CaMKII is a kinase that is involved in cytoskeletal remodelling and the differentiation 
response (44, 45). Western blotting for phosphorylated CaMKII (Figure 3.9B) showed that 
CaMKII was also activated and its phosphorylation had a similar bi-phasic time-dependent 
activation to ERK phosphorylation, implicating CaMKII in the TGF-β1-dependent signalling 
pathways involved in myofibroblast differentiation. Neither ERK1/2 nor CaMKII 
phosphorylation fluctuated over the 3 hours, if cells remained in serum-free conditions 
(Supplementary Figure 3.SB) 
Whether ERK and CaMKII activation were independent of each other was investigated using 
the chemical inhibitor of ERK phosphorylation, PD98059; and the chemical inhibitor of 
CaMKII, KN-93. PD98059 inhibited ERK activation (Figure 3.9C) following TGF-β1 
stimulation, attenuating both peaks of the bi-phasic activation profile. Similarly, KN-93 
attenuated both peaks of CaMKII activation (Figure 3.9D), as expected. In addition, KN-93 
had no effect on ERK1/2 signalling and the bi-phasic activation was retained (Figure 3.9E). 
Interestingly, PD98059 inhibited CaMKII phosphorylation (Figure 3.9F), suggesting that 
ERK activation was a necessary upstream mediator of CaMKII activation. Since CaMKII 
activation was abolished following incubation with the chemical inhibitor of ERK1/2, the 
results shown here suggest that following the addition of TGF-β1, ERK is activated first 
leading to the down-stream activation of CaMKII. 
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3.2.7 The Relationship Between EGFR-CD44 Co-localisation in Lipid Rafts and the 
Activation of Early Differentiation Signalling of the EGFR-ERK1/2-CaMKII Pathway 
To confirm that it was raft-associated co-localisation that was responsible for the induction of 
ERK and CaMKII, nystatin was used to disrupt lipid rafts and then Western blotting was used 
to examine the phosphorylation of EGFR, ERK1/2 and CaMKII (Figure 3.10). Nystatin 
inhibited the early signalling phase of TGF-β1-dependent EGFR (Figure 3.10A), ERK 
(Figure 3.10B); and CaMKII (Figure 3.10C) phosphorylation, without affecting the late 
activation phase of either kinase. The loss of the early ERK and CaMKII signalling phases 
and the fibroblast resistance to differentiation following nystatin treatment, confirmed that the 
early signalling phase was primarily responsible for initiation of fibroblast to myofibroblast 
differentiation, as previously reported [267]; and that it was initiated in lipid rafts. 
Additionally, the expression of TGF-βRI and the activation of the Smad2 pathway remained 
unaffected by nystatin treatment (Supplementary Figure 3.SC). 
3.2.8 The Organisation of CD44 Co-localisation with EGFR and Downstream 
Intracellular Signalling by HA 
HAS2-regulated HA synthesis is a key mediator of TGF-β1-dependent myofibroblast 
differentiation and proliferation. HAS2 is the enzyme primarily responsible for upregulation 
of HA synthesis in fibroblasts, following TGF-β1-induced differentiation to myofibroblasts 
[244, 297, 305, 306]. The Institute of Nephrology has previously shown that HAS2 is an 
important mediator of differentiation in fibroblasts [160, 195]. Transfection with siRNA 
targeting HAS2 (siHAS2) reduced HAS2 mRNA expression by 4-fold and prevented HAS2 
upregulation in response to TGF-β1 (Figure 3.11A). The upregulation of α-SMA mRNA by 
TGF-β1 was prevented by siHAS2 transfection (Figure 3.11B); and CD44 co-
immunoprecipitation with EGFR was also prevented following siHAS2 transfection (Figure 
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3.11C). Whether HA production by HAS2 was a direct regulator of the ERK and CaMKII 
intracellular signalling pathways leading to phenotypic change was investigated by Western 
blotting for protein phosphorylation following transfection with siHAS2 or scrambled siRNA. 
The fibroblasts transfected with siHAS2 had attenuated TGF-β1 activation of EGFR (Figure 
3.11D), ERK (Figure 3.11E) and CaMKII (Figure 3.11F). In addition, both the early and late 
peaks of the bi-phasic signalling pattern were lost. The loss of early ERK and CaMKII 
phosphorylation peaks supports previous studies that have shown that HAS2 impairment in 
aged cells inhibits fibroblast differentiation [160]. In addition, the attenuation of the late 
phosphorylation peaks supports previous findings, highlighting HAS2 and HA as necessary 
mediators of fibroblast proliferation [195].  
3.2.9 The Role of HA in the Regulation of CD44 Membrane Dynamics 
To determine whether cell-surface HA was necessary for CD44 co-localisation with EGFR 
and membrane dynamics and behaviour, Confocal Microscopy and FRAP analysis were used, 
following hyaluronidase treatment (Figure 3.12). Interestingly, CD44 co-localisation with 
EGFR was partially lost, following hyaluronidase treatment (Figure 3.12A-B). CD44 
movement was restored in myofibroblasts incubated with hyaluronidase from both 
Streptomyces (S) and bovine testicular (BT) sources (Figure 3.12C-E). However, the MF 
indicated that hyaluronidase alone was not sufficient to restore mobility to the levels 
observed in fibroblasts. These data suggest that HAS2 production of the HA pericellular coat 
was partly responsible for the sequestration and anchoring of CD44 into lipid raft domains, 
where it co-localised with EGFR and enables the resulting differentiation signalling response. 
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Figure 3.1.  Phenotypic Changes in Myofibroblast Differentiation. A. Cells were grown to 70% confluent 
monolayers and growth arrested for 48 hours. Cells were then incubated in serum-free medium alone 
(fibroblasts) or in medium containing 10ng/ml TGF-β1 for 72 hours (myofibroblasts). The expression of α-
SMA (green) was examined by immunocytochemistry, nuclei were visualised by Hoechst stain. Images 
shown are a representation of 5 independent experiments. Original magnification x400. The mRNA 
expression of B. α-SMA, C. EDA-FN, D. HAS2 and E. TSG-6, was analysed using QPCR. Results are 
shown as the mean ± s.e.m. of 3 individual experiments. **P=<0.01. 
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Figure 3.2. CD44 and EGFR Co-localisation in Myofibroblasts. A. Cells were grown to 70% confluent 
monolayers and growth arrested for 48 hours. Cells were then incubated in serum-free medium alone 
(fibroblasts) or in medium containing 10ng/ml TGF-β1 for 72 hours (myofibroblasts). Confocal Laser 
Scanning Microscopy was used to examine the expression of EGFR (green; FITC) and CD44 (red; PE-R). 
Areas of co-localisation are shown in the merged images (yellow; enlarged images shown in blue boxes). 
Images shown are a representation of 5 independent experiments. Original magnification x630. B. Co-
localisation of EGFR and CD44 was analysed by immunoprecipitation for EGFR, followed by 
immunoblotting for CD44. Image shown is representative of 3 individual experiments. C. Western blot 
analysis of total CD44 protein in fibroblasts and myofibroblasts. GAPDH was used as a loading control. 
Representative blot is shown. Densitometry graph shown is ± s.e.m. of 3 individual experiments. N/S = no 
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Figure 3.3. Both CD44 and EGFR are Required for Signal Transduction. A. Fibroblasts were transfected 
with a scrambled siRNA sequence or siRNA targeting CD44, prior to treatments with or without AG1478 for 
1 hour, before TGF-β1 for 72 hours. Phosphorylation of EGFR and ERK1/2 was analysed by Western 
blotting. Total EGFR and ERK1/2 proteins were used as loading controls. Image shown is representative of 3 
independent experiments. B. Densitometric analysis of p-EGFR, normalised to total EGFR. Graph shows ± 
s.e.m. of 3 independent experiments. C. Densitometric analysis of p-ERK1/2, normalised to total ERK1/2. 
Graph shows ± s.e.m. of 3 independent experiments. D. QPCR was used to confirm CD44 mRNA 
knockdown by siCD44. Results shown are ± s.e.m. of 3 individual experiments. E. QPCR was used to 
analyse α-SMA mRNA, following siCD44 and 10μM AG1478 cellular treatments. Results shown are ± 
s.e.m. of 3 individual experiments. **P=<0.01. 
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Figure 3.4. The Membrane Dynamics of CD44 and EGFR. A. Sample time-lapse series of fluorescent 
recovery, after photobleaching (FRAP) experiments. Original magnification x630. Fibroblasts or 
myofibroblasts were grown to 70% confluent monolayers on 22mm diameter glass coverslips, in 35mm 6-
well tissue culture plates. Cells were growth arrested in serum-free medium for 48 hours. FRAP was 
performed at 37°C by photobleaching an approximately 10µm area of the cell membrane (indicated by white 
boxes on bright-field images). The recovery of fluorescence into this area (indicated by white arrows) was 
quantified and expressed as a fraction of the fluorescence intensity (FI) of a second region of membrane, 
outside of the photobleached area (FI Ratio). Complete quantified time-courses, average diffusion constants 
(D) and mobile fractions (MF) are shown for: B. EGFR in fibroblasts; C. CD44 in fibroblasts; D. EGFR in 
myofibroblasts; and E. CD44 in myofibroblasts. All results shown are representative of 5 independent 
experiments. Statistics shown are ± s.e.m. of 5 independent experiments. 
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Figure 3.5. Co-localisation is Lipid Raft Associated and Not Cytoskeletal. Cells were grown to 70% confluence, growth arrested for 48 hours and treated with 5µM 
cytochalasin-B or 50µg/ml nystatin for 1 hour. Following 72 hours of incubation in serum-free media with or without 10ng/ml TGF-β1, cells were fixed and stained for A. 
α-SMA visualisation or B. EGFR (green) and CD44 (red) (areas of co-localisation in yellow). Original magnification x630. The expression of C. α-SMA mRNA and D. 
HAS2 mRNA, were assessed by QPCR. Results are shown as the mean ± s.e.m. of 3 individual experiments. E. Western blotting and densitometry analysis of total EGFR, 
CD44 and ERK1/2 proteins, from whole cell lysates. Immunoblots are representative of 3 individual experiments and the densitometry analysis is displayed as the mean ± 
s.e.m. of 3 individual experiments. *P=<0.05, **P=<0.01, N/S = no significance. 
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Figure 3.6. CD44 and EGFR Co-localisation with Lipid Raft Marker CTX-B. Fibroblasts or myofibroblasts were grown on 22mm diameter glass coverslips and 
examined for A. EGFR (green; FITC) and CTX-B binding (red; TRITC); and B. CD44 (green; FITC) and CTX-B binding (red; TRITC), using Confocal Laser Scanning 
Microscopy (areas of co-localisation shown in yellow; areas of CTX-B binding with EGFR marked by white arrows). Images are representative of 5 individual 
experiments. Original magnification x630. C. Cells were treated with nystatin (50µg/ml) or MβCD (10mM) for 1 hour, before examination of EGFR or CD44 expression 
(green; FITC) and CTX-B binding (red; TRITC), (areas of EGFR or CD44 expression without CTX-B binding marked by white arrows). Images are representative of 3 
individual experiments. Original magnification x630. D. Co-localisation of EGFR or CD44 with CTX-B was quantified (Mander’s Co-localisation Coefficient). Statistical 
analysis includes the average Pearson’s Correlation Coefficient (Rr) and Intensity Correlation Quotient (ICQ) for each experimental condition.  Results shown are ± s.e.m. 
of 3 independent experiments. **P=<0.01. 
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Figure 3.7. Membrane Fraction Analysis in Fibroblasts and Myofibroblasts. Cells were grown to 
confluence and growth arrested for 48 hours. Cells were incubated in A. serum-free medium alone 
(fibroblasts) or B. serum-free medium containing 10ng/ml TGF-β1 for 72 hours (myofibroblasts). Cellular 
membrane preparations were separated in a discontinuous OptiPrep gradient by ultracentrifugation. Fractions 
were analysed for the presence of EGFR and CD44. Cav-1 was used to detect fractions positive for lipid 
rafts, and EEA-1 for non-raft fractions. Lipid raft fractions were confirmed using CTX-HRP dot-blots for 
each fraction. Positive and negative control dot-blots were used to confirm the specificity of CTX-HRP. C. 
Quantification of the percentage of EGFR and CD44 found within lipid raft fractions 5-6 in fibroblasts and 
myofibroblasts. Results shown are ± s.e.m. of 3 independent experiments. D. Flow Cytometry analysis of cell 
surface expression of Cav-1 in fibroblasts and myofibroblasts. Unlabelled cells were used as intensity 
controls. Bar graph of relative intensity shown is ± s.e.m. of 3 individual experiments. N/S = no significance; 
**P=<0.01. 
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Figure 3.8. Lipid Raft Disruption Inhibits Myofibroblast Differentiation. Cells were grown to 70% confluence and growth arrested for 48 hours. Cells were incubated 
with 50µg/ml nystatin for 1 hour, before incubation in serum-free medium alone or containing 10ng/ml TGF-β1 for 72 hours. A. α-SMA expression (green) was examined 
by immunocytochemistry. Nuclei visualised by Hoechst stain (blue). Naïve IgG was used for negative controls. Images are representative of 3 independent experiments. 
Original magnification: x400. B. Cells were examined for α-SMA mRNA using QPCR. Results are shown as the mean ± s.e.m. of 3 individual experiments. C. EGFR 
(green; FITC) and CD44 (red; PE-R) expression was examined by immunocytochemistry. Areas of co-localisation are shown in yellow. Nuclei visualised by Hoechst stain 
(blue). Naïve IgG was used for negative controls. Images are representative of 5 individual experiments. Original magnification: x400. D. The co-localisation of CD44 with 
EGFR was quantified (Mander’s Co-localisation Coefficient). Statistical analysis includes the average Pearson’s Correlation Coefficient (Rr) and Intensity Correlation 
Quotient (ICQ) for each experimental condition. Results shown are ± s.e.m. of 5 individual experiments. **P=<0.01. 
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Figure 3.9. Intracellular Signalling Through ERK1/2 and CaMKII. Confluent fibroblast monolayers were 
growth arrested for 48 hours and were subsequently incubated with 10ng/ml TGF-β1, for up to 3 hours. The 
phosphorylation of A. ERK1/2 and B. CaMKII proteins was assessed by Western blot analysis at the indicated 
times. Western blot analysis for the appropriate total proteins was performed to ensure equal loading of protein 
samples. Following scanning densitometry, phosphorylated ERK1/2 and CaMKII expression was corrected for 
the expression of total ERK1/2 and CaMKII protein respectively; and is represented as ± s.e.m. of 3 separate 
experiments. Cells were pre-treated with 10µM MEK/ERK inhibitor PD98059(+) or left untreated(-) (C. and 
F.), or 10µM CaMKII inhibitor KN-93(+) with the inactive isomer KN-92(-) as a control (D. and E.) for 1 
hour. Phosphorylation of ERK1/2 (C. and E.) and CaMKII (D. and F.) proteins was assessed by Western blot 
analysis at the indicated times. Western blot analysis for the appropriate total proteins was performed to ensure 
equal loading of protein samples. Following scanning densitometry, alterations in phosphorylated ERK1/2 and 
CaMKII expression were corrected for the expression of total ERK1/2 and CaMKII protein, respectively. 
Representative blots of 3 independent experiments are shown and densitometry graphs show ± s.e.m. of 3 
separate experiments. *P=<0.05; **P=<0.01. 
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Figure 3.10. The Early Phase of Signalling is Dependent on Lipid Raft Integrity. Confluent monolayers of 
fibroblasts were growth arrested in serum-free medium for 48 hours. Subsequently, cells were incubated with 
(+) or without (-) 50µg/ml nystatin for 1 hour, before incubation with 10ng/ml TGF-β1 for up to 3 hours. A. 
Phosphorylation of EGFR was assessed by Western blot analysis at the indicated times. Western blot analysis 
for total EGFR protein was performed to ensure equal loading of protein samples. Densitometry graph shows ± 
s.e.m. of 3 individual experiments. B. Phosphorylation of ERK1/2 was assessed. Western blot analysis for total 
ERK1/2 protein was performed to ensure equal loading of protein samples. Densitometry graph shows ± s.e.m. 
of 3 individual experiments. C. Phosphorylation of CaMKII was assessed. Western blot analysis for total 
CaMKII protein was performed to ensure equal loading of protein samples. Densitometry graph shows ± s.e.m. 
of 3 individual experiments. All blots shown are representative of 3 separate experiments. *P=<0.05; 
**P=<0.01. 
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Figure 3.11. CD44-EGFR Co-localisation and Signalling is HA-regulated. Fibroblasts were grown to 70% confluence and were growth arrested in serum-free medium 
for 24 hours. Subsequently, cells were transfected with scrambled siRNA (control) or HAS2 siRNA for 24 hours, before incubation with 10ng/ml TGF-β1 for up to 72 hours. 
A. QPCR analysis to confirm knockdown of HAS2 mRNA. Data shown is ± s.e.m. of 3 individual experiments. B. QPCR was used to examine α-SMA mRNA expression. 
Data shown is ± s.e.m. of 3 individual experiments. C. Immunoprecipitation of EGFR followed by immunoblotting of CD44. Image shown is representative of 3 separate 
experiments. D. Western blot analysis of phosphorylated and total EGFR at the indicated times and corrected densitometry graph. E. Western blot analysis of phosphorylated 
and total ERK1/2 at the indicated times and corrected densitometry graph. F. Western blot analysis of phosphorylated and total CaMKII at the indicated times and corrected 
densitometry graph. All blots shown are representative of 3 separate experiments and all densitometry graphs show ± s.e.m. of 3 separate experiments.  **P=<0.01. 
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Figure 3.12. The HA Pericellular Coat Maintains CD44-EGFR Co-localisation. A. Myofibroblasts were grown to 70% confluence and Confocal Laser Scanning 
Microscopy was used to assess the effect of hyaluronidase treatments on EGFR (green; FITC) and CD44 (red; PE-R) co-localisation in myofibroblasts (white arrows indicate 
areas of no co-localisation). Images are representative of 3 individual experiments. Original magnification x630. B. Receptor co-localisation was quantified (Mander’s Co-
localisation Coefficient). Statistical analysis includes the average Pearson’s Correlation Coefficient (Rr) and Intensity Correlation Quotient (ICQ) for each experimental 
condition. Results shown are ± s.e.m. of 3 individual experiments. The recovery of fluorescence into a photobleached area was quantified and expressed as a fraction of the 
fluorescence intensity (FI) of a second region of membrane, outside of the photobleached area (FI Ratio). Complete quantified time-courses, average diffusion constants (D) 
and mobile fractions (MF) are shown for: C. CD44 in myofibroblasts; D. CD44 in myofibroblasts treated with 1U/mL streptomyces (S) hyaluronidase, and E. CD44 in 
myofibroblasts treated with 100µg/ml bovine testicular (BT) hyaluronidase. Results are shown are representative of 3 independent experiments. **P=<0.01. 
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3.3 Discussion 
This Chapter provides insights into the mechanisms controlling TGF-β1-dependent 
differentiation of fibroblasts to myofibroblasts, through the interaction of CD44 with EGFR 
in lipid rafts. The HA receptor, CD44, can function as a co-receptor, physically associating 
with several membrane-bound proteins, resulting in modulation of intracellular signal 
transduction pathways and facilitating the formation of specialised signalling complexes [307, 
308].  In light of these reports, I sought to determine if a similar system operated during 
myofibroblast differentiation. The data reported here support previous findings, where 
following TGF-β1 stimulated differentiation, CD44 and EGFR co-localised in dermal 
fibroblasts [160] and also in oral fibroblasts, but only if in a HA-rich environment [195].  
Although the myofibroblast phenotype is well documented, the mechanism leading to 
differentiation from fibroblasts has had limited detailing. Investigation into the co-
localisation between CD44 and EGFR that was previously suggested [160, 195], and the 
cellular location of this association could characterise a differentiation-unique mechanism 
that results in myofibroblast generation and therefore, contributes to progressive fibrosis. The 
results reported here illustrate that EGFR was held static, at discrete, membrane-bound sites, 
whilst CD44 was free to diffuse within the plasma membrane. Following TGF-β1-induced 
differentiation, EGFR remained static, while the ability of CD44 to diffuse freely was 
attenuated as it became co-localised with EGFR. It was, therefore, determined that the co-
localisation mechanism was a result of CD44 movement directed toward the cellular location 
of EGFR.    
Analysis of the possibilities of the cellular structure where CD44 and EGFR co-localisation 
takes place used cellular treatments with cytochalasin-B and nystatin. The loss of α-SMA 
generation in cytochalasin-B treated cells was likely to be a result of cytochalasin-B 
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disruption of the cellular population of CD44, rather than through an inhibition of receptor 
association. It was also noted that there was knockdown of total CD44 and ERK1/2 protein in 
cytochalasin-B treated cells, compared to both untreated and nystatin treated cells, further 
supporting the hypothesis that inhibition of differentiation was from direct knockdown of key 
components involved in the response. Nystatin, on the other hand, was able to inhibit α-SMA 
generation and CD44-EGFR co-localisation, without attenuating total CD44 and ERK1/2 
proteins. The combination of data from the chemical treatments of cells and FRAP 
experimentation, suggests that CD44 can exist in two populations, one with high mobility and 
cytoskeletal association in resting fibroblasts; and the other with restricted movement and 
interaction with EGFR potentially held in membrane bound lipid rafts in myofibroblasts. 
Further examination to clarify the localisation of EGFR revealed that in both fibroblasts and 
myofibroblasts, EGFR was associated and co-localised with cholesterol-rich micro-domains 
or lipid rafts [309]. These findings supported previous reports of EGFR being bound in lipid 
raft domains in other cell systems [310]; and of lipid rafts as regulators of EGFR and other 
receptors [288, 311, 312]. CD44 was found to co-localise with lipid raft domains after 
differentiation of fibroblasts to myofibroblasts, supporting the hypothesis that CD44 re-
localisation to EGFR in lipid rafts was implicated in the differentiation pathway.  Co-
localisation of EGFR and CD44 was lost when lipid rafts were disrupted; and these data 
support fibroblast lipid rafts as the areas where EGFR aggregated and to which CD44 moved 
to, associating with EGFR during phenotypic change. The disruption of lipid rafts also 
resulted in prevention of α-SMA upregulation, following TGF-β1-induced differentiation of 
fibroblasts at both mRNA and protein levels, antagonising the induction of myofibroblasts. 
The data reported here suggest that lipid rafts are essential structures for accommodation of 
EGFR-CD44 complexes and the subsequent differentiation signalling. As CD44 motility was 
reduced, but not completely abolished, in myofibroblasts and was also found in membrane 
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fractions positive for EEA-1, it can be concluded that CD44 is present in multiple regions of 
fibroblasts and myofibroblasts and indeed the cellular membrane. This coincides with 
previously published data, which shows CD44 as being bound to the cell cytoskeleton [290], 
able to move to membrane bound lipid rafts [279] and co-localise with other proteins [290, 
302, 307], attributing to its repertoire of roles and cellular functions.  
It is well known that TGF-β1 can induce activation of the ERK signalling pathway.  Several 
studies have proposed a contributory role of ERK signalling in the promotion of the fibrotic 
response [313, 314]; and have also shown that ERK1/2 activation was required for TGF-β1-
driven proliferation in both oral and dermal fibroblasts [195]. The results shown here confirm 
that there is a two-peak or “bi-phasic” activation profile of ERK1/2, dubbed the early and late 
signalling responses.  In addition, the data presented in this chapter also showed a co-incident 
bi-phasic activation of the kinase, CaMKII, at the same time-points as ERK1/2, suggesting 
both may be involved and play a large role in TGF-β1-dependent responses.  Previous 
research in cancer cell lines demonstrated that CaMKII is centrally involved in cytoskeletal 
reorganisation and modification [290] and that HA-CD44 interaction mediated CaMKII-
dependent cellular migration, independently of ERK1/2 phosphorylation. In this chapter’s 
investigations, inhibition of ERK phosphorylation prevented activation of CaMKII, 
suggesting that ERK and CaMKII are closely associated.  In contrast, inhibition of CaMKII 
did not attenuate ERK signalling. These data demonstrate that ERK activation is upstream of 
CaMKII in differentiating fibroblasts and that ERK1/2 activation is a regulator of CaMKII 
activation with both required for the subsequent differentiation response.  
I propose that the early ERK1/2 and CaMKII responses are involved in the induction of 
fibroblast differentiation, as abolition of membrane-bound lipid rafts with nystatin resulted in 
the attenuation of both ERK1/2 and CaMKII early waves of activation. In contrast, the late 
activation remained in cells pre-treated with nystatin, suggesting that the late signalling 
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response of ERK1/2 and CaMKII leading to proliferation was indicative of another 
originating source that was not in lipid raft domains. This has been suggested in research 
highlighting how EGFR can be susceptible to ligand-free activation and can produce a 
proliferation response, when it has been released to non-lipid raft areas of the cell membrane 
[287, 289]. However, it is not known whether this occurs in fibroblasts, in the absence of HA 
or CD44.  
Several previous studies have underlined the importance of HA in fibroblast function and 
wound healing [241, 244, 297, 315, 316].  It was, therefore, sought to determine whether HA 
synthesis and upregulation through HAS2 were necessary steps leading to EGFR 
phosphorylation, receptor co-localisation; and both ERK and CaMKII intracellular signalling. 
I have also investigated whether HAS2 activity was the primary modulator of the 
differentiation pathway, independent of the TGF-β1-SMAD signalling pathway.  Here it is 
shown that inhibition of HAS2 attenuated activation of EGFR and both signalling phases of 
ERK and CaMKII phosphorylation, confirming that HAS2 was an essential component in the 
TGF-β1-mediated differentiation pathway. It was also demonstrated that removal of the HA-
pericellular coat with hyaluronidase released CD44 from static membrane domains, thus 
partially restoring the potential of movement throughout the cell membrane, indicating that 
there may be further changes to CD44 that have taken place to maintain its association with 
lipid rafts and EGFR. The data presented here highlight the importance of the HA-pericellular 
coat in orchestrating CD44 to enable modulation of intracellular signalling pathways. 
Previous work from our laboratory reported that HAS2 and EGFR overexpression could 
restore the differentiation potential of aged fibroblasts [160]. However, it was also 
demonstrated that HAS2 overexpression alone was not enough to initiate EGFR-CD44 
coupling or differentiation and that TGF-β1 stimulation was also required [195]. The data 
presented in this chapter indicate that HAS2 activation mediates differentiation through 
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initiating CD44 sequestration into lipid rafts and the co-localisation with EGFR, leading to 
phosphorylation of EGFR and subsequently, ERK and CaMKII signalling. Therefore, HAS2-
regulated HA synthesis is a major determining factor in the phenotypic activation of 
fibroblasts. This change in phenotype, however, also involves the simultaneous activation of 
the classical Smad-mediated signalling pathway, initiated by TGF-β1 binding to its receptor 
[160].   
The data presented in this chapter provides mechanistic insights into the process of transition 
between scarring and scar-free tissue repair. The data also extends the findings from our 
laboratory that demonstrated the important regulatory role of HA-rich pericellular matrices in 
the co-ordination of TGF-β1-dependent fibroblast differentiation [260]. Combining previous 
results with the current findings suggests that stimulation of differentiation in response to 
TGF-β1 requires a HA-rich matrix, functionality of CD44; and EGFR associated with 
cholesterol-rich membrane-bound lipid rafts. HA and HA pericellular coat formation 
facilitates TGF-β1-dependent fibroblast differentiation through HA-CD44 binding and 
relocation, promoting interaction between the CD44 and EGFR within lipid rafts. This then 
promotes specific intracellular signal transduction through the ERK-CaMKII pathway, acting 
to complement the Smad pathway, resulting in myofibroblastic transformation (as 
summarised in Figure 3i). 
In summary, the data reported in this Chapter demonstrated, in-depth, the mechanism of 
CD44 co-localisation with EGFR, providing a key cellular compartment for this receptor 
interaction and the signalling mechanisms involved in contribution to successful 
myofibroblast differentiation. These results may yield valuable insights into potential targets 
for preventative measures or therapeutic treatments for progressive fibrosis. In light of this 
chapter’s findings and previously gathered data, the role of EGFR in the differentiation 
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mechanism can be described as pivotal. The following chapter will examine the dysfunctions 
of differentiation deriving from the age-associated loss of EGFR by investigation into the 
regulation of EGFR transcription and synthesis; and use experimental techniques in order to 
restore EGFR expression and function and therefore, myofibroblast differentiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3i. Summarised and updated cell signalling mechanism for fibroblast-myofibroblast 
differentiation. Additional detailing includes HA-dependent CD44-EGFR co-localisation in lipid rafts 
(yellow), CaMKII activation downstream of ERK1/2 (light-green pathway), indication of the bi-phasic 
ERK1/2-CaMKII signalling with early phase association to pro-differentiation; and HAS2 gene 
upregulation (red arrow) dependent on the EGFR branch of the differentiation response.    
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4.1 Introduction 
4.1.1 Loss of EGFR in Age-associated Dysfunction of Myofibroblast Differentiation  
The synergistic effects between TGF-β1 and EGFR signalling have been previously 
demonstrated [317-319]; and were further explored in the previous results chapter. Earlier 
studies have also demonstrated that TGF-β1 induces the expression of high-affinity EGFR in 
stromal fibroblasts [320] and in epidermal cell lines TGF-β1 increased tyrosine 
phosphorylation of EGFR that was not dependent on protein synthesis [321]. Previous studies 
[322] and work from the Institute of Nephrology [160, 195] reported that TGF-β-mediated 
Smad phosphorylation was independent of TGF-β1-mediated EGFR signalling. This 
indicated that the TGF-βRI and EGFR signalling pathway were crucial, yet independent, 
events for TGF-β1-mediated myofibroblastic differentiation.  
Furthermore, studies revealed that EGFR levels preferentially declined during cellular ageing 
of fibroblasts regardless of whether the cellular ageing occurred in vivo or in vitro [159]. This 
was highlighted by a loss in ligand binding sites per cell. EGFR mRNA levels were also 
diminished, in parallel with reduced surface and total EGFR protein. An age-related 
transcriptional control element remains to be identified, the results of the study by Shiraha et 
al. suggest that this preferential loss of EGFR was caused by a gradual loss of mRNA 
transcriptional activity, although the factors regulating said activity in this context are not yet 
fully understood. 
Although age-related failure of TGF-β1-induced myofibroblast differentiation was reported 
to be associated with the inability to induce HAS2, a decrease in HA synthesis and a lack of 
pericellular coat formation; HA synthesis and coat assembly restored by forced expression of 
HAS2 followed by TGF-β1 stimulation [244], did not restore the myofibroblast phenotype. 
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Studies, including those from the Institute of Nephrology, have demonstrated that the loss of 
EGFR expression and its responsiveness in aged cells was central to age-related resistance to 
differentiation [159, 160]. Investigation into the factors limiting EGFR transcription and 
protein synthesis in aged fibroblasts, could help unravel a potential method for the restoration 
of EGFR in aged cells and thus help restore potential to undergo differentiation. 
4.1.2 EGF and EGFR Signalling 
Epidermal growth factor (EGF) is a 53 amino acid growth factor and cytokine involved in 
signalling pathways promoting cell proliferation, survival and differentiation [323]. Its cell 
surface receptor, EGFR (ErbB-1; HER1 in humans) is the cell-surface receptor for members 
of the EGF-family of extracellular protein ligands. EGFR is a member of the ErbB family of 
receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), 
HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4) [324].  
EGFR exists on the cell surface as a transmembrane receptor and is activated by the binding 
of it ligands, including EGF, TGF-α, HB-EGF and more [324]. ErbB2 has no known direct 
activating ligand and may be in an activated state constitutively, or become active upon 
heterodimerisation with other family members, such as EGFR. Upon activation by its growth 
factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active 
homodimer [325]. However, there is some evidence that preformed inactive dimers may also 
exist before ligand binding [271]; and their activity may be regulated by other proteins, 
receptors or lipids. An example of which includes high-density cholesterol lipid rafts (or lipid 
micro domains), areas within the cell membrane which have been reported to sequester and 
contain receptors to limit or modulate their activity [288, 311]. In addition to forming 
homodimers, EGFR may pair with another member of the ErbB receptor family, such as 
ErbB2/Her2/neu, to create an activated heterodimer [326]. There is also evidence to suggest 
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that clusters of activated EGFR exist, although it remains unclear whether this clustering is 
important for activation itself, occurs subsequent to activation of individual dimers, or that 
these clusters are held within specific cellular locations, such as lipid rafts; in order to 
regulate their signalling potential [327, 328]. 
 
 
 
 
EGFR dimerisation stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a 
result, auto-phosphorylation of several tyrosine residues occurs in the C-terminal domain of 
EGFR. This auto-phosphorylation elicits downstream activation and signalling through 
several other proteins that associate with the phosphorylated tyrosines, through their own 
phosphotyrosine-binding SH2 domains [325]. These downstream signalling proteins initiate 
several signal transduction cascades, including the MAPK/ERK, Akt, JNK and JAK 
pathways (Figure 4i) [1-3, 5, 6], leading to DNA synthesis, cell proliferation, migration, 
adhesion, survival, or differentiation. The kinase domain of EGFR also cross-phosphorylates 
tyrosine residues of other receptors with which it is aggregated with [329, 330]; and can itself 
be activated in that manner, as demonstrated by CD44 [259]. 
Figure 4i. EGFR intracellular signalling 
pathways - cytokine/ligand induced 
phosphorylation of EGFR leads to 
intracellular protein kinase cascades, among 
these are the Akt/mTOR, JAK/STAT, MAPK 
and MEK/JNK pathways. Figure compiled 
from Andl et al. 2004 [1], Cocoran et al. 2012 
[2], Cordero et al. 2012 [3], Dobashi et al. 
2009 [5], and Hashimoto et al. 1999 [6]. 
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4.1.3 MicroRNA Regulation of EGFR and Age-associated Loss of Differentiation 
A major mechanism controlling EGFR expression could be regulation by microRNAs 
(miRNAs). These short, single-stranded and looped, 18-24 nucleotide non-coding RNA 
molecules function as post-transcriptional regulators of gene expression, by binding and 
actively inhibiting the expression of mRNA (through affecting the stability and translation of 
mRNAs), to moderate cell function. In brief (summarised in Figure 4ii), miRNAs are 
transcribed by RNA polymerase II as part of primary transcripts (pri-miRNAs), which can be 
within either protein-coding or non-coding regions of genes and intronic or exonic regions of 
DNA. The pri-miRNA is cleaved by Drosha ribonuclease III enzyme to produce a stem-loop 
precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer 
ribonuclease to generate a miRNA duplex, consisting of the mature miRNA (miRNA-5p) and 
antisense miRNA (miRNA-3p) products. The mature miRNA is incorporated into a RNA-
induced silencing complex (RISC), which recognises target mRNAs (3’UTR regions) 
through either perfect or imperfect base pairing with the miRNA; and results in translational 
inhibition or destabilisation of the target mRNA.  
Among the predicted miRNA targets for the EGFR 3’ UTR, the one which is most commonly 
associated with EGFR transcriptional inhibition is miRNA-7 (miR-7). Although the mature 
miR-7 with predicted EGFR mRNA inhibitory action is located at the pri-miRNA locus for 
miR-7-1, loci exist at miR-7-2 and miR-7-3 sites within the human genome. Whether or not 
the pre-miRNA generated from the pri-miRNA for miR-7-2 and miR-7-3 contribute to the 
overall expression of active and mature miR-7, capable of inhibitory action against EGFR, is 
not clear and warrants investigation. Several studies highlight the activity of miR-7 in 
different cell systems and its role in different disease states. miR-7 has been shown to 
antagonise EGFR expression [331], to be involved in EGFR-related cancer progression [332, 
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333], and to regulate EGFR-mediated development [334].   However, whether or not miR-7 
is implicated in age-associated loss of EGFR and therefore, fibroblast resistance to 
differentiation, has yet to be investigated and could provide key insights into the down 
regulation of EGFR that correlates with cellular ageing.   
 
 
 
 
 
 
 
4.1.4 Summary of Aims 
The hypothesis for this results Chapter is that age-related miR-7 upregulation may be central 
to the loss of the HA-dependent EGFR signalling pathway. Herein, this results Chapter will 
aim to investigate how miR-7 affects the cellular expression and functionality of EGFR and 
whether there is implication of a role in the cellular resistance to differentiation; and to detail 
the functional consequences arising from miR-7 upregulation in young cells. In addition, this 
chapter aims to demonstrate that inhibition of miR-7 can rescue the differentiation response 
Figure 4ii. Pathway of microRNA generation – The primary transcript of miRNA (pri-miRNA) is transcribed 
from the cell DNA, Drosha then cleaves out the stem-looped precursor miRNA (pre-miRNA). The pre-miRNA 
is exported and then cleaved by Dicer into a miRNA duplex, separation of which leads to the mature miRNA 
(miRNA-5p), which when coupled with RNA-induced silencing complex (RISC) can bind the 3’UTR of a 
mRNA target, resulting in the inhibition of translation or degradation of the mRNA. Figure adapted from Catto, 
et al. 2011 [4]. 
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in in vitro aged fibroblasts. Furthermore, once a novel mechanism in which miR-7 regulates 
the HA-mediated CD44/EGFR signalling pathway can be described, this chapter will then 
examine whether miR-7 has an influence over CD44 movement, therefore highlighting 
whether miR-7 can indirectly regulate HA and CD44; and the subsequent loss of 
differentiation in response to TGF-β1 stimulation. 
Specifically the aims of this Chapter are to investigate the following areas in detail: 
i. Characterisation of the age-associated loss of TGF-β1-dependent differentiation with 
increasing cell PDL. 
ii. Investigate the loss of EGFR in ageing fibroblasts, through determination of EGFR 
promoter activity in aged cells. 
iii. Examination and analysis of microRNA regulation of EGFR, through: 
a. In silico based analysis of miR seed sites on the EGFR 3’ UTR. 
b. Overexpression of miR-7 in young fibroblasts. 
c. Inhibition of miR-7 in aged fibroblasts. 
iv. Analysis of the indirect effects of miR-7 upregulation or inhibition on other key 
components of the myofibroblast differentiation mechanism. 
Fulfilling the aims listed above will help to explain the loss of EGFR in ageing fibroblasts, 
which could potentially apply to other cell types. Additionally, it will provide insights into 
the regulation of the differentiation mechanisms in the ageing process, providing potential 
targets for the promotion of fibroblast and myofibroblast function in cases of chronic non-
healing wounds. Furthermore, fulfilment of the aims could provide means for the inhibition 
of myofibroblast formation, in cases where prevention or treatment of fibrosis is required.   
 119 
4.2 Results 
4.2.1 Characterisation of Age-associated Loss of Differentiation and CD44-EGFR Co-
localisation 
The age-associated loss of myofibroblast differentiation can lead to the failure of wound 
contraction and resolution, with the potential to lead to non-healing chronic wounds in the 
elderly. To characterise the loss of differentiation and failure to obtain the myofibroblast 
phenotype, cells of increased passage or PDL were stained to visualise α-SMA stress fibre 
formation through the use of immunocytochemistry (Figure 4.1A). With increasing PDL, the 
cells’ ability to generate α-SMA stress-fibres in response to TGF-β1 decreased to the point of 
late cell passage (PDL 29), when cells were nearing senescence. These were negative for α-
SMA staining. To assess the transcriptional activity of key components of the differentiation 
mechanism, QPCR was used to analyse expression of α-SMA (Figure 4.1B) and HAS2 
(Figure 4.1C) mRNA. Again, increasing PDL correlated with decreasing expression of both 
genes. The difference between young (PDL 17) and aged (PDL 29) fibroblasts was a 10-fold 
reduction in the expression of both mRNAs.   
Additional investigation into the co-localisation potential of CD44 and EGFR in aged 
fibroblasts was examined by labelling EGFR (green) and CD44 (red) in live cells, using 
Confocal Laser Scanning Microscopy (Figure 4.2A). It was found that the co-localisation 
between CD44 and EGFR was lost in aged cells, as areas of the cell membrane were positive 
for EGFR staining independent of areas positive for CD44 staining. Quantification of 
receptor co-localisation (Figure 4.2B) demonstrated the loss of co-localisation in aged cells, 
compared to the young counterparts. The percentage of CD44 (red) with EGFR (green) was 
approximately 80% in young cells treated with TGF-β1, but this was reduced to less than 
10% in aged cells treated with TGF-β1. The data from these findings suggest the loss of the 
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ability to differentiate was multi-factorial, involving decreased α-SMA and HAS2 expression 
and the inability of CD44 to co-localise with EGFR.  
4.2.2 The Importance of EGFR in the Differentiation Response  
The EGFR tyrosine phosphorylation inhibitor, AG1478, was used to determine how the 
inhibition of EGFR signalling affects the expression of crucial components that are usually 
upregulated during myofibroblast differentiation. Young fibroblasts were treated for 1 hour 
with 10μM AG1478, prior to incubation with serum-free medium alone and serum-free 
medium containing 10ng/ml TGF-β1 for 72 hours. QPCR was used to measure the expression 
of HAS2 (Figure 4.3A), α-SMA (Figure 4.3B) and EDA-FN (Figure 4.3C) mRNA. Results 
show that upregulation of HAS2, α-SMA, and EDA-FN by TGF-β1 was completely 
attenuated if cells were treated with AG1478, indicating the importance of TGF-β1 
transactivation of the fully functional EGFR pathway in myofibroblast differentiation.  
Previous studies [159, 160, 244] have demonstrated a loss of EGFR that correlates with 
increasing fibroblast PDL. However, the mechanism responsible for this loss of expression is 
not clear. To determine the extent of EGFR loss in our cell system, we analysed EGFR 
mRNA, total protein, cell surface expression, and constitutive EGFR promoter activity in 
young and aged fibroblasts. EGFR mRNA, analysed by QPCR, was found to be significantly 
downregulated in aged fibroblasts (Figure 4.4A). This was reflected in age-associated loss of 
both EGFR total protein, as determined by Western blot (Figure 4.4B); and cell surface 
expression, as determined by Flow Cytometry (Figure 4.4C). Interestingly, when the activity 
of the EGFR promoter was tested using a luciferase reporter construct, no observable 
differences in luminescent intensity were observed between young and aged cells (Figure 
4.4D), suggesting that the down-regulation of EGFR mRNA and protein were not necessarily 
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a result of reduced levels of transcription factors binding to the EGFR promoter; and thus the 
aged-associated loss of EGFR could be a consequence of post-transcriptional activity. 
4.2.3 Differences in Receptor Membrane Dynamics Between Young and Aged 
Fibroblasts 
The loss of EGFR expression in aged fibroblasts has been reported to impact on a reduced 
differentiation potential through a loss of the interaction between CD44 and EGFR, an 
important step in driving fibroblast to myofibroblast transformation [160, 195, 335]. The 
previous chapter highlighted the importance of CD44 membrane motility in contribution to 
EGFR interaction. Here, we examined whether the receptor behaviours of EGFR and CD44 
altered in aged cells by using FRAP. Representative FRAP images are shown for young 
fibroblast EGFR and CD44 (Figure 4.5A). EGFR was found to remain within static domains 
across the membrane, regardless of cellular age (Figure 4.5B-C).  In contrast, while CD44 
had the potential to move throughout the membrane in young fibroblasts (Figure 4.5D), this 
was lost in aged fibroblasts (Figure 4.5E). These data suggest that CD44 mobility could be 
another contributor to the age-associated loss of differentiation; and could explain why 
previously overexpressed EGFR alone [160] was not sufficient to fully restore aged fibroblast 
differentiation to myofibroblasts. 
4.2.4 MicroRNA-7 Targeting of the EGFR mRNA 3’UTR and Changes With Ageing 
MicroRNA-7 (miR-7) has been reported to target and prevent EGFR production in many 
instances, such as in cancers and during development [332-334]. In silico analysis revealed 
one highly conserved and two poorly conserved seed sites for miR-7 within the 3’ UTR of 
EGFR mRNA (Figure 4.6A).  In order to determine whether or not miR-7 was upregulated in 
aged fibroblasts, miR-RT followed by QPCR was used. Results showed that miR-7 was 
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found to have a higher expression in aged fibroblasts and in cells stimulated with TGF-β1, 
when compared to young untreated control cells (Figure 4.6B). These data coincide with the 
downregulation of EGFR mRNA and protein in aged fibroblasts, as seen in Figure 4.4. It was 
next sought to determine which of the miR-7 loci, miR-7-1 (Figure 4.6C) or miR-7-2 (Figure 
4.6D), were predominantly responsible for mature miR-7 expression and its upregulation by 
TGF-β1 and in aged fibroblasts. To analyse the expression of the miR-3p (3-prime) strand of 
each miR-7 loci, miR-QPCR was used. The expression of miR-7-1-3p coincided with the 
expression of mature miR-7, whilst the expression of miR-7-2-3p showed no significant 
difference in cells treated with TGF-β1 or between young and aged fibroblasts, confirming 
that miR-7-1 was the active locus for mature miR-7 expression.   
4.2.5 The Effect of Overexpressing miR-7 in Young Fibroblasts 
Analysis of the effect of overexpression of miR-7 was examined through transfection of pre-
miR-7 into young fibroblasts. The relative expression of miR-7 was determined by QPCR; 
and in cells transfected with pre-miR-7, the results showed a significantly large increase in 
the levels of miR-7 present (Figure 4.7A). EGFR mRNA was found to be significantly 
downregulated in cells transfected with pre-miR-7 (Figure 4.7B), whilst α-SMA (Figure 4.7C) 
and HAS2 (Figure 4.7D) mRNA failed to be induced by TGF-β1 treatment. Transfection of 
pre-miR-7 also prevented the upregulation of the myofibroblastic marker, EDA-FN [336] 
mRNA, by TGF-β1 (Figure 4.7E). These data indicated that miR-7 upregulation had the 
potential to negatively regulate the essential components of myofibroblast differentiation 
[160, 195, 196, 244]. Similarly, both total EGFR protein (Figure 4.7F) and EGFR cell surface 
expression (Figure 4.7G) were found to be approximately halved in the presence of pre-miR-
7 transfections. To determine whether or not pre-miR-7 transfected cells were still able to 
differentiate following TGF-β1 stimulation, α-SMA staining was assessed using 
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immunocytochemistry. α-SMA fibre formation was lost in cells transfected with pre-miR-7, 
indicating a prevention of differentiation (Figure 4.7H). 
4.2.6 The Effect of Inhibiting miR-7 Activity in Aged Fibroblasts 
In order to test the hypothesis that miR-7 was effectively inhibiting the differentiation 
response in aged fibroblasts, transfection of miR-7 locked nucleic acids (LNA) was used to 
bind and inhibit free miR-7 within these cells. As predicted, EGFR mRNA was upregulated 
in miR-7 LNA transfected cells, compared to negative control LNA transfected cells; and did 
not fall when the cells were treated with TGF-β1 (Figure 4.8A). In cells transfected with 
miR-7 LNA α-SMA (Figure 4.8B), HAS2 (Figure 4.8C) and EDA-FN (Figure 4.8D) mRNA 
were significantly upregulated, following TGF-β1 stimulation. Total EGFR protein (Figure 
4.8E) and cell surface expression (Figure 4.8F) were also increased. Determination of cellular 
differentiation was tested and in cells that had been transfected with miR-7 LNA, there was 
fluorescence for α-SMA intracellular fibres (Figure 4.8G), indicating that the aged fibroblasts 
had their ability to differentiate restored if miR-7 was prevented from acting. These data 
demonstrate the effectiveness of targeting miR-7 in restoring the differentiation response in 
aged fibroblasts, revealing a potentially valuable mechanism to target in chronic non-healing 
wounds in the elderly. 
4.2.7 Analysis of CD44 Membrane Motility in the Presence and Absence of miR-7 or HA 
The conclusions from the previous Chapter suggested that the loss of HA-dependent CD44 
motility in the membrane could prevent the CD44/EGFR interaction necessary for 
differentiation [160, 195, 337]. Observations from the results presented in Figure 4.5 showed 
a loss of CD44 motility in aged fibroblasts. It was, therefore, examined whether 
overexpression or inhibition of miR-7 would affect CD44 membrane movement. Young 
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fibroblasts were transfected with either a scrambled pre-miR sequence (Figure 4.9A) or with 
pre-miR-7 (Figure 4.9B). Interestingly, in cells transfected with pre-miR-7, the potential for 
CD44 movement throughout the membrane, as highlighted by the diffusion constant (D) and 
mobile fraction (MF), dropped significantly (both P=<0.01), when compared to the 
scrambled control transfection. These data are indicative of miR-7 having an indirect action 
on CD44 receptor behaviour, possibly through a HA-dependent mechanism. To test this 
hypothesis, DMSO (0.6% v/v) control (Figure 4.9C) or 4-methylumbelliferone (4MU) 
(Figure 4.9D) treatments were performed on resting fibroblasts, prior to FRAP analysis. Cells 
treated with 4MU had significantly lower D and MF values (both P=<0.01), suggesting that 
cellular presence and synthesis of HA was required for CD44 membrane motility.  
It was then examined whether the inhibition of miR-7 in aged fibroblasts could restore CD44 
movement, through the transfection of negative control LNA (Figure 4.10A) and miR-7 LNA 
(Figure 4.10B). When aged cells were transfected with miR-7 LNA, the diffusion constant 
was increased, when compared to negative control LNA transfected cells (P=<0.05). The MF 
of CD44, although significantly increased (P=<0.05), was not restored to the levels shown in 
younger fibroblasts (P=<0.01 vs. Fig. 2D).  
It was hypothesised that the reason for the restoration seen in miR-7 inhibitory experiments 
was due to an upregulated presence of HAS2-produced HA. To test this hypothesis, we 
transfected aged fibroblasts with an empty vector (Figure 4.10C) or with a HAS2 
overexpression vector (Figure 4.10D). In cells overexpressing HAS2, there was an observable 
restoration in CD44 diffusion, compared to the empty vector control (P=<0.05). The MF was 
also increased (P=<0.01), but again not to the full extent of young fibroblasts (P=<0.05 vs. 
Figure 4.5D). These data illustrate an alternative mechanism through which miR-7 can 
regulate the differentiation response. When taken together with the inhibition of HAS2 
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mRNA shown when overexpressing miR-7 in young fibroblasts (Figure 4.7D) and the 
restoration of HAS2 mRNA expression shown in aged fibroblasts transfected with miR-7 
LNA (Figure 4.8C), these data suggest that there may be a HA-dependent regulation of CD44 
membrane motility that is operational in young, but not aged, fibroblast cells.            
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Figure 4.1. Age-associated Loss of Myofibroblast Differentiation. Young and aged fibroblasts of PDL 17, 
21, 25 and 29; were grown to confluence and growth arrested for 48 hours. Cells were then incubated in 
serum-free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours. A. Cells were stained for α-
SMA (green) using immunohistochemistry (Hoechst stained nuclei in blue). Images shown are representative 
of 3 independent experiments, naïve IgG was used in place of primary antibody for negative controls. Original 
magnification x400. B. α-SMA and C. HAS2 mRNA expression over the PDL range was assessed by QPCR, 
results are shown as the mean ± s.e.m. of 3 individual experiments, **P=<0.01. 
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Figure 4.2. Age-associated Loss of CD44-EGFR Co-localisation. Young (PDL 17) and aged (PDL 29) 
fibroblasts were grown to confluence and growth arrested for 48 hours. Cells were then incubated in serum-
free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours. A. Cells were stained for EGFR 
(FITC; green) and CD44 (PE-R; red) and visualised using Confocal Laser Scanning Microscopy (areas of co-
localisation are shown in yellow). Images shown are representative of 3 independent experiments. Original 
magnification x630. B. Co-localisation of CD44 (PE-R) with EGFR (FITC) was quantified (Mander’s Co-
localisation Coefficient). Statistical analysis includes the average Pearson’s Correlation Coefficient (Rr) and 
Intensity Correlation Quotient (ICQ) for each experimental condition.  Results shown are the mean ± s.e.m. of 
3 independent experiments. **P=<0.01. 
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Figure 4.3. Inhibition of EGFR Signalling Prevents Differentiation. Young fibroblasts were grown to 
confluent monolayers and were growth arrested for 48 hours. Cells were treated with 10μM EGFR inhibitor, 
AG1478, for 1 hour, prior to incubation in serum-free medium alone or in medium containing 10ng/ml TGF-
β1 for 72 hours. The expression of A. HAS2, B. α-SMA and C. EDA-FN mRNA was examined by QPCR and 
results are shown as the mean ± s.e.m. of 3 individual experiments, **P=<0.01. 
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Figure 4.4. Changes in the Expression of EGFR Between Young and Aged Fibroblasts. Young and aged 
fibroblasts were grown to confluent monolayers and growth arrested for 48 hours. Cells were then incubated in 
serum-free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours. A. The expression of EGFR 
mRNA was examined by QPCR and results are shown as the mean ± s.e.m. of 3 individual experiments. B. 
Western blot analysis of total EGFR protein in young and aged fibroblasts. GAPDH was used as a loading 
control. Representative blot is shown and densitometry graph shown is the mean ± s.e.m. of 3 individual 
experiments. C. Flow Cytometry analysis of cell surface expression of EGFR in young (green) and aged (red) 
fibroblasts. Unlabelled cells (black) were used as intensity controls. Bar graph of relative intensity shown is 
the mean ± s.e.m. of 3 individual experiments. D. Young or aged fibroblasts were grown to 70% confluence 
and transiently transfected with either an empty pGL3b vector or pGL3b-EGFR. Luminescence was measured 
averaged. Cells were co-transfected with Renilla to measure efficiency and to normalise data. Graph shown is 
the mean ± s.e.m. of 3 individual experiments. N/S = no significance, **P=<0.01. 
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Figure 4.5. Analysis of Receptor Membrane Dynamics in Young and Aged Fibroblasts. A. Sample 
time-lapse series of fluorescent recovery after photobleaching (FRAP) experiments. Original magnification 
x630. Young or aged fibroblasts were grown to 70% confluent monolayers on 22mm diameter glass 
coverslips, in 35mm 6-well tissue culture plates. Cells were growth arrested in serum-free medium for 48 
hours. FRAP was performed at 37°C by photobleaching an approximately 10μm area of the cell membrane 
(indicated by white boxes). The recovery of fluorescence into this area (indicated by white arrows) was 
quantified and expressed as a fraction of the fluorescence intensity (FI) of a second region of membrane, 
outside of the photobleached area (FI Ratio). Complete quantified time-courses, average diffusion constants 
(D) and mobile fractions (MF) are shown for: B. EGFR in young fibroblasts; C. EGFR in aged fibroblasts; 
D. CD44 in young fibroblasts and E. CD44 in aged fibroblasts. All results shown are mean ± s.e.m of 5 
independent experiments. 
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Figure 4.6. Analysis of miR-7 in Young and Aged Cells. A. Highly conserved and poorly conserved 
microRNA-7 (miR-7) seed sites on the 3’ UTR of EGFR mRNA, as determined by in silico analysis with 
TargetScan v6.2. Young and aged fibroblasts were grown to confluent monolayers and growth arrested for 
48 hours. Cells were then incubated in serum-free medium alone or in medium containing 10ng/ml TGF-β1 
for 72 hours. The expression of B. miR-7 (miR-7-1-5p), C. miR-7-1-3p and D. miR-7-2-3p was examined 
by miR-QPCR. Results are shown as mean ± s.e.m. of 3 individual experiments. N/S = no significance, 
**P=<0.01. 
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Figure 4.7. Overexpression of miR-7 Attenuates the Differentiation Response. Young fibroblasts were grown to confluent monolayers and growth arrested for 24 
hours before transient transfection with either scrambled pre-miR or pre-miR-7. The relative expressions of A. miR-7, B. EGFR mRNA, C. α-SMA mRNA, D. HAS2 
mRNA and E. EDA-FN mRNA, were examined by QPCR, following incubation in serum-free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours. 
Results shown are mean ± s.e.m. of 3 individual experiments. F. Western blot analysis of total EGFR protein in young and aged fibroblasts. GAPDH was used as a 
loading control. Representative blot is shown and densitometry results shown are the mean ± s.e.m. of 3 individual experiments. G. Flow cytometry analysis of cell 
surface expression of EGFR in young (green) and aged (red) fibroblasts. Unlabelled cells (black) were used as intensity controls. Bar graph of relative intensity is shown 
as the mean ± s.e.m. of 3 individual experiments. H. Cells were incubated in serum-free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours and then 
analysed by immunocytochemistry for α-SMA. Representative images are shown for 3 individual experiments. *P=<0.05, **P=<0.01. 
 133 
Figure 4.8. Inhibition of miR-7 Rescues the Differentiation Response in Aged Fibroblasts. Aged fibroblasts were grown to confluent monolayers and growth arrested 
for 24 hours, before transient transfection with either negative control LNA or miR-7 LNA. The relative expressions of A. EGFR mRNA, B. α-SMA mRNA, C. HAS2 
mRNA and D. EDA-FN mRNA, were examined by QPCR, following incubation in serum-free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours. 
Results shown are the mean ± s.e.m. of 3 individual experiments. E. Western blot analysis of total EGFR protein in young and aged fibroblasts. GAPDH was used as a 
loading control. Representative blot is shown and densitometry graph shown is mean ± s.e.m. of 3 individual experiments. F. Flow Cytometry analysis of cell surface 
expression of EGFR in young (green) and aged (red) fibroblasts. Unlabelled cells (black) were used as intensity controls. Bar graph of relative intensity shown is mean ± 
s.e.m. of 3 individual experiments. G. Cells were incubated in serum-free medium alone or in medium containing 10ng/ml TGF-β1 for 72 hours; and then analysed by 
immunocytochemistry for α-SMA. Representative images are shown for 3 individual experiments. *P=<0.05, **P=<0.01. 
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Figure 4.9. Overexpression of miR-7 Inhibits CD44 Motility in Young Fibroblasts. Young fibroblasts 
were grown to 70% confluent monolayers on 22mm diameter glass coverslips, in 35mm 6-well tissue culture 
plates. Cells were growth arrested in serum-free medium for 48 hours. FRAP was performed at 37°C by 
photobleaching an approximately 10μm area of the cell membrane. The recovery of fluorescence into this 
area was quantified and expressed as a fraction of the fluorescence intensity (FI) of a second region of 
membrane, outside of the photobleached area (FI Ratio). Complete quantified time-courses, average 
diffusion constants (D) and mobile fractions (MF) are shown for CD44 in: young cells transfected with A. 
scrambled pre-miR or B. pre-miR-7; and cells treated with C. control DMSO (0.6% v/v) or D. 24 hours with 
0.5μM 4MU, prior to FRAP analysis. All results shown are mean ± s.e.m. of 5 independent experiments. 
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Figure 4.10. Inhibition of miR-7 Restores CD44 Motility in Aged Fibroblasts. Aged fibroblasts were 
grown to 70% confluent monolayers on 22mm diameter glass coverslips, in 35mm 6-well tissue culture 
plates. Cells were growth arrested in serum-free medium for 48 hours. FRAP was performed at 37°C by 
photobleaching an approximately 10μm area of the cell membrane. The recovery of fluorescence into this 
area was quantified and expressed as a fraction of the fluorescence intensity (FI) of a second region of 
membrane, outside of the photobleached area (FI Ratio). Complete quantified time-courses, average 
diffusion constants (D) and mobile fractions (MF) are shown for CD44 in: young cells transfected with A. 
negative control LNA, B. miR-7 LNA, C. empty pCR3.1 Vector, or D. pCR3.1-HAS2 overexpression 
Vector. All results shown are mean ± s.e.m. of 5 independent experiments. 
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4.3 Discussion 
The data reported in this Chapter provide additional mechanisms and insights into the age-
associated loss of TGF-β1-dependent, fibroblast to myofibroblast differentiation. The 
importance of EGFR and its loss in cellular ageing has been described recently and been 
shown to have a significant effect on the myofibroblast differentiation pathway [160, 297, 
337], going some way towards explaining the mechanisms of resistance to TGF-β1-
stimulated differentiation [159, 160]. In light of these reports and the loss of differentiation 
and CD44-EGFR co-localisation potential with increasing cell PDL as observed in this results 
Chapter, it was sought to determine the extent of the loss of EGFR in aged fibroblast cells 
and further detail the EGFR deficiency at multiple levels including its transcriptional, 
translational and cell surface expression. Figure 4.3 defined and highlighted the importance 
of functional EGFR signalling in the differentiation response. The data reported here support 
previous findings of the age-associated loss of EGFR at the mRNA and protein levels. 
However, the activity of the EGFR promoter was not found to be significantly different 
between young and aged fibroblasts. The maintenance of EGFR promoter activity indicated 
that the transcription factors involved in EGFR transcription were unlikely to be affected in 
an age-dependent manner; and that there was another factor responsible for the loss of EGFR 
mRNA, protein and cell-surface expression. I, therefore, hypothesised that age-associated 
loss of EGFR could be regulated through the presence of mRNA inhibitors, such as miRNAs.   
The results in this study also illustrated an age-associated loss of CD44 receptor membrane 
motility, as demonstrated by FRAP Confocal Microscopy. The HA receptor, CD44, can 
function as a co-receptor, physically associating with several membrane-bound proteins, 
resulting in modulation of intracellular signal transduction pathways and facilitating the 
formation of specialised signalling complexes [307, 308, 338].  The ability to do so with 
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EGFR plays a key role in myofibroblast differentiation as demonstrated by the previous 
results chapter. Whilst CD44 was free to diffuse within the plasma membrane of young 
fibroblasts, the ability of CD44 to diffuse freely was attenuated in aged cells. Since the loss of 
HA production by aged cells has also been described previously [244], we determined CD44 
mobility to be HA-dependent and thus, a loss of overall HA could contribute to the loss of 
CD44 cell membrane movement in aged fibroblasts. Cell treatments with 4MU demonstrated 
that removal of HA production did indeed result in a loss of CD44 membrane motility. 
Multiple reports have described miR-7 as having an important role in the regulation of EGFR 
in cancer and development [331, 332, 334]. However, this relationship between miR-7 and 
EGFR has not been described in other areas of EGFR function, such as fibroblast 
differentiation or age-associated loss of phenotype. In silico analysis identified the highly 
conserved seed site for miR-7-1 derived mature miR-7 on the 3’UTR of the EGFR mRNA. 
The upregulated levels of miR-7 reflect the downregulated EGFR mRNA present in aged 
fibroblasts. Additionally, an interesting observation was made in the young fibroblast group, 
wherein miR-7 was upregulated and EGFR mRNA downregulated, in response to TGF-β1. 
Whether this change to miR-7; and in turn EGFR mRNA, is directly modulated by TGF-β1 
stimulation is not currently known and requires further investigation. However, a possible 
mechanism of miR-7 activity has been shown through its upregulated expression by EGFR-
dependent c-Myc activation [332].  
Interestingly, through miR-7 overexpression in young fibroblasts, the outcome was able to 
mimic the decreased expression of EGFR observed in aged fibroblasts, further supporting a 
role for miR-7 in age-associated regulation of EGFR and the differentiation response. 
Furthermore, the inhibition of miR-7 in aged fibroblasts significantly induced EGFR mRNA, 
protein and cell-surface expression, together with HAS2 mRNA. Additionally, in response to 
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TGF-β1 treatment in the presence of miR-7 inhibition, there was successful upregulation of 
α-SMA fibre formation and induction of α-SMA, HAS2 and EDA-FN mRNA, indicating the 
restored differentiation of fibroblasts to myofibroblasts. 
The importance of HA-CD44 in mediating differentiation [339, 340] and the TGF-β1-
induced, myofibroblast response [160, 196, 244, 297, 337], has been previously documented. 
Next, the effect of miR-7 overexpression and inhibition on CD44 motility in the cellular 
membrane was examined. Overexpression of miR-7 in young cells resulted in diffusion rates 
of CD44, declining to similar levels as those found in aged fibroblasts. Similarly, knockdown 
of HA synthesis by 4MU treatment reduced CD44 membrane motility. In addition, the 
inhibition of miR-7 in aged fibroblasts restored the diffusion rates of CD44, to levels 
observable in young fibroblasts. Since inhibition of miR-7 with LNA was able to upregulate 
both EGFR and HAS2 mRNA, the hypothesis that overexpression of HAS2 in aged 
fibroblasts could restore CD44 movement was tested. HAS2 overexpression and miR-7 LNA 
transfection restored CD44 movement in aged fibroblasts to rates observable in young 
fibroblasts. It was proposed that HAS2 synthesis of HA was an important mechanism 
mediating CD44 lateral movement throughout the cellular membrane and that miR-7 could 
regulate HAS2 expression through the inhibition of EGFR and components of its signalling 
pathway, therefore indirectly affecting CD44 movement in order to prevent cellular 
differentiation. Indeed, miR-7 has been shown to inhibit the protein kinase B/mammalian 
target of rapamycin (Akt/mTOR) pathway downstream of EGFR signalling [331, 333]; and 
an association between Akt and HAS2 production has previously been illustrated [341, 342]. 
Explanation of how miR-7 inhibition could rescue age-associated loss of differentiation, 
whilst EGFR overexpression alone could not [160], may be a result of an effect on the other 
mRNA targets of miR-7. In silico analysis of miR-7 seed sites revealed potential targets on 
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neither HAS2, α-SMA nor CD44. However, there were several targets of miR-7 within the 
EGFR signalling pathway. The activation of these targets is necessary for HAS2 induction, 
the reorganisation of the actin cytoskeleton, α-SMA upregulation and myofibroblast 
differentiation. These targets included MAPK/ERK, CaMKII, Rho-GTPase, phosphoinositide 
3-kinase (PI3K), Akt and mTOR. EGFR overexpression in aged fibroblasts [160] failed to 
successfully restore differentiation. It is possible that this was due to an elevated expression 
of miR-7 in aged cells, not only inhibiting EGFR mRNA, but also the production of its 
downstream targets and thus, HAS2 and α-SMA gene induction. Bypassing the EGFR 
pathway and also overexpressing HAS2 could restore differentiation; and this was likely 
through the increased production of HA, restoration of CD44 membrane motility and its 
interaction with EGFR, solidifying the signalling response of EGFR and providing sufficient 
activity to trigger the differentiation response in aged fibroblasts.  
The results shown in this Chapter can be summarised through the proposition of a mechanism 
in which miR-7 upregulation in aged cells is able to downregulate EGFR protein and 
expression through targeting EGFR mRNA for breakdown. miR-7 also has additional targets 
within the EGFR-dependent signalling pathway that directly regulate HAS2 production. The 
consequence of miR-7 activity, therefore, results in the downregulation of the key cellular 
components, EGFR and HAS2, involved in fibroblast to myofibroblast differentiation. 
Additionally, as a direct result of reduced HAS2 expression, there is a reduction in HA 
production and binding to CD44, compromising its ability to move throughout the cellular 
membrane and therefore, a reduction in its interaction with EGFR in response to TGF-β1 
[160, 195, 308], an essential step in driving differentiation (summarised in Figure 4iii). 
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The loss of cellular phenotype and response to stimulation is a pivotal change in cellular 
ageing. Age-related loss of fibroblast-to-myofibroblast differentiation is often associated with 
failure of normal wound healing and contraction, leading to chronic non-healing wounds in 
the elderly. Chronic non-healing wounds have been estimated to affect 4% of the UK 
population over the age of 65; and the morbidity associated with this impaired wound healing 
is estimated to cost the health service in excess of £1 billion annually in the UK [153] and $9 
billion in the United States [343]. With the costs rising in correlation with the ageing 
population’s ever-increasing lifespans, chronic wounds pose a real problem to present and 
future healthcare across the world.  
The data reported in this chapter provide a novel insight into the targeting of miR-7 in aged 
fibroblasts, in order to rescue and promote differentiation into myofibroblasts and therefore, 
drive effective wound healing in the elderly. The following results chapter investigates the 
mechanism by which miR-7 expression is upregulated through increased transcription factor 
binding to its promoter region; and assessment of the impact of 17β-estradiol (E2) on the 
fibroblast phenotype and miR-7 expression, in light of reports of E2 interactions with EGFR 
and the stimulation of HAS-produced HA [344-348]. 
 
Figure 4iii. Summary of the actions of miR-7 derived from cellular ageing (increasing PDL). Increased 
expression of miR-7 leads to the inhibition of EGFR and its signalling, causing a decreased synthesis of HA and 
therefore, a reduction in CD44 motility within the cell membrane. These cumulate in the loss of TGF-β1 
stimulated, fibroblast to myofibroblast differentiation. 
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5.1 Introduction 
5.1.1 Transcriptional Regulation of MicroRNA 
The growing family of miRNAs regulate a diverse range of cellular processes and can impact 
on the progression of various diseases, through RNA-mediated gene-silencing mechanisms. 
Many current studies focus on regulatory functions of miRNAs, few are directed towards 
their transcriptional regulation. Although work into defining the structural features of miRNA 
promoters is limited, characterisation of miRNA promoter regions has gone some way to 
predicting miRNA transcription start sites.  
Advancements in computational and biochemical methods [349-351] have revealed that 
many miRNAs use their own transcription start sites (TSS), whether they are located within 
non-protein coding DNA between genes (intergenic) or embedded within the introns of 
protein coding genes (intronic). However, some intragenic (within introns or exons) miRNAs 
use host gene TSS [352]. Recent studies of miRNA transcription have elucidated that 
intragenic miRNAs are co-transcribed by RNA polymerase II, or independently transcribed 
from their own RNA polymerase II or III initiation sites [353, 354]. It is, therefore, important 
when determining the TSS for miRNA, to take into consideration RNA polymerase II and III 
initiation sites within the promoter sequence.   
Modifications to histones on promoter regions can provide some indication of where putative 
TSSs begin, such as trimethylation of lysine-4 of histone-3 (H3K4me3) and acetylation of 
lysine-9/14 of histone-3 (H3K9/14Ac). These have proven to be valuable markers of 
transcriptionally active promoters [355-358]. TSS identification has also been hampered by 
difficulty in determining start sites proximal to the mature miRNA sequence, especially when 
pri-miRNAs can have large and variable lengths [359, 360]. Despite this, an additional 
characteristic of transcriptionally active genes was observed, they were found to be 
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nucleosome-free within 100-130bp surrounding their TSS [361, 362]. A combination of these 
observations with reoccurring sequences commonly found within known TSS and at the 5’ 
end of mRNA (TSS and cap analysis gene expression (CAGE) tags respectively), has led to 
the development of search engine software to help identify putative TSS of pri-miRNAs 
[352]. These techniques will be used in this chapter to help elucidate putative TSS for miR-7.  
Several lines of evidence have recently emerged to suggest that miRNAs participate in self-
regulatory loops, modulating their own expression. Recently, miR-145 was identified to be 
dependent on TP53 activation, which in turn could stimulate miR-145 expression [363]. It 
was also reported that several miRNAs regulate the expression of receptors and are 
themselves regulated by those same receptors in cancer cell-lines [364]. Since many miRNAs 
can have multiple mRNA targets, further study of the interaction between miRNAs and their 
regulatory factors may help illustrate their role in normal function and disease progression. 
It has been previously indicated that miR-7 was a key mediator of EGFR signalling in lung 
cancer cells [332, 333]. It was found that c-Myc bound to the miR-7 promoter and enhanced 
its activity; and this was dependent on the activation of the EGFR-regulated Ras/ERK/c-Myc 
pathway [332]. In addition, miR-7 has been reported to target Akt and blocking the EGFR-
mediated PI3K/Akt pathway also attenuated miR-7 expression [365]. These studies highlight 
two self-regulatory loops for miR-7 expression. However, in the cellular ageing of fibroblasts, 
the expression of EGFR is lost as highlighted in previous studies [159, 160] and the results of 
the previous Chapter, therefore suggesting the activity of Ras/ERK/c-Myc and the EGFR-
dependent PI3K/Akt pathway would also be diminished. Therefore, the upregulated 
expression of miR-7 in aged fibroblasts is likely to be through an alternative receptor or 
signalling pathway, that is persistently activated through cellular ageing and can potentially 
activate c-Myc, Akt or additional enhancers of miR-7 expression. This results Chapter will 
further investigate the promoter region for miR-7 and any changes in transcription factors in 
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response to cytokine treatments, to help describe an alternative mechanism of miR-7 
upregulation. 
5.1.2 17β-Estradiol (E2) 
17β-Estradiol (E2) is a derivative of the sex hormone estrogen and has the greatest potency of 
the estrogen by-products [366, 367]. Although E2 has greater serum abundance in females, it 
is also present in males as an active metabolic product of testosterone. However, the serum 
levels of E2 in elderly men (20-60pmol/L) are roughly comparable to those of elderly women 
(<35pmol/L). Therefore, in old age there is little discrepancy between gender and E2 levels 
[368]. E2 in vivo is interconvertible with estrone [367] and its main role is in reproduction. 
However, it also plays an important role in other organ systems and bone metabolism [369-
371].  
During the reproductive years, most E2 in women is produced by the granulosa cells of the 
ovaries, through estrone to E2 conversion by 17β-hydroxysteroid dehydrogenase [367]. 
Smaller amounts of E2 are also produced by the adrenal cortex and in men, by the testes. In 
both sexes, testosterone is converted to E2 by aromatisation [372, 373] and adipose tissues 
can produce active precursors of E2 [374].  
E2 enters cells freely and interacts with cytoplasmic target cell receptors, estrogen receptor-α 
(ERα) and estrogen receptor-β (ERβ). The ER-complex can enter the nucleus of the target 
cell [375]; and regulate gene transcription through the modulation of additional transcription 
factors and binding to specific DNA sequences. This ultimately leads to modulation of gene 
expression and mRNA transcription, DNA replication and cellular proliferation. In plasma, 
E2 is largely bound to globulin or albumin and only a fraction (2.21% ± 0.04%) is free and 
biologically active [376].  
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Changes in the body shape affecting bones, joints, fat structure and deposition; and skin 
composition, are modified by E2 [374, 377-380]. The development and progression of 
cancers such as breast cancer, ovarian cancer and endometrial cancer, have also been cited as 
E2 driven [381-383]. Interestingly, it has also been noted that E2 treatments protect against 
cellular senescence [384].  
5.1.3 E2 in Wound Healing 
A link between estrogen and ageing has been previously established. Differences in gene 
expression between young and aged wound biopsies were found to be largely estrogen 
regulated [385]. Other studies demonstrated that both E2 and estrogen accelerated wound 
healing in ovariectomised mice [386]. 
The receptor mechanism through which E2 signals is of importance, as several studies have 
highlighted. E2 treatments in ERβ-null mice resulted in a negative effect on wound healing. 
This was also found in vitro in keratinocytes, with the researchers concluding that the 
inhibition of wound healing was via ERα activation [387]. Both human skin fibroblasts and 
keratinocytes have been shown to express ERα in the cytosol and ERβ in the nuclear 
compartment. However, in fibroblasts, ERβ had a higher basal expression, which increased 
when fibroblasts were treated with E2, promoting a pro-wound healing response [388-391]. 
Interestingly, human mammary fibroblasts and oral epithelial cells only express ERβ [390, 
392]; and human lung fibroblasts preferentially express ERβ [392]. When these cells were 
treated with E2, an increased proliferative response was observed in vivo and in vitro [390, 
392]. E2 treatments also increased secretions of HGF [391], the growth factor that is 
persistently expressed by oral mucosal fibroblasts and thought to potentiate their ability to 
rapidly proliferate and migrate. Additionally, the expression of epidermal ERβ was deemed 
to mediate effective skin healing [393]. 
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Furthermore, ERα signalling caused decreases in HAS1 mRNA in VSMCs and resulted in an 
anti-proliferative effect [394]. E2 treatment was found to protect the HA matrix from 
photoageing in mice, by stimulating the upregulation of HAS3 in keratinocytes in vitro and in 
vivo [395]. E2 was also reported to increase the levels of HAS2 in mouse cumulus cells 
(granulosa cells surrounding the oocyte) [347]; and increase the HA content in the skin of 
mice [396]. 
Previous studies have indicated the co-ordinated actions of ER with EGFR [397, 398]. 
Changes in ER and EGFR expression followed similar profiles under E2 treatments and in 
inhibition studies, suggesting the two could be co-regulated [399]. Furthermore, the 
combined inhibition of ER and EGFR caused anti-proliferative effects in cancer cells [400]. 
However, it has recently been reported that in MCF-7 breast cancer cells, E2 treatments were 
detrimental to EGFR expression in an ERα- and miR-7-dependent manner [401]. Since the 
results from the previous Chapter demonstrate the regulatory effect of miR-7 in the age-
associated loss of differentiation, this Chapter will investigate whether E2 treatment of 
fibroblasts (young and aged), regulate HAS, EGFR, miR-7, and their potential to differentiate. 
5.1.4 Summary of Aims 
The advantage of targeting miRNAs as therapeutic approaches is in their specificity, efficacy 
and markedly reduced toxicity, as compared to current treatment programmes. Previous 
reports have shown successful prevention of aberrantly over-expressed miRNAs with 
antagomirs [402, 403]. On the other hand, the effects remain transient, requiring continued 
treatment to maintain efficacy. Undesirable off-target effects that may arise from synthetic 
miRNA recognition of non-target mRNAs bearing partial homology, are also important 
factors for consideration. Instead, defining the processes that regulate miRNA expression 
could help to facilitate the discovery of novel therapeutics to correct aberrant expression, 
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through the targeting of disease or condition specific regulators of miRNA, which may prove 
more effective than direct transient inhibition of miRNAs. 
Specifically this results Chapter will aim to explore the following in depth: 
i. Assessment of the primary contributor from the differentiation pathway controlling 
the transcriptional regulation and upregulation of miR-7. 
ii. Examination of the miR-promoter in detail using in silico analysis. 
iii. The analysis of specific transcription factor regulation of miR-7 by; 
a. Determination of which pathway is responsible for the activation of 
transcription factors of interest. 
b. Through direct pathway inhibitor experiments. 
iv. Assessment of the changes within young and aged fibroblasts, treated with E2. 
v. Investigation into the changes to specific transcription factor activation with TGF-β1 
and E2 treatment time-courses. 
vi. To test whether combinational treatments with TGF-β1 and E2 are beneficial and can 
restore the differentiation potential in aged fibroblasts. 
Investigation into the listed points will help to develop a detailed functional and mechanistic 
sequence of events that could help to explain the increased expression of miR-7 in response 
to TGF-β1 and cellular ageing, therefore addressing the issue of EGFR loss and age-
associated loss of myofibroblast differentiation. The data generated in this Chapter could 
reveal specific targets for therapeutic treatment of aberrant miR-7 expression, which could 
potentially benefit and help restore ideal wound healing conditions for fibroblasts in chronic 
non-healing wounds in the elderly. 
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5.2 Results 
5.2.1 Elucidation of the miR-7 Activating Pathway 
Understanding the mechanism of regulation of miR-7 and the resultant suppression of EGFR 
and HAS2 mRNA, would allow specific targeting of the key elements of differentiation 
dysfunction, aiding the restoration of myofibroblastic properties in the chronic wounds of the 
elderly or to prevent the development of progressive fibrotic diseases. In order to elucidate 
which branch of the differentiation pathway, TGF-βRI-mediated or EGFR-mediated, was 
responsible for the upregulation of miR-7 and the down-regulation of EGFR, as observed in 
the previous Chapter, the chemical inhibitor of TGF-βRI or Alk5 receptor family activation, 
SB431542; and the chemical inhibitor of EGFR activation, AG1478, were used as treatments 
for cells, prior to TGF-β1 or EGF stimulation (Figure 5.1). Following treatments, the mRNA 
levels of EGFR (Figure 5.1A) and α-SMA (Figure 5.1B) were assessed by QPCR.  
Treatments with SB431542 or AG1478 alone had no effect on the mRNA levels of either 
EGFR or α-SMA. TGF-β1 or EGF decreased the mRNA expression of EGFR. However, 
when SB431542 was used as a pre-treatment, only EGF reduced EGFR mRNA levels. 
Additionally, when AG1478 was used as a pre-treatment, the down-regulation was attenuated, 
suggesting that EGFR is self-regulatory and controlled through the HA-CD44/EGFR 
signalling arm of the differentiation response. The only treatment that was successful in the 
upregulation of α-SMA mRNA was TGF-β1 treatment alone, confirming that both branches 
of the differentiation pathway are required; and that TGF-β1 activated EGFR through the 
HA-CD44 mechanism, as discussed in the previous Chapters. These data also highlight that 
EGF stimulation of the EGFR-mediated branch alone is not sufficient enough to upregulate 
α-SMA levels and therefore, drive differentiation.  
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The expression of miR-7 was also assessed (Figure 5.1C) and where EGFR mRNA decreased 
(treatments with TGF-β1, EGF, or EGF+SB431542), miR-7 expression was significantly 
increased. These data support the findings from the EGFR mRNA assessment, in that the 
EGFR-mediated branch of the differentiation pathway is primarily responsible for the 
upregulation of miR-7. TGF-β1 is only able to upregulate miR-7, when EGFR is activated. 
These data indicate an EGFR-miR-7 self-regulatory loop, wherein a pathway activated by 
EGFR is able to upregulate miR-7 expression, which in turn can degrade EGFR mRNA.   
5.2.2 Analysis of the miR-7 Promoter and Associated Transcription Factors 
The miR-7 promoter has been reported to be within a -600bp to -300bp region upstream of 
the miR-7 coding region [332]. To further the investigation into a mechanism for miR-7 
regulation, in silico analysis of the putative TSS for miR-7 and therefore, the promoter region, 
was carried out (Figure 5.2A). Using a combination of CAGE, TSS, and H3K4me3 tags, the 
putative TSS for pri-miR-7 was determined to be approximate to -250bp upstream of the 
miR-7 coding region, as indicated by the density of highly conserved CAGE and TSS tags 
flanked by H3K4me3 sites. Therefore, a sequence -624bp to -200bp upstream of the coding 
region (Figure 5.2B) was analysed in silico for putative transcription factor binding sites 
(Figure 5.2C). Interestingly, multiple signal transducers and activators of transcription (STAT) 
binding sites were present within the promoter sequence, including sites for STAT1, 
interferon-stimulated regulatory element (ISRE); and interferon-stimulated transcription 
factor 3γ (ISGF3G), upstream of a likely TSS location, as indicated by RNA polymerase III 
proximal sequence element (RNA Pol. III PSE); a strong determinant for the recruitment of 
RNA polymerase III. These potential transcription factor-binding sites suggest a strong 
possibility that STAT activation could contribute to the upregulated expression of miR-7, a 
plausible mechanism, especially since EGFR activation of the JAK/STAT pathway is 
possible [1, 3]. The underlined sequences denote the primer sequences selected for use in 
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miR-7 promoter luciferase reporter investigations, using TGF-β1 or EGF stimulation in the 
absence or presence of SB431542 or AG1478 (Figure 5.3). Fibroblasts were transfected with 
empty pGL3b (white bars) or miR-7-pGL3b (black bars, the chosen miR-7 promoter 
fragment ligated into a luciferase reporter construct). Similarly to the results from relative 
miR-7 expression analysis, both TGF-β1 and EGF were able to trigger the miR-7 promoter. 
However, when the Alk5 inhibitor, SB431542, was used as a pre-treatment, only EGF 
stimulation produced a luminescent response from the reporter construct. Treatment with 
AG1478, followed by TGF-β1 or EGF, produced luminescent responses. However, these 
were significantly attenuated from the treatments without the EGFR inhibitor. In light of the 
reported STAT and ISRE transcription factor binding sites within the miR-7 promoter, 
interferon γ (IFNγ) was used to test whether the upregulated promoter activity was a 
consequence of STAT activation. The results show that IFNγ induced the largest promoter 
activity. These data suggest that the activation of the miR-7 promoter is firstly EGFR-
mediated in the TGF-β1-dependent differentiation response; and that this is likely through the 
activation of STATs. 
To further examine the hypothesis of STAT-activated upregulation of miR-7, the mRNA of 
STAT1 was assessed by QPCR (Figure 5.4). STAT1 mRNA was upregulated approximately 
4-fold in response to TGF-β1, EGF, EGF+SB431542, or IFNγ treatments (Figure 5.4A). It 
was also shown that STAT1 mRNA levels were increased in aged fibroblasts, when 
compared to their young counterparts (Figure 5.4B). Western blotting was used to assess 
changes in levels of phosphorylated STAT1 in the various experimental treatment conditions 
(Figure 5.4C). Phosphorylated levels of STAT1 were upregulated 2-fold in response to TGF-
β1, 4-fold in response to EGF; and 10-fold in response to IFNγ. Treatments with AG1478 
attenuated this phosphorylation. These data suggest that STAT1 is upregulated and activated 
following TGF-β1 stimulation, by the EGFR-mediated branch of the differentiation response.   
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5.2.3 The Role of the JAK/STAT Pathway in miR-7 Regulation 
Investigation into the extent of the JAK/STAT pathway and its activation in the regulation of 
differentiation components and miR-7 was performed, by inhibiting the activation of JAK, 
using JAK inhibitor I, followed by QPCR analysis. The α-SMA upregulation by TGF-β1 was 
not affected by the inhibition of JAK (Figure 5.5A). The down-regulation of EGFR by TGF-
β1 and IFNγ was prevented by JAK inhibition (Figure 5.5B). Interestingly, inhibition of JAK 
significantly increased HAS2 mRNA levels in both TGF-β1 and IFNγ stimulated cells, 
although IFNγ treatment alone did not change HAS2 expression (Figure 5.5C). Furthermore, 
inhibition of JAK attenuated the miR-7 upregulation by both TGF-β1 and IFNγ treatments 
(Figure 5.5D). The results shown here illustrate the role of the JAK/STAT pathway in miR-7 
regulation, acting through a pathway that is independent of the TGF-β1-Smad pathway and 
the control of α-SMA expression. 
5.2.4 The Effects of E2 on the Phenotype of Young and Aged Fibroblasts  
The effects of E2 on fibroblasts and keratinocytes have been well documented [387-392], 
although whether E2 treatment has any effect on the differentiation response or the regulation 
of miR-7 has not yet been investigated. To determine whether E2 treatment affected the 
phenotype of young and aged fibroblasts, cells were incubated in serum-free media alone 
(white bars) or with 100nM E2 (black bars) for 72 hours. QPCR analysis of mRNA targets 
indicated that E2 treatment had no effect on α-SMA expression (Figure 5.6A). It did, 
however, significantly upregulate EGFR (Figure 5.6B) and HAS2 (Figure 5.6C) in both 
young and aged cells. Furthermore, E2 treatment downregulated miR-7 expression in young 
and aged fibroblasts (Figure 5.6D). To investigate the effect of E2 on cell proliferation, an 
alamarBlue assay was used (Figure 5.6E). Both the young (white boxes) and aged (black 
boxes) fibroblasts had significantly higher fluorescent intensity readings when incubated with 
E2, indicating the positive effect that E2 treatment had on proliferation. These data suggest 
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that E2 treatment is beneficial to fibroblasts, especially those that are nearing senescence, by 
restoring the levels of EGFR, HAS2 and miR-7, to those similarly observed in resting young 
fibroblasts, as well as increasing the potential for cells to continue to divide.  
5.2.5 The Relationship Between miR-7 Regulation, TGF-β1 and E2 Stimulation  
The results shown in this Chapter thus far indicate a relationship between miR-7, TGF-β1-
dependent differentiation and E2 restoration of young fibroblast characteristics; all of which 
revolve around the EGFR-mediated branch of the differentiation pathway and the activation 
of the JAK/STAT1 signalling pathway. To further investigate this functional and mechanistic 
relationship, time-course experiments were performed and analysed by Western blotting and 
QPCR. TGF-β1 treatment over the course of 72 hours resulted in the gradual accumulation of 
phosphorylated STAT1, with no changes in the total STAT1 protein (Figure 5.7A). In 
contrast, phosphorylation of STAT1 decreased after 48 hours of E2 treatment; and this trend 
continued onto the 72 hour time-point (Figure 5.7B). Next, the mRNA expression of STAT1 
was assessed. With TGF-β1 treatment, STAT1 mRNA was significantly upregulated at the 72 
hour time point (Figure 5.7C), whilst E2 treatment had no significant affect on STAT1 
mRNA expression (Figure 5.7D). 
QPCR of EGFR mRNA and miR-7 under TGF-β1 and E2 treatments, assessed further 
consequences of changes in STAT1 activation. The levels of EGFR mRNA expression 
consistently decreased over the 72 hour time course, when cells were incubated with TGF-β1 
(Figure 5.8A), the opposite was observed in cells incubated with E2 (Figure 5.8B). In contrast 
to EGFR expression, the expression of miR-7 was inversely correlated. miR-7 was 
consistently upregulated by TGF-β1, with a significantly increased 4-fold and 7-fold 
expression changes at 48 and 72 hours, respectively (Figure 5.8C). Additionally, miR-7 was 
significantly downregulated with E2, with a 2-fold and 4-fold decrease at 48 and 72 hours 
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respectively. (Figure 5.8D). It was therefore determined that 72 hours of treatment with E2 
was sufficient to upregulate EGFR, whilst downregulating miR-7. 
It was next investigated whether 72 hours of treatment with E2, followed by 72 hours of 
TGF-β1 was effective at restoring the differentiation response in aged fibroblasts. In cells that 
were treated with E2 followed by TGF-β1, expression of EGFR was maintained (Figure 5.9A) 
and expression of HAS2 significantly upregulated, compared to untreated controls (Figure 
5.9B). The levels of miR-7 initially downregulated by E2 treatment, returned to those seen in 
untreated control cells, following TGF-β1 (Figure 5.9C). The myofibroblastic markers α-
SMA (Figure 5.9D) and EDA-FN (Figure 5.9E), were both significantly upregulated when 
cells were incubated with E2, followed by TGF-β1. To test whether α-SMA stress-fibres were 
forming within the cells following treatments, the cells were permeabilised and stained for α-
SMA (Figure 5.9F). In cells that had receieved both E2 and TGF-β1 treatments, there was a 
noticeable increase in the intensity of the α-SMA stain and although stress-fibres were not 
formed throughout the entire cell, there were bundles present. These data suggest that pre-
treatment of cells with E2 can “prepare” aged cells for TGF-β1-dependent differentiation, 
through the upregulation of key components, EGFR and HAS2; and the down-regulation of 
the limiting factor, miR-7; indicating that optimisation of E2 treatments in combination with 
TGF-β1 could be beneficial for restoration of the differentiation response in cells nearing 
senescence. 
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Figure 5.1. Determination of the miR-7 Upregulation Pathway. Fibroblasts were grown to confluence, 
growth arrested and incubated in serum-free media containing 0.6% (v/v) DMSO, 10µM SB431542 or 
10µM AG1478 for 1 hour, before the media was replaced with serum-free media alone, media containing 
10ng/ml TGF-β1, or media containing 10ng/ml EGF for 72 hours. RNA was extracted, purified, and reverse 
transcribed and then QPCR was used to analyse the mRNA expression of A. EGFR and B. α-SMA. C. miR-
QPCR was used to analyse miR-7 expression. All results are shown as the mean ± s.e.m. of 3 independent 
experiments. **P=<0.01.    
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Figure 5.2. In Silico Analysis of the miR-7 Promoter Region. In silico analysis was used to determine A. the putative TSS for miR-7, dashed blue box indicates the 
region predicted to contain the TSS and upstream promoter sequence. Image was generated and analysed using miRStart computational software (Institute of 
Bioinformatics and Systems, National Chiao Tung University, Hsinchu, Taiwan). B. Diagram of miR-7 coding region and upstream promoter region used for analysis, 
dashed blue box indicates region used for promoter studies. C. The promoter region for miR-7 was analysed for recognised transcription factor binding sites. Transcription 
factors of interest are labelled and underlined sections indicate the primers used for promoter amplification. Promoter sequence was analysed for transcription factors using 
MatInspector (Genomatix Software, Munich, Germany). 
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Figure 5.3. Analysis of miR-7 Promoter Activity. Fibroblasts were grown to 60-70% confluence and 
transfected with either empty pGL3b (white bars) or miR-7-pGL3b (black bars). The indicated cellular 
treatments were performed 24 hours post-transfection and the promoter activity analysed after a further 24 
hours. Co-transfection of Renilla was used to measure transfection efficiency and for normalisation of data. 
The results shown are the means of the firefly luciferase/Renilla luciferase ratios ± s.e.m. of 3 independent 
experiments. *P=<0.05, **P=<0.01. 
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Figure 5.4. Induction of STAT1 Activation and Expression. A. Young fibroblasts were grown to 
confluence, growth arrested and stimulated with the indicated treatments for 72 hours, before STAT1 mRNA 
was assessed by QPCR. Results are shown as the mean ± s.e.m. of 3 independent experiments. B. Young or 
aged cells were grown to confluence and STAT1 mRNA was assessed by QPCR. Results are shown as the 
mean ± s.e.m. of 3 independent experiments. C. Young fibroblasts grown to confluence were growth arrested 
and incubated with the indicated treatments. Protein was extracted and Western blotting was used to assess the 
phosphorylation of STAT1. Total STAT1 protein was used as a loading control and for normalisation. The 
results shown are the mean ± s.e.m. of 3 independent experiments. *P=<0.05, **P=<0.01. 
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Figure 5.5. The Effects of Inhibiting the JAK/STAT Pathway. Fibroblasts were grown to confluence, 
growth arrested and incubated with 15nM JAK Inhibitor I for 1 hour, prior to incubation in serum-free media 
alone, media containing 10ng/ml TGF-β1, or media containing 10ng/ml IFNγ for 72 hours. QPCR was used to 
analyse the expression of A. α-SMA mRNA, B. EGFR mRNA, C. HAS2 mRNA and D. miR-7. Results are 
shown as the mean ± s.e.m. of 3 independent experiments. *P=<0.05, **P=<0.01. 
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Figure 5.6. The Effects of E2 on Young and Aged Fibroblasts. Young or aged fibroblasts were grown to 
confluence, growth arrested and incubated with serum-free media alone (white bars) or media containing 
100nM E2 (black bars), for 72 hours. QPCR was used to analyse the expression of A. α-SMA mRNA, B. 
EGFR mRNA, C. HAS2 mRNA and D. miR-7. Results are shown as the mean ± s.e.m. of 3 independent 
experiments. E. Young (white boxes) and aged (black boxes) fibroblasts were incubated with E2 over 72 hours. 
At each indicated time-point, the proliferation rates were measured by the addition of 10% (v/v) alamarBlue for 
1 hour, before fluorescent intensity analysis with an optical plate reader. *P=<0.05, **P=<0.01. 
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Figure 5.7. Regulation of STAT1 by TGF-β1 and E2. Fibroblasts were grown to confluence, growth arrested 
and incubated with serum-free media alone, media containing 10ng/ml TGF-β1, or media containing 100nM 
E2 over 72 hours. Protein was extracted and Western blotting was used to assess the changes in 
phosphorylation of STAT1 with A. TGF-β1 treatment and B. E2 treatment. Total STAT1 protein was used to 
ensure equal loading and for normalisation of densitometry. Results shown are the mean ± s.e.m. of 3 
independent experiments. QPCR was used to analyse the expression of STAT1 mRNA with C. TGF-β1 
treatment and D. E2 treatment. Results are shown as the mean ± s.e.m. of 3 independent experiments. N/S= no 
significance, *P=<0.05, **P=<0.01. 
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Figure 5.8. Regulation of EGFR and miR-7 by TGF-β1 and E2. Fibroblasts were grown to confluence; 
growth arrested and incubated with serum-free media alone, media containing 10ng/ml TGF-β1, or media 
containing 100nM E2 over 72 hours. RNA was extracted and purified and then QPCR was used to analyse the 
expression of EGFR mRNA with A. TGF-β1 treatment and B. E2 treatment, and the expression of miR-7 with 
C. TGF-β1 treatment and D. E2 treatment. Results are shown as the mean ± s.e.m. of 3 independent 
experiments. *P=<0.05, **P=<0.01. 
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Figure 5.9. E2 and Subsequent TGF-β1 Treatment Restores Differentiation in Aged Fibroblasts. Aged fibroblasts were grown to confluence; growth arrested and 
incubated with either serum-free media alone, media containing 10ng/ml TGF-β1, or media containing 100nM E2 for 72 hours. An additional treatment with media 
containing 10ng/ml TGF-β1 was made to E2 treated cells for a further 72 hours. The expression of A. EGFR mRNA, B. HAS2 mRNA, C. miR-7, D. α-SMA mRNA and E. 
EDA-FN mRNA, was analysed using QPCR. Results are shown as the mean ± s.e.m. of 3 independent experiments. F. Immunocytochemistry was used for 70% confluent 
cells, staining for the visualisation of α-SMA protein. Images displayed are representative of 5 individual experiments. *P=<0.05, **P=<0.01. 
50μm 
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5.3 Discussion 
The data reported in this Chapter provide an important mechanistic insight into the regulation 
of miR-7 by STAT1 activation; and unveils novel interactions between the cytokines that 
directly or indirectly modulate miR-7 expression and the phenotype of fibroblasts. The role of 
miR-7 in the regulation of EGFR and its pathway has been reported in many instances and in 
different species [332-334], highlighting its conserved function. However, this Chapter and 
the previous results Chapter examined miR-7 expression in the context of cellular ageing and 
wound healing, specific studies that have not been performed before.  
As shown in the previous Chapter, the activity of the EGFR promoter was not modulated by 
cellular ageing and a candidate for the suppression of EGFR expression, miR-7, was 
determined to suppress the production of EGFR protein at the mRNA level, pre-translation. 
Therefore, understanding the principal factor(s) in the upregulation of miR-7 transcription 
was an important first step of this investigation and it was determined, through the use of cell 
surface receptor inhibitors, that the EGFR signalling branch (HA-CD44-mediated) of the 
differentiation pathway was responsible for the upregulation of miR-7 expression and the 
suppression of EGFR mRNA; a self-regulatory loop involving the EGFR upregulation of 
miR-7, with miR-7 in turn, causing the downregulation of EGFR. Examination of the miR-7 
promoter was ideal for furthering the investigation, as isolating transcription factors that 
enhance the miR-7 transcription would provide targets for interventional measures. The 
promoter region of miR-7 was elucidated using previous studies [332] and in silico analysis 
of TSS associated tags. Determining which transcription factors were binding to the miR-7 
promoter and enhancing miR-7 transcription was the next step of the investigation; and it was 
noted that there was an abundance of interferon regulated elements, specifically STATs, in 
the putative promoter region. 
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To further investigate the involvement of STATs and whether the EGFR pathway was 
responsible for increased miR-7 promoter activity, the promoter region was ligated into a 
luciferase reporter plasmid. The data shown suggested that EGFR was capable of mediating 
the promoter activity of miR-7; and the induction by IFNγ treatment supported the hypothesis 
that STATs were the responsible transcription factors. These data led to the hypothesis of a 
potential mechanism involving EGFR activation of the JAK/STAT pathway, which has been 
reported previously [1, 3]; and was further supported by the EGFR-mediated phosphorylation 
of STAT1 as shown in Figure 5.4. However, the fluctuations in STAT1 mRNA expression 
did not seem to impact on the total STAT1 protein present from whole cell lysates, a change 
that may be seen at longer time-points. The inhibition of JAK did not alter TGF-β1 
upregulation of α-SMA, providing evidence that the differentiation pathway was independent 
in function from the EGFR-mediated JAK/STAT pathway. However, when JAK was 
inhibited, EGFR mRNA did not down-regulate and HAS2 mRNA increased in the presence 
of TGF-β1 or IFNγ, suggesting multiple functions of STATs on the regulation of 
differentiation pathway components. Suppression of EGFR through miR-7 upregulation may 
be separate from HAS2 suppression (possibly through an alternative miRNA), a mechanism 
that should be investigated further. 
The effects of E2 on wound healing have been an area of research that has generated much 
interest over recent years [346, 380, 386, 387, 395]. Although previous research has shown 
the changes in fibroblasts treated with E2, exploring the links between E2 and its effect on 
the proteins necessary for myofibroblast differentiation has had limited attention. The results 
in this Chapter illustrated the changes of EGFR, HAS2 and miR-7 expression in young and 
aged fibroblasts, by E2 treatment. Whether E2 also affects translational or post-translational 
changes in EGFR, HAS2 and HA synthesis is not known and warrants further investigation. 
The data that is shown here revealed a means by which incubation of aged cells with E2 
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“prepared” the cells for the subsequent TGF-β1 treatment by increasing the expression of the 
mRNA for key components (EGFR and HAS2), whilst decreasing the expression of the 
pathway limiter (miR-7). Additionally, it was shown that E2 followed by TGF-β1 treatment 
was able to restore the ability of aged fibroblasts to form α-SMA stress-fibres. 
The in vitro benefits of E2 on fibroblasts described here indicate a mechanism of action that 
downregulates miR-7 and thereby relieves the suppression placed on EGFR mRNA, 
increasing its expression. Therefore, further investigation is required to elucidate the specific 
interactions or functional and mechanistic outcomes of direct actions by E2 treatment.  
Two areas of investigation warrant further analysis, the first is to assess the direct action of 
E2 on the miR-7 promoter. In silico analysis identified a sequence motif within the promoter 
region used, for estrogen response elements (IR3) and estrogen receptor (ER) binding, 
potentially indicative of a transcriptional suppression role. Through experiments exploring E2 
stimulation using either site deletions or ER inhibition, the effect of E2 on the miR-7 
promoter could be explored. Additionally, it was observed that the phosphorylation of 
STAT1 was reduced the longer cells were incubated with E2. The second area of 
investigation would be examination of whether E2 has direct effects on other STAT targets 
(e.g. STAT3), the production of activators of STATs, such as IFNγ, the previously reported 
downregulation of IL-6 [105, 404-407]; and their corresponding cell surface receptors, could 
help detail a full mechanism of action for E2 and explain its impact on miR-7, EGFR, HAS2 
and the differentiation pathway in fibroblasts.  
Specifically, analysis of IL-6 would be of primary interest as the correlation between cellular 
ageing and IL-6 has been previously reported in a plethora of studies [408, 409]; and the 
serum concentrations of IL-6 have been reported to increase with progressing age [410], 
although one study did not observe this correlation [411]. IL-6 is also a potent activator of 
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STATs and stimulates increased production of STAT mRNA [412, 413], which would go 
some way to supporting the observations made in this results Chapter. Furthermore, a broader 
analysis of changes in miRNAs under TGF-β1 and E2 treatments in young and aged 
fibroblasts, using microarrays, could indicate other miRNAs that may be present and actively 
inhibiting the differentiation pathway components. 
Although with direct E2 treatment in vitro, the fibroblasts established beneficial outcomes, 
the effects of circulating serum levels of E2 in vivo may have a limited effect on the 
fibroblasts within the dermis or in other organ systems. Additionally, when combined with 
the low levels of estrogen in men and in post-menopausal women, E2 application may only 
be of therapeutic significance in terms of wound healing, when used to upregulate factors lost 
from cellular ageing. It can be concluded from the data presented in this results Chapter that a 
combinational treatment of E2 and TGF-β1 to aged fibroblasts was beneficial in reversing the 
age-associated loss of differentiation. The initial E2 treatments had a profound effect on 
fibroblasts, upregulating the key components needed for successful differentiation (EGFR, 
HAS2) and downregulating the limiting factors (p-STAT1, miR-7). The subsequent 
incubation with TGF-β1 was, therefore, able to drive myofibroblast differentiation, as shown 
by the production of myofibroblastic markers (α-SMA, EDA-FN). However, the treatment 
regime of 72 hours of E2 followed by 72 hours of TGF-β1 incubation may require further 
optimisation in order to achieve the best results.  
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Chapter 6 
 
General Discussion 
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The data presented in this thesis advances the knowledge of a complex cellular mechanism: 
fibroblast to myofibroblast differentiation. A detailed pathway of action was described, 
encompassing the various components of differentiation. A key finding was the alterations in 
behavioural dynamics of the HA receptor, CD44, within the cell membrane. The rate at 
which CD44 diffused throughout the membrane changed with cellular ageing and during 
differentiation. However, the loss of CD44 motility in each case was for different reasons. 
Figure 6i illustrates an explanation of the behavioural changes of CD44, under various 
conditions. 
 
a) Fibroblasts – In young, resting fibroblasts, CD44 diffused rapidly throughout the cell 
membrane. The movement of CD44 within the membrane could be essential for its fast re-
localisation and association with multiple proteins [281-283, 290], its role as a co-receptor for 
Figure 6i. Illustrated explanation of the behavioural changes in CD44 interactions and membrane motility, with 
cellular ageing, myofibroblast differentiation and various cellular treatments. 
 169 
rapid induction of intracellular signalling [414, 415]; and its cleavage which can drive 
migration in lung cancer cells [416]. A possible explanation for the motility of CD44 may lie 
with its biochemical properties. One CD44 receptor in itself has low affinity for binding HA, 
when multiple CD44 bind HA, the affinity and binding strength between CD44 clusters and 
HA increases [417-419]. It could be that there is constant association and disassociation of 
free CD44 with HA, due to a ratio of high levels of CD44 to low levels of HA. There is 
currently no literature on CD44 membrane dynamics and therefore, there is limited insight 
and revelations on the functional significance of CD44 diffusion potential. This thesis 
investigated CD44 movement and provides a viable hypothesis for HA-dependent CD44 
movement and its requirement for co-receptor interactions.  
b) Myofibroblasts – Changes in the production of HA and the HA pericellular coat are 
marked in myofibroblast differentiation [244, 252]. Following myofibroblast differentiation, 
the changes in HA production have a distinct effect on the mobility of CD44 within the cell 
membrane. Here, it is proposed that the loss of CD44 motility was due to strong binding to 
multiple HA-chains present on the myofibroblast cell surface, balancing the HA:CD44 ratio; 
and combined with CD44 association with EGFR in lipid rafts, following acylation or 
palmitoylation of CD44 [279, 315] (a possible effect of TGF-βRI activation). There is limited 
research on what protein or pathway is responsible for CD44 conformational and functional 
change. It has been reported that PKC (a downstream target of TGF-βRI phosphorylation 
[420]) may have a role in this [283, 421]. Strong associations with EGFR and multiple HA-
chains hold CD44 in clusters. Due to hyaladherin upregulation/release following TGF-β1 
stimulation; TSG-6, IαI or other hyaladherins cross-link HA chains forming a rigid network 
surrounding the cell; the HA pericellular coat [247, 422, 423]. This coat formation “locks” up 
the CD44 in the membrane and in lipid rafts. One limiting step for CD44-EGFR co-
localisation and differentiation is acylation/palmitoylation of CD44, described in 
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chondrocytes as being a necessary step for CD44 association with lipid raft micro-domains 
[279]. Treatment with the palmitoylation inhibitor, 2-bromo-palmitate, inhibited CD44 
association with lipid rafts and downstream signalling events [279, 424]. This modification to 
CD44 was found to occur on cysteine residues of the CD44 cytoplasmic tail (cys286 or cys295). 
Mutation of these sites reduced palmitic acid incorporation into CD44 and prevented CD44-
lipid raft association. This also prevented HA internalisation and CD44 turnover in CD44 
transfected, COS-7 cells [425], indicating the important function of lipid-rafts. These reports 
raise questions about whether the association of CD44 with lipid rafts has regulatory effects 
on other CD44 related functions, such as cell signalling or co-receptor interactions. The data 
presented here would suggest that is the case and that targeting the protein responsible for 
CD44 acylation may be a useful mechanism for prevention of the TGF-β1 differentiation of 
fibroblast to myofibroblasts. 
c) Aged Fibroblasts – The loss of HA synthesis, cell-surface EGFR and CD44 transcription, 
were factors identified as contributors to age-associated dysfunction of differentiation; 
findings supported by previous research [160, 195, 244]. The data suggests that in aged 
fibroblasts, CD44 had reduced membrane diffusion ultimately deemed to be HA-regulated 
(restored by HAS2 overexpression). As such, it could be speculated that low levels of HA 
present on the aged fibroblast attenuated movement of CD44 between HA binding points. 
The loss of HA synthesis by HAS2, a consequence of diminished EGFR levels, was found to 
be liable for the reduced motility of CD44. This proposal was supported through pre-miR-7 
transfection into young fibroblasts, which produced an aged-like phenotype with reduced 
CD44 movement. These findings raise the question, how does inhibition of miR-7 result in 
HAS2 upregulation and HA production? Measurements of the levels of HA and activated 
EGFR as a result of miR-7 LNA transfection, would provide useful answers and information. 
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d) Hyaluronidase Treated Myofibroblasts – The hypothesis that HA was involved in 
regulating CD44 membrane movement was tested by using hyaluronidase, to remove the HA 
pericellular coat prior to FRAP analysis. The data suggest that although CD44 could remain 
in association with EGFR, the loss of HA released clusters of CD44 and restored their 
membrane motility. The results provided a key insight into the role of the HA pericellular 
coat in orchestrating intracellular signalling, regulating CD44 activity and stabilising the 
myofibroblast phenotype. Targeting the HA pericellular coat may be one way to reverse the 
myofibroblast phenotype and limit or prevent progressive fibrosis. 
e) 4MU Treated Fibroblasts – Inhibition of HA synthesis has proven to be detrimental to 
HA pericellular coat formation and cell function [244, 245], resulting in the failure of 
differentiation. The data reported here suggest that HA can modify CD44 membrane motility. 
Therefore, 4MU removal of HA synthesis was used to further test this hypothesis. The results 
showed CD44 diffusion rate and mobile fraction decreased. The loss of CD44 movement may 
primarily be a consequence of the loss of HA binding regions that CD44 could move between.  
This research highlights CD44, lipid rafts; and the HA-pericellular coat/hyaladherin network, 
as potential targets for intervention of fibrosis or promotion of efficient wound healing. It 
also advances our understanding of specific receptor function and behavioural modifications 
driving cellular change. CD44 functions as a co-receptor, with indications of specialised 
actions, e.g. association with lipid raft proteins in a HA- and acylation-dependent manner 
[424, 425]. Therefore, defining the mechanism involved in the acylation of CD44, following 
TGF-β1 stimulation, would be an appropriate course for future investigation, as the data 
showed CD44 association with lipid rafts was required to activate intracellular signalling 
cascades involved in promoting differentiation. Although the application of CD44 dynamics 
would be limited in a clinical scenario, assessing the movement potential of CD44 using 
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FRAP and Confocal Microscopy could be an effective way of elucidating whether or not live 
ex vivo cells from tissue biopsies have either progressed to a fibrotic or protomyofibrotic state, 
or whether the cell is senescent or near to senescence.  
When considering the targeting of lipid rafts, it would be important to consider their overall 
function. Depletion of cholesterol from lipid rafts may have a preventative effect on 
myofibroblast differentiation. However, it would not be a feasible option for targeting, due to 
their importance in regulating signalling, endocytosis and structural properties of the cell 
membrane [284, 287, 298, 299, 311]. Additionally, reports have suggested that the forced 
release of EGFR from cholesterol rich lipid rafts may result in ligand independent activation 
[289]. Thus, the effects of nystatin depletion of cholesterol may be in the short-term. 
Therefore, blocking CD44 movement into lipid rafts may be a favoured alternative. 
Furthermore, identification of the structural features of CD44 and how it activates EGFR 
would help target specific regions of the protein, without disrupting major functions (such as 
endocytosis [279]) important for cell survival. One recently described interaction of CD44 
that may be involved in mediating EGFR association is the transmembrane glycoprotein, 
emmprin (basigin/CD147) [426]. This is a protein involved in the induction of HA synthesis 
in tumour cell lines [427], through the increase of HAS2 expression [428]. Inhibition using 
targeted siRNA to emmprin may provide insight into whether it has functional significance in 
myofibroblast development. Additionally, if a specific CD44v is involved in the activation of 
EGFR, then its variable exon coding region and resultant function (e.g. CD44v3 “handle 
receptor” GAG-site and binding of EGF/HB-EGF or driving cell invasiveness [262, 429]), 
could be targeted directly.  
This thesis also explored the differences in phenotypic expression between young fibroblasts 
and in vitro aged fibroblasts, to identify key differences to explain the loss of EGFR protein 
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and the reduction in TGF-β1-stimulated, HA upregulation that were previously found [160, 
244]. With each proliferation, cells approach the phenomenon known as cellular senescence, 
by which point normal diploid cells cease to divide and lose phenotypic qualities and 
functions. The number of cellular divisions depends on cell type and source [430-432]. 
Senescent cells remain metabolically active and generally adopt an irregular, flattened 
morphology; and altered gene expression and secretion profiles [433]. In one study, the 
eradication of senescent cells by drug-induced apoptosis in mice, led to resistance against 
age-associated diseases [434]. Cellular senescence is causally implicated in generating age-
related phenotypes. As such the reversal of lost function in near senescent cells could prevent 
or delay tissue dysfunction. 
The accumulation of senescent fibroblasts within tissues has been suggested to play an 
important role in mediating impaired wound healing in the elderly. As fibroblasts near 
senescence, their responsiveness to extracellular signals diminish [435] and they exhibit a 
decreased ability to divide in response to damage or cell loss [436, 437]. Such alterations are 
thought to be responsible for the physiological deterioration and limited tissue regeneration 
observed in ageing individuals. Reversing the resistance to TGF-β1-driven differentiation in 
near senescent cells could provide a valid approach to promoting the efficient wound healing, 
that is required in elderly patients with chronic non-healing wounds.   
The inhibitory effect of miR-7 on EGFR expression has been documented in several 
instances, including its dysfunctional regulation of EGFR in cancers [332-334, 401]. As a 
potent inhibitor of EGFR mRNA, miR-7 was chosen for in-depth investigation in order to 
determine whether it had a role in the dysfunction of differentiation, arising from cellular 
ageing.  
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Category Term Count Percent P-Value 
miR-7 Targets Phospho-protein 247 59.5% 6.60e-21 
 
 
Table 6i demonstrates the involvement of miR-7 in the regulation of biochemical pathways, 
with the majority of predicted miR-7 targets (59.5%) implicated in protein signalling 
pathways. The pathways with the most targets included are shown below in table 6ii.  
 
 
 
The in silico analysis of miR-7 target pathways indicates predicted suppression of 
myofibroblast differentiation, changes to cell morphology (FA upregulation), actin 
Pathway Count Percent P-Value Notable Targets 
Cancers 14 3.4% 5.20e-2 
EGFR, FGF11, IGF-1R, PI3Kδ, 
PI3K3γ, PKCβ 
Focal Adhesion 13 3.1% 3.20e-3 
COLIa2, COLIIa1, EGFR, IGF-1R, 
integrin-α9, integrin-β8, PI3Kδ, 
PI3K3γ, PKCβ, vinculin 
Actin Cytoskeleton 
Regulation 
11 2.7% 3.40e-2 
PI3Kδ, PI3K3γ, FGF11, EGFR, 
Ras, Raf, integrin-α9, integrin-β8, 
ErbB/EGFR Signalling 8 1.9% 4.80e-3 
CaMKIIδ, EGFR, PI3Kδ, PI3K3γ, 
PKC, Raf, Ras, ERK1/2, c-Myc, 
Akt, mTOR 
Insulin Signalling 8 1.9% 4.40e-2 
ERK1/2-S/TK1, IRS1, IRS2, 
PI3Kδ, PI3K3γ, Raf 
mTOR Signalling 7 1.7% 1.50e-3 
EGFR, Akt, mTOR, PI3Kδ, 
PI3K3γ, ERK1/2, PKCβ 
Table 6i. In silico analysis of TargetScan database for miR-7 targets cross-referenced with GoDAVID target 
analysis software. The majority (59.5%) of known/predicted miR-7 targets of repression are proteins involved in 
activation and signalling pathways (phospho-proteins). The Fisher Exact P-value is displayed (lower value = 
more enriched gene-analysis; represents the certainty of  in silico accuracy).  
Table 6ii. In-depth GoDAVID software analysis of precise pathways that contain targets for miR-7. Included 
are counts, percentage of total phospho-proteins (Table 6i) involved in each pathway, The Fisher Exact P-
value is displayed (lower value = more enriched gene-analysis; represents the certainty of  in silico accuracy). 
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cytoskeleton reorganisation; and EGFR and mTOR signalling. Therefore, the upregulation of 
miR-7 in aged cells could impact on several pathways, involved in differentiation and 
proliferation [5, 365, 438, 439] (summarised in Figure 6ii). The observed effects of miR-7 
overexpression on myofibroblast differentiation have helped in detailing the intricacies of the 
pathway, reinforcing the importance of the EGFR-HAS2-HA-CD44 relationship. EGFR is 
the initiating receptor in many of the miR-7 targeted pathways (particularly ErbB and mTOR). 
Therefore, the inhibition of EGFR by miR-7 is likely a major factor in the decrease of HAS2 
expression, lowering HA synthesis and diminishing CD44 membrane movement and co-
localisation with EGFR, following TGF-β1 stimulation. Additionally, other signalling 
proteins are notable targets of miR-7 and may be involved in driving HAS2 transcription 
(PI3K/Akt/mTOR [440]), or CD44 modulation (PKC [420, 421]). 
 
 
 
 
 
 
 
 
Figure 6ii. Summary of the pathways investigated in this thesis, known/predicted miR-7 targets are indicated 
by a red star. Adapted from GoDAVID software analysis for miR-7 targets of the ErbB/EGFR signalling 
pathway. 
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Since c-Myc is a predicted target of miR-7 and is also downstream of EGFR activity, an 
alternative pathway for miR-7 transcriptional activation was proposed. The in silico analysis 
of the miR-7 promoter fragment indicated several STAT binding sites. The data show that 
EGFR and IFNγ upregulation of miR-7 was prevented when the JAK/STAT pathway was 
inhibited. The increased miR-7 expression was only seen at 72 hours, post-TGF-β1 
stimulation, leading to the conjecture that this mechanism may be in place to prevent 
excessive EGFR pathway signalling; a dysfunctional occurrence that seems to present in 
many cancers [333, 441-443].  
The persistence of miR-7 expression in aged fibroblasts may be due to an over-active STAT 
pathway, but this was not investigated in detail here. The reported increase of IL-6 (a potent 
STAT activator) with ageing [408, 410, 444] may be responsible. The concise regulation of 
miR-7 (i.e. transient transfection of inhibitors or through blocking the IL-6 pathway) could 
reverse age-associated loss of differentiation and promote wound healing in chronic non-
healing wounds. Alternatively, the detected expression of miR-7 in wound biopsies could 
serve as indication of the prognosis of rate of recovery. 
Furthering the investigation into potential suppressors of miR-7, and in light of reports of E2 
upregulation of EGFR [397-399] and beneficial effects on wounds [386], E2 treatment of 
aged fibroblasts was performed to examine the potential for enhancing wound healing or 
fibroblast function. The results shown here suggest a potentially viable role for E2 as a 
promoter of fibroblast differentiation, in the presence of TGF-β1. Preliminary data indicated 
that IL-6 and STAT1/3 are upregulated by TGF-β1; and E2 had the opposite effect. Since 
STAT1/3 are targets of downstream IL-6 and EGFR signalling, the current hypothesis is that  
E2 acts independently of EGFR signalling in fibroblasts and has direct effects via 
transcriptional activation (EGFR, HAS2) or repression (IL-6, STAT1, STAT3). The effects 
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on miR-7 could, therefore, be a result of this proposed mechanism of action (summarised in 
figure 6iii).  
 
E2-dependent suppression of inflammation could contribute to its pro-healing properties, as 
chronic inflammation can cause failure of wound resolution and chronic non-healing wounds 
[445, 446]. E2 has been noted to have beneficial effects on wound healing through ERβ [390, 
393]. The actions of ERα have been described as having the opposite effect [387, 394]. The 
proposed mechanism of action for ERβ in fibroblasts is through its suppression of IL-6, a 
function shown in various cell types [404-407, 447]. Through this inhibitory mechanism, the 
downregulatory effects on miR-7 could be explained. Interestingly, during in silico analysis, 
it was noted that a site for ER binding was predicted to be present on the miR-7 promoter 
fragment used for investigation in this thesis. This site overlapped with STAT/ISRE sites and 
analysis of suppression of miR-7 promoter activity by E2 would be worth examining in future 
experiments. Additionally, the upregulatory effects of E2 on EGFR and HAS2 would also 
require investigation, whether this action is primarily down to miR-7 inhibition or through E2 
responsive sites within the promoter regions of both EGFR and HAS2. Elucidating which of 
Figure 6iii. Proposed mechanism of actions resulting from E2 stimulation in fibroblasts. Full lines are 
hypothesised direct effects and dashed lines are hypothesised indirect effects (green; stimulatory, red; 
inhibitory).  
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the ERs, ERα or ERβ is active in fibroblasts and their precise actions, could highlight a novel 
target to exploit in order to promote wound healing in vivo. 
By targeting miR-7, multiple potential routes of inhibition have been identified to drive 
EGFR and HAS2 upregulation, and myofibroblast differentiation in the presence of TGF-β1. 
These data also help explain why there is limited clinical success when treating non-healing 
wounds, application of antibiotics and growth factors may go some way in helping improve 
the wound environment, but without treating the underlying reason for inherent impaired 
cellular activity (fibroblast resistance to growth factors), limited success would be expected. 
The data provided here indicate targets for therapeutic intervention, that when targeted 
singularly or in combination, could provide a valid form of therapy for chronic non-healing 
wounds. The aberrant expression of miR-7 in aged cells could be a marker of age-associated 
resistance to differentiation, significantly changing the fibroblast cell proteome expression. 
Whether miR-7 upregulation is purely a senescence-associated mechanism or a result of the 
persistent expression of inflammatory factors (IFNγ, IL-6) and primarily through a STAT 
dependent pathway, or whether the two scenarios are causative or coincidental, remains to be 
clarified. Accordingly, the results clearly demonstrated the possibility of reversing the aged 
phenotype to the functionally active young phenotype, by restoration of EGFR, HAS2 and 
HA-dependent, CD44 motility.  
What are the actual ramifications of these findings for age-related wound healing? One must 
be careful in applying the results of the findings from in vitro experiments to in vivo clinical 
problems. However, the implications of this study are that interventions to improve healing in 
the elderly need to be targeted toward improving cell responsiveness, by enhancing signalling 
and augmenting the cell response. The data support the use of a) inhibiting miR-7 activity 
through miR-7 LNA transfer to non-healing wounds in the elderly, or b) counter-acting the 
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actions of miR-7 directly, through the use of E2 treatment as a more rationale therapy than 
the application of growth-factors, since the rate limiting step is the EGFR pathway and 
downstream signalling, as opposed to the availability of TGF-β1 and Smad phosphorylation. 
That being said, investigation into additional effects arising from treatment concerning E2 
and TGF-β1 pathways should be performed, as both have been reported as being implicated 
and have excessive expression in many cancers [381, 382, 448, 449]. 
Progression of the research toward clinical scenarios would need to involve intermediate 
stages: 3D cell cultures or collagen gels can be used to effectively measure and quantify the 
physical activity of myofibroblasts [450], required to support the actions of miR-7 inhibition 
on aged fibroblasts. Fibroblast isolation from chronic wound biopsies has been deemed safe 
and does not hamper the wound-healing outcome [451]. Therefore, the next stage would be 
using cells acquired ex vivo; from healthy control patients and a varying range of biopsies 
from non-healing wound edges. Beyond the context of wound healing, 3D culture models 
may provide useful in studying associations between receptor function and behavioural 
changes which indicate innate function e.g. ECM co-ordinated intracellular signalling 
induced through HA (in an in vivo-like environment, not possible in 2D plate cultures); and 
successful incorporation of miR-7 inhibitors (miR-7 LNA or E2) into cells in a 3D culture, 
optimisation of technique before transferring into animal models. 
The work outlined in this thesis identified several novel and functional relationships between 
HA, CD44, EGFR and miR-7. These included cellular localisation and functional 
significance of the cellular location, the importance of transcriptional regulation, and routes 
of intervention. One implication of this system is the capacity for HA to regulate cellular 
phenotype. The data suggests this may be achieved through direct association and driven 
function with CD44, as highlighted in figure 6i. Additionally, with replicative ageing the 
 180 
increase in miR-7 by increased secretion of inflammatory factors (the upregulated secretion 
of factors, such as IL-6, IFNγ; their receptors may be a direct result of cellular ageing; and 
loss of transcriptional control of these proteins), indicated changes at the genetic level that 
contribute to the regulation of myofibroblast differentiation. The proposed pathway of E2 
action in figure 6iii illustrates potential mechanisms of counteractive measures to miR-7 
transcription and its EGFR-suppressing activity. In conclusion, this work demonstrated that 
in the cellular ageing of fibroblasts, EGFR was lost due to a steady and persistent increase in 
miR-7 expression, resulting in the loss of downstream EGFR responses, including HAS2 
expression, HA synthesis and a loss of CD44 membrane motility. This ultimately resulted in 
the loss of CD44-EGFR co-localisation in lipid rafts and the loss of the EGFR-mediated 
branch of the differentiation response, i.e. a resistance to myofibroblast differentiation. The 
figures provided here are starting points to be built upon for future investigation. Further 
studies to elucidate details of the interactions between CD44 and EGFR in lipid rafts, the 
relation between STAT activation and the resultant miR-7 transcription; and the extent of the 
effects of E2 on this relationship and the differentiation pathway, should provide new 
opportunities for modifying the wound healing response and for ameliorating clinical 
conditions that involve age-related complications or alternatively, progressive fibrosis.    
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Appendix 1: Buffers and Reagents 
 
 
Solution Contents    
Blocking Buffer: 5%(w/v) Dried Skimmed Milk Powder, 0.5%(v/v) Tween-20, 20ml PBS 
   
Reducing Buffer (3x): 62.5mM Tris, 30%(v/v) Glycerol, 6%(w/v) SDS, 0.03%(w/v) Bromophenol-blue, 25%(v/v) β-mercaptoethanol, 10ml dH2O 
   
Reducing Buffer (1x): 62.5mM Tris, 10%(v/v) Glycerol, 2%(w/v) SDS, 0.01%(w/v) Bromophenol-blue, 8.3%(v/v) β-mercaptoethanol, 10ml dH2O  
   
Running Buffer (10x): 30g/L Tris, 144g/L Glycine, 10g/L SDS, 1L dH2O, pH8.3    
Running Buffer (1x): 100ml 10x Running Buffer, 900ml dH2O    
Transfer Buffer (10x): 30g/L Tris, 144g/L Glycine, 1L dH2O, pH8.3    
Transfer Buffer (1x): 80ml 10x Transfer Buffer, 200ml Methanol, 720ml dH2O    
TAE Buffer (1x): 40mM Tris, 20mM Acetic Acid, 1mM EDTA, 1L dH2O    
PCR Loading Buffer: 30%(v/v) Glycerol, 0.1%(w/v) Orange(/Blue)-G    
Phosphate Buffered 
Saline (PBS): 
2.68mM KCl, 1.47mM KH2PO4, 137mM NaCl, 8.1mM 
Na2HPO4 
   
Cytokine Buffer: 4mM HCl, 1mg/ml BSA, in PBS    
Mild Stripping Buffer: 15g/L Glycine, 1g/L SDS, 1%(v/v) Tween-20, 1L dH2O, pH2.2    
Stripping Buffer: 20g/L SDS, 7.57g/L Tris, 100mM/L β-mercaptoethanol, 1L dH2O, pH6.7 
   
Wash Buffer (5x): 0.5%(v/v) Tween-20, 1L PBS    
Wash Buffer (1x): 0.1%(v/v) Tween-20, 1L PBS    
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Appendix 2: Supplemental Data 
 
 
 
 
 
Supplementary Figure 3.S. A. Cell surface and total protein expression of EGFR and CD44 in 
50μg/mL nystatin and 10ng/mL TGF-β1 treated fibroblasts. B. Untreated and 0.06%(v/v) DMSO 
solvent time-course controls for pERK1/2 / ERK1/2 signalling time-courses. C. Western blot 
analysis of p-Smad2/Smad2 and TGF-βRI/GAPDH in cells treated with 50μg/mL nystatin and 
10ng/mL TGF-β1 time-courses. N/S = no significance. 
